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“We are going to die, and that makes us the lucky ones. 
Most people are never going to die because they are never 
going to be born. The potential people who could have been 
here in my place but who will in fact never see the light of 
day outnumber the sand grains of Arabia. Certainly those 
unborn ghosts include greater poets than Keats, scientists 
greater than Newton. We know this because the set of 
possible people allowed by our DNA so massively exceeds 
the set of actual people. In the teeth of these stupefying odds 
it is you and I, in our ordinariness, that are here. We 
privileged few, who won the lottery of birth against all odds, 
how dare we whine at our inevitable return to that prior state 
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Abstract 
For the first part of this thesis the addition of various organozinc reagents to [1.1.1]propellane 
was investigated. This was first achieved using allylic organozinc halides (Scheme A). The 
additions proceeded with an extraordinarily high stereoselectivity, as only the products 
resulting from an allylic rearrangement were observed. The resulting zincated BCPs were 
successfully trapped using Negishi-type cross-couplings, thiolations, cobalt-catalyzed 
electrophilic aminations, as well as copper-mediated allylations and acylations. The protocol 
showed a good tolerance of functional groups, such as esters and nitriles, due to the 
relatively low reactivity of the organozinc halides. 
 
Scheme A. Summary of the addition of allylic organozinc halides to [1.1.1]propellane. 
 
The methodology was extended to various zinc enolates, prepared from ketones, esters and 
nitriles through the deprotonation with LDA, followed by a transmetalation with ZnCl2 
(Scheme B). Once again the resulting zincated BCPs were submitted to different electrophilic 
trapping reactions, such as protonations, copper-catalyzed allylations, palladium-catalyzed 
Negishi-type cross-couplings, acylations and cyanations. The protocol was also used to 
synthesize a BCP-bioisoster of the synthetic opioid pethidine. 
VIII 
 
Scheme B. Summary of the addition of zinc enolates to [1.1.1]propellane. 
 
The high regioselectivity of the reaction was rationalized using DFT calculations, which 
showed that the allylic rearrangement proceeds via a cyclic transition state involving ZnBr2, 
LiCl, the allylic zinc halide and [1.1.1]propellane. 
  
IX 
The topic of the second part of this thesis was the metalation of various nitrogen containing 
heterocycles using TMP bases. This was first achieved in the case of 1,3,4-oxadiazole using 
the base TMP2Zn∙2LiCl (Scheme C). The resulting zincated 1,3,4-oxadiazole was reacted in 
a series of Negishi-type cross-couplings with electron-deficient, electron-rich and heterocyclic 
iodides. The mono substituted 1,3,4-oxadiazoles were then metalated a second time using 
TMP2Zn∙2MgCl2∙2LiCl, followed by a series of copper-catalyzed electrophilic aminations 
using hydroxylamino benzoates. 
 
Scheme C. Summary of the functionalization of 1,3,4-oxadiazole. 
 
N-propyl and N-benzyl 1,2,4-triazole were investigated as a second heterocyclic system 
(Scheme D). In this case the first metalation was achieved using TMPMgCl∙LiCl or 
TMPZnCl∙LiCl. The metalated 1,2,4-triazoles were subsequently submitted to a variety of 
electrophilic trapping reactions, including copper-catalyzed allylations and acylations, as well 
as Negishi-type cross-couplings and copper-catalyzed electrophilic aminations. A second 
metalation was performed on two different substrates using the same TMP bases. 
X 
 
Scheme D. Summary of the functionalization of 1,2,4-triazoles. 
 
Finally, the functionalization of 1H-imidazo[1,2-b]pyrazole was explored (Scheme E). The 
free NH-group of the heterocycle was protected with a SEM-group. The first functionalization 
was achieved via a selective bromination in the 7-position using NBS, followed by a bromine-
magnesium exchange and different electrophilic trapping reactions. A second selective 
metalation in the 3-position was performed using TMPMgCl∙LiCl. The metalated 
intermediates could once again be reacted with a variety of electrophiles. The third 
metalation with (TMP)2Zn∙MgCl2∙2LiCl went selectively in the 2-position and allowed the 
synthesis of a multitude of acylation and cross-coupling products. 
XI 
 
Scheme E. Summary of the functionalization of 1H-imidazo[1,2-b]pyrazole. 
 
The treatment of 2,3,7-trifunctionalized 1H-imidazo[1,2-b]pyrazoles with 
(TMP)2Zn∙MgCl2∙2LiCl let to the formation of a series of novel 1H,1'H,5H,5'H-6,6'-biimidazo-
[1,2-b]pyrazolylidenes, which exhibited fluorescence in solution under UV-light (Scheme F). 
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Part I: Highly Regioselective Addition of 




1.1 Properties of [1.1.1]Propellane 
The term propellane was first introduced in 1966 by Ginsburg et. al. to describe tricyclic 
hydrocarbons, which share a common carbon-carbon single bond.1 The established 
shortened nomenclature defines them as [k.l.m]propellanes, where k, l and m indicate the 
size of the three bridges (k ≥ l ≥ m). Based on the size of the rings forming the propellane the 
hybridization of the bridgehead carbons changes significantly, thus influencing the reactivity 
of the central bond. Propellanes with large rings (k + l + m > 8) usually behave similar to 
common hydrocarbons, while small-ring propellanes (k + l + m ≤ 8) exhibit a unique reactivity 
that is typically attributed to their highly strained nature.2 This unique reactivity is especially 
prevalent in the smallest member of the propellane family, [1.1.1]propellane and will be 
discussed in the following sections. 
 
1.1.1 Synthesis of [1.1.1]Propellane 
[1.1.1]Propellane was first synthesized by Wiberg et. al. in 1982 through the reaction of 
1,3-dibromobicyclo[1.1.1]pentane with butyllithium.3 Subsequently, Szeimies et. al. develop-
ped a more convenient way to access [1.1.1]propellane,4 which is still being used to this day 
with only minor modifications. For this synthesis 3-chloro-2-(chloromethyl)prop-1-ene is first 
converted to 1,1-dibromo-2,2-bis(chloromethyl)cyclopropane via a cyclopropanation with 
dibromocarbene. Then two subsequent bromine-lithium exchanges with methyllithium lead to 
two intramolecular ring closures and thus form [1.1.1]propellane (Scheme 1).5 The tricyclic 
compound is surprisingly stable even at room temperature and can be stored in ethereal 
solution below 0 °C for months without significant amounts of decomposition or 
polymerization.6 
                                               
1 J. Altman, E. Babad, J. Itzchaki, D. Ginsburg, Tetrahedron 1966, Suppl. 8, 279-304. 
2 A.-D. Schlüter, H. Bothe, J.-M. Gosau, Makromol. Chem. 1991, 192, 2497-2519. 
3 K. B. Wiberg, F. H. Walker, J. Am. Chem. Soc. 1982, 104, 5239-5240. 
4 a) K. Semmler, G. Szeimies, J. Belzner, J. Am. Chem. Soc. 1985, 107, 6410-6411; b) J. 
Belzner, U. Bunz, K. Semmler, G. Szeimies, K. Opitz, A.-D. Schlüter, Chem. Ber. 1989, 122, 
397-398. 
5 K. R. Mondanaro, W. P. Daily, Org. Synth. 1998, 75, 98-101. 




Scheme 1. Synthesis of [1.1.1]propellane according to Szeimies.4,5 
 
1.1.2 Nature of the Central Carbon-Carbon Bond 
A consequence of the bonding situation in [1.1.1]propellane is that the bridgehead carbons 
deviate strongly from the tetrahedral coordination typically found in sp3-hybridized systems, 
as the central bond is inverted. The exact nature of this central bond has been extensively 
studied and debated over the years.  
On one hand there is evidence pointing at a strong bonding interaction between the 
bridgehead carbons: From the enthalpy change during the conversion of 
bicyclo[1.1.1]pentane into [1.1.1]propellane plus two hydrogen atoms Wiberg et. al. 
calculated the strength of the central bond to be between approximately 65 kcal∙mol−1 by 
assuming a C-H bond dissociation energy of 104 kcal∙mol−1 (Scheme 2).3 In addition, a 
diradical triplet state of [1.1.1]propellane was calculated to lie 79 kcal∙mol−1 higher than the 
singlet state.7 The exceptionally short distance between the bridgehead carbons of only 
1.6 Å, as determined by low-temperature X-ray diffraction8 and gas-phase electron 
diffraction9 also hints at a strong bonding interaction alongside the central bond. 
 
Scheme 2. Calculation of the strength of the central bond in [1.1.1]propellane as performed 
by Wiberg.3 
 
On the other hand some observations seem to contradict the existence of the central bond: It 
was discovered that the electron density at the bond critical point of the bridge bond is 
                                               
7 a) J. E. Jackson, L. C. Allen, J. Am. Chem. Soc. 1984, 106, 591-599; b) D. Feller, E. R. 
Davidson, J. Am. Chem. Soc. 1987, 109, 4133-4139. 
8 P. Seiler, Helv. Chim. Acta 1990, 73, 1574-1585. 
9 L. Hedberg, K. Hedberg, J. Am. Chem. Soc. 1985, 107, 7257-7260. 
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depleted, as indicated by a positive Laplacian ∇2ρ(r) of the electron density ρ(r).10 The 
Laplacian is the sum of all unmixed partial derivatives in the Cartesian coordinates xi and 








The bond critical point refers to a maximum, minimum or saddle point of the charge density 
along the binding path between two atoms.11 A positive Laplacian of the electron density at 
the bond critical point is typically associated with ionic bonds. As the central bond is formed 
between two identical atoms with identical electronegativity one would however expect it to 
be of covalent nature.12 In addition, [1.1.1]propellane also displays a negative total overlap 
population, which according to Mulliken points at an anti-bonding interaction.13 Molecular 
orbital calculations resulted in a closed-shell singlet state with the HOMO being a bonding 
molecular orbital connecting the bridgehead atoms, and the LUMO being its anti-bonding 
counterpart.14 However, the HOMO has an overall destabilizing character, as evidenced by 
the fact that it gets stabilized when the central bond is stretched.7a,14 In addition, the removal 
of electron density from the HOMO, either through ionization to the radical cation or through 
halogen bonding, results in a shortening of the bridge bond.7b,15 
 
1.1.3 The Central Bond in [1.1.1]Propellane as a Charge-Shift Bond 
A possible explanation for the seemingly contradicting properties of the central bond in 
[1.1.1]propellane was proposed by Shaik et. al. who classified it as a “charge-shift bond”:16 In 
modern valence bond (VB) theory the VB wave function Ψ(VB) of a bond A-X is seen as a 
combination of a covalent form Φcov (A∙-∙X), which is stabilized via spin pairing, and two ionic 
forms Φion(A+X−) and Φ’ion(A−X+), which are stabilized via electrostatic interactions 
(equation 2): 
                                               
10 M. Messerschmidt, S. Scheins, L. Grubert, M. Plätzel, G. Szeimies, C. Paulmann, P. 
Luger, Angew. Chem. Int. Ed. 2005, 44, 3925-3928. 
11 K. B. Wiberg, R. F. W. Bader, C. D. H. Lau, J. Am. Chem. Soc. 1987, 109, 985-1001. 
12 Y. Yang, J. Phys. Chem. A 2012, 116, 10150-10159. 
13 M. D. Newton, J. M. Schulman, J. Am. Chem. Soc. 1972, 94, 773-778. 
14 W. D. Stohrer, R. Hoffmann, J. Am. Chem. Soc. 1972, 94, 779-786. 
15 a) E. Honegger, H. Huber, E. Heilbronner, W. P. Dailey, K. B. Wiberg, J. Am. Chem. Soc. 
1985, 107, 7172-7174; b) J. Joy, E. Akhil, E. D. Jemmis, Phys. Chem. Chem. Phys. 2018, 
20, 25792-25798. 
16 a) S. Shaik, D. Danovich, B. Silvi, D. L. Lauvergnat, P. C. Hiberty, Chem. Eur. J. 2005, 11, 
6358-6371; b) S. Shaik, D. Danovich, W. Wu, P. C. Hiberty, Nat. Chem. 2009, 1, 443-449. 
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Ψ(VB) = c1Φcov + c2Φion + c3Φ’ion (2) 
In conventional covalent or ionic bonds only one of these three terms constitutes the majority 
of the bonding energy. Even in polar-covalent bonds the bonding energy is typically mostly 
attributed to Φcov with one of the ionic terms being of secondary importance. However, in 
some cases, for example in the F2 and HF molecules, this simplified description is not able to 
correctly describe the bonding situation, as there is a significant amount of covalent-ionic 
mixing. This mixing leads to a resonance energy stabilization, the “charge-shift resonance 
energy” (REcs), which is defined as the energy difference between the ground state and the 
major VB structure (either covalent or ionic). Bonds in which the REcs contributes to more 
than 50% of the overall bonding energy are considered charge-shift bonds.16 Shaik et. al. 
calculated Φcov to be the predominant component of the central bond in [1.1.1]propellane with 
a weight of 62%. The two ionic components each have a weight of 19%. However, the 
calculated energy of the covalent VB structure of [1.1.1]propellane at the experimentally 
determined bridgehead bond length of 1.6 Å was +11 kcal∙mol−1, while the ground state lies 
at −61 kcal∙mol−1. Thus, the bridgehead bond in [1.1.1]propellane exhibits an exceptionally 
large REcs of 72 kcal∙mol−1 and can be classified as a charge-shift bond. In addition, the 
covalent VB structure was found to be repulsive with its energy decreasing when the 
bridgehead bond is stretched from 1.6 to 1.8 Å. Only when accounting for REcs the calculated 
ground state correctly predicts the energetic minimum at the equilibrium distance of 1.6 Å 
(Figure 1). Such a discrepancy between the covalent dissociation curve and the ground state 
dissociation curve is also typical for charge-shift bonds.17 
                                               





Figure 1. Dissociation curves for the ground state, covalent VB structure and the nonbonding 
state of [1.1.1]propellane as calculated by Shaik at the BOVB level.17 
 
1.2 From [1.1.1]Propellane to Bicyclo[1.1.1]pentanes 
A consequence of the unique bonding situation in [1.1.1]propellane is its “omniphilic” 
reactivity towards cations, anions as well as radicals.18 While the reactions with cationic 
reagents typically result in a mostly unselective cage fragmentation,19 the reactions with 
anions20 and radicals21 result in the formation of bicyclo[1.1.1]pentanes (BCPs). This includes 
                                               
18 A. J. Sterling, A. B. Dürr, R. C. Smith, E. A. Anderson, F. Duarte, Chem. Sci. 2020, 11, 
4895-4903. 
19 a) K. B. Wiberg, W. P. Dailey, F. H. Walker, S. T. Waddell, L. S. Crocker, M. D. Newton, 
J. Am. Chem. Soc. 1985, 107, 7247-7257; b) D. Lasányi, G. L. Tolnai, Org. Lett. 2019, 21, 
10057-10062; c) S. Yu, A. Noble, R. B. Bedford, V. K. Aggarwal, J. Am. Chem. Soc. 2019, 
141, 20325-20334. 
20 a) R. Gianatassio, J. M. Lopchuk, J. Wang, C.-M. Pan, L. R. Malins, L. Prieto, T. A. Brandt, 
M. R. Collins, G. M. Gallego, N. W. Sach, J. E. Spangler, H. Zhu, J. Zhu, P. S. Baran, 
Science 2016, 351, 241-246; b) J. M. Lopchuk, K. Fjelbye, Y. Kawamata, L. R. Malins, C.-M. 
Pan, R. Gianatassio, J. Wang, L. Prieto, J. Bradow, T. A. Brandt, M. R. Collins, J. Elleraas, J. 
Ewanicki, W. Farrell, O. O. Fadeyi, G. M. Gallego, J. J. Mousseau, R. Oliver, N. W. Sach, J. 
K. Smith, J. E. Spangler, H. Zhu, J. Zhu, P. S. Baran, J. Am. Chem. Soc. 2017, 139, 3209-
3226; c) J. M. E. Hughes, D. A. Scarlata, A. C.-Y. Chen, J. D. Burch, J. L. Gleason, Org. Lett. 
2019, 21, 6800-6804; for the addition of organometallics see section 1.3. 
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the anionic strain-release aminations by Baran20a,b and Gleason,20c as well as the 
triethylborane catalyzed radical additions by Anderson21e (Scheme 3). 
 
Scheme 3. Strain-release amination20b and triethylboran catalyzed radical addition to 
[1.1.1]propellane.21e 
 
The bicyclo[1.1.1]pentane moiety has sparked a lot of interest in recent years as a bioisoster 
in pharmaceutical compounds. As the dihedral angle between the two substituents in a BCP 
derivative is 180° they have been explored as bioisosteres for both para-phenyl22 as well as 
                                                                                                                                                   
21 a) K. B. Wiberg, S. T. Waddell, K. Laidig, Tetrahedron Lett. 1986, 27, 1553-1556; b) K. B. 
Wiberg, S. T. Waddell, J. Am. Chem. Soc. 1990, 112, 2194-2216; c) J. Kanazawa, K. Maeda, 
M. Uchiyama, J. Am. Chem. Soc. 2017, 139, 17791-17794; d) R. M. Bär, S. Kirschner, M. 
Nieger, S. Bräse, Chem. Eur. J. 2018, 24, 1373-1382; e) D. F. J. Caputo, C. Arroniz, A. B. 
Dürr, J. J. Mousseau, A. F. Stepan, S. J. Mansfield, E. A. Anderson, Chem. Sci. 2018, 9, 
5295-5300; f) M. L. J. Wong, J. J. Mousseau, S. J. Mansfield, E. A. Anderson, Org. Lett. 
2019, 21, 2408-2411; g) J. Nugent, C. Arroniz, B. R. Shire, A. J. Sterling, H. D. Pickford, M. 
L. J. Wong, S. J. Mansfield, D. F. J. Caputo, B. Owen, J. J. Mousseau, F. Duarte, E. A. 
Anderson, ACS Catal. 2019, 9, 9568-9574; h) S. K. Rout, G. Marghem, J. Lan, T. Leyssens, 
O. Riant, Chem Commun. 2019, 55, 14976-14979; i) J. Nugent, B. R. Shire, D. F. J. Caputo, 
H. D. Pickford, F. Nightingale, I. T. T. Houlsby, J. J. Mousseau, E. A. Anderson, Angew. 
Chem. Int. Ed. 2020, 59, 11866-11870; j) J. H. Kim, A. Ruffoni, Y. S. S. Al-Faiyz, N. S. 
Sheikh, D. Leonori, Angew. Chem. Int. Ed. 2020, 59, 8225-8231. 
22 a) A. F. Stepan, C. Subramanyam, I. V. Efremov, J. K. Dutra, T. J. O’Sullivan, K. J. DiRico, 
W. S. McDonald, A. Won, P. H. Dorff, C. E. Nolan, S. L. Becker, L. R. Pustilnik, D. R. Riddel, 
G. W. Kauffman, B. L. Kormos, L. Zhang, Y. Lu, S. H. Capetta, M. E. Green, K. Karki, E. 
Sibley, K. P. Atchinson, A. J. Hallgreen, C. E. Oborski, A. E. Robshaw, B. Sneed, C. J. 
O’Donnell, J. Med. Chem. 2012, 55, 3414-3424; b) Y. P. Auberson, C. Brocklehurst, M. 
Furegati, T. C. Fessard, G. Koch, A. Decker, L. La Vecchia, E. Briard, ChemMedChem 2017, 
12, 590-598; c) Y. L. Goh, Y. T. Cui, V. Pendharkar, V. A. Adsool, ACS Med. Chem. Lett. 
2017, 8, 516-520. 
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alkyne23 moieties (Scheme 4), for example in resveratol (para-phenyl)22c or tazarotene 
(alkyne).23 When substituting the para-phenyl unit with a bicyclo[1.1.1]pentane a significant 
improvement of some physicochemical properties over multiple different examples was 
observed. This included a decrease in undesired nonspecific binding (NSB) as well as an 
increased water solubility.22b In addition, BCPs have been used as potential bioisosteres for 
terminal tert-butyl groups,24 as well as rigid-linear linkers in rods, liquid crystals, molecular 
rotors and polymers.25 
 
Scheme 4. Bicyclo[1.1.1]pentanes as bioisosteres of para-phenyl22c and alkyne23 moieties. 
 
1.3 Addition of Organometallic Compounds to [1.1.1]Propellane 
The first successful addition of organometallic reagents to [1.1.1]propellane was described in 
1998 by S. Guffler in his Ph.D. thesis under the guidance of G. Szeimies.26 His work included 
the addition of several aryl and alky Grignard reagents to [1.1.1]propellane, a reactivity that 
was further developed by de Meijere,27 Knochel,23 Aggarwal28 and Cossy.29 The main 
                                               
23 I. S. Makarov, C. E. Brocklehurst, K. Karaghiosoff, G. Koch, P. Knochel, Angew. Chem. Int. 
Ed. 2017, 56, 12774-12777. 
24 a) M. R. Barbachyn, D. K. Hutchinson, D. S. Toops, R. J. Reid, G. E. Zurenko, B. H. Yagi, 
R. D. Schaadt, J. W. Allison, Bioorg. Med. Chem. Lett. 1993, 3, 671-676; b) M. V. Westphal, 
B. T. Wolfstädter, J.-M. Plancher, J. Gatfield, E. M. Carreira, ChemMedChem 2015, 10, 461-
469. 
25 a) A. M. Dilmaç, E. Spuling, A. de Meijere, S. Bräse, Angew. Chem. Int. Ed. 2017, 56, 
5684-5718; b) G. M. Locke, S. S. R. Bernhard, M. O. Senge, Chem. Eur. J. 2019, 25, 4590-
4647. 
26 S. Guffler, Wege zu 1,3-disubstituierten Bicyclo[1.1.1]pentanen: synthetische und mecha-
nistische Aspekte, Ph.D. thesis, Humboldt-Universität Berlin, 1998. 
27 M. Messner, S. I. Kozhushkov, A. de Meijere, Eur. J. Org. Chem. 2000, 1137-1155. 
28 a) S. Yu, C. Jing, A. Noble, V. K. Aggarwal, Angew. Chem. Int. Ed. 2020, 59, 3917-3921; 
b) S. Yu, C. Jing, A. Noble, V. K. Aggarwal, Org. Lett. 2020, 22, 5650-5655. 
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advantage of this methodology is the formation of BCP-Grignards, which can be further 
functionalized to access a multitude of different BCP derivatives. The range of reported 
follow-up reactions includes nickel- and palladium-catalyzed cross couplings,23,27 three-
component couplings with organoboronic esters,28a iridium-catalyzed asymmetric allylic 
substitutions,28b copper-catalyzed alkylations,29 and the reaction with ethyl chloroformate23 
(Scheme 5). 
 
Scheme 5. Addition of Grignard reagents to [1.1.1]propellane followed by different 
functionalizations.23,26-29 
 
In addition, some reactions of [1.1.1]propellane with organo-alkali reagents have been 
reported: Aggarwal et. al. achieved a successful addition of secondary and tertiary 
alkyllithium reagents, whereas primary alkyllithiums were unreactive at −78 °C and let to 
polymerization at elevated temperatures.28a Walsh et. al. developed a synthetic route towards 
BCP benzylamines by adding 2-azaallyllithiums to [1.1.1]propellane, followed by an acidic 
work-up (Scheme 6a).30 The same group also reported the addition of sodium 2-aryl-1,3-
                                                                                                                                                   
29 C. Andersen, V. Ferey, M. Daumas, P. Bernardelli, A. Guérinot, J. Cossy, Org. Lett. 2020, 
22, 6021-6025. 
30 R. A. Shelp, P. J. Walsh, Angew. Chem. Int. Ed. 2018, 57, 15857-15861. 
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dithiyl anions, leading to BCP dithianes, which could easily be transformed into either BCP 
ketones or gem-difluoro BCPs31 (Scheme 6b). 
 
Scheme 6. Addition of 2-azaallyllithiums30 and sodium 2-aryl-1,3-dithiyl anions31 to 
[1.1.1]propellane. 
 
1.4 Organozinc Reagents 
Organozinc reagents were among the first synthesized organometallic reagents, with 
E. Frankland reporting the formation of ethyl zinc iodide and diethylzinc starting from ethyl 
iodide and granulated zinc in 1849.32 
Due to the significantly higher electronegativity of zinc (1.65 calculated according to the 
Pauling scale) compared to lithium (0.98) or magnesium (1.31),33 the carbon-metal bond in 
organozinc reagents is less polarized, which results in a lower reactivity (Figure 2). This 
leads to an increased functional group tolerance, allowing for clean reactions in the presence 
of moieties that would be attacked by organomagnesium or organolithium reagents, such as 
                                               
31 N. Trongsiriwat, Y. Pu, Y. Nieves-Quinones, R. A. Shelp, M. C. Kozlowski, P. J. Walsh, 
Angew. Chem. Int. Ed. 2019, 58, 13416-13420. 
32 E. Frankland, Liebigs Ann. Chem. 1849, 71, 171-213. 
33 a) L. Pauling, J. Am. Chem. Soc. 1932, 54, 3570-3582; b) A. L. Allred, J. Inorg. Nucl. 
Chem. 1961, 17, 215-221. 
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carbonyl compounds or nitriles.34 This functional group tolerance is even observed in the 
case of allylic organozinc reagents, which are significantly more reactive than alkylic, 
aromatic or even benzylic organozinc reagents, due to the higher ionic character of the allylic 
carbon-zinc bond.35 
 
Figure 2. Comparison of the electronegativities of lithium, magnesium and zinc according to 
Pauling.33 
 
There are three main ways to synthesize organozinc reagents.36 The most common strategy 
is the oxidative insertion of elemental zinc into organic halides.37 These reactions are 
especially successful if activated zinc is utilized, which can be generated through the 
reduction of zinc chloride with lithium naphthalenide (Rieke-zinc).38 Another way to improve 
                                               
34 a) R. Dieter, Tetrahedron 1999, 55, 4177-4236; b) T. Harada in The Chemistry of 
Organozinc Compounds (Ed.: I. M. Zvi Rappoport), John Wiley & Sons, Ltd, Chichester, UK, 
2007, pp. 685-711; c) P. Knochel, H. Leuser, L.-Z. Cong, S. Perrone, F. F. Kneisel in 
Handbook of Functionalized Organometallics (Ed. P. Knochel), John Wiley & Sons, Ltd, New 
York, United States, 2008, pp. 251-346. 
35 a) G. Courtois, A. Al-Arnaout, L. Miginiac, Tetrahedron Lett. 1985, 26, 1027-1030; b) P. 
Knochel, R. Singer, Chem. Rev. 1993, 93, 2117-2188; c) M. Nakamura, A. Hirai, M. Sogi, E. 
Nakamura, J. Am. Chem. Soc. 1998, 120, 5846-5847; d) I. Marek, G. Sklute, Chem. 
Commun. 2007, 1683-1691; e) H. Ren, G. Dunet, P. Mayer, P. Knochel, J. Am. Chem. Soc. 
2007, 129, 5376-5377; f) M. Ellwart, P. Knochel, Angew. Chem. Int. Ed. 2015, 54, 10662-
10665; g) Y. Dembélé, C. Belaud, P. Hitchcock, J. Villiéras, Tetrahedron Asymmetry 1992, 3, 
351-354; h) V. Nyzam, C. Belaud, F. Zammattio, J. Villiéras, Tetrahedron Asymmetry 1996, 
7, 1835-1843; i) C. Sämann, P. Knochel, Synthesis 2013, 45, 1870-1876. 
36 D. Haas, J. M. Hammann, R. Greiner, P. Knochel, ACS Catal. 2016, 6, 1540-1552. 
37 G. Dagousset, C. Francois, T. Leon, R. Blanc, E. Sansiaume-Dagousset, P. Knochel, 
Synthesis 2014, 46, 3133-3171. 
38 a) R. D. Rieke, R. T.-J. Li, T. P. Burns, S. T. Uhm, J. Org. Chem. 1981, 46, 4323-4324; 
b) L. Zhu, R. M. Wehmeyer, R. D. Rieke, J. Org. Chem. 1991, 56, 1445-1453; c) R. D. Rieke, 
M. V. Hanson, J. D. Brown, Q. J. Niu, J. Org. Chem. 1996, 61, 2726-2730; d) R. D. Rieke, 
Science 1989, 246, 1260-1264. 
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the insertion of elemental zinc into organic halides is the addition of lithium chloride to the 
reaction mixture (Scheme 7).39 
 
Scheme 7. Synthesis of organozinc reagents via oxidative insertion.39 
 
A further well-established way towards organozinc reagents is the transmetalation of lithium 
or magnesium organometallics with different zincII salts. This reactivity stems from the higher 
electronegativity of zinc compared to the other metals. Thus, the resulting organozinc 
reagent and the formed metal salt are thermodynamically more stable than the starting 
materials (Scheme 8).40 
 
Scheme 8. Synthesis of organozinc reagents via transmetalation.40 
 
                                               
39 a) A. Krasovskiy, V. Malakov, A. Gavryushin, P. Knochel, Angew. Chem. Int. Ed. 2006, 45, 
6040-6044; b) N. Boudet, S. Sae, P. Sinha, C.-Y. Liu, A. Krasovskiy, P. Knochel, J. Am. 
Chem. Soc. 2007, 129, 12358-12359. 
40 a) R. F. W. Jackson in Organozinc Reagents – A Practical Approach (Eds.: P. Knochel, P. 
Jones), Oxford University Press, Oxford, UK, 1999, pp. 37-56; b) S. Lemaire, I. N. Houpis, T. 
Xiao, J. Li, E. Digard, C. Gozlan, R. Liu, A. Gavryushin, C. Diène, Y. Wang, V. Farina, P. 
Knochel, Org. Lett. 2012, 14, 1480-1483. 
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Finally, the directed metalation of unsaturated, aromatic and heterocyclic molecules using 
various zinc TMP bases (TMP = 2,2,6,6-tetramethylpiperidyl) gives access to the corres-
ponding zinc reagents (Scheme 9).41 
 
Scheme 9. Synthesis of organozinc reagent via directed metalation.41 
 
  
                                               
41 a) T. Bresser, P. Knochel, Angew. Chem. Int. Ed. 2011, 50, 1914-1917; b) A. Unsinn, M. J. 
Ford, P. Knochel, Org. Lett. 2013, 15, 1128-1131; the different TMP bases are discussed in 




Unlike organomagnesium or organolithium reagents, an addition of organozinc halides to 
[1.1.1]propellane has not yet been reported. Indeed, preliminary experiments showed that 
alkyl-, aryl- and benzylzinc halides were not able to react with [1.1.1]propellane even under 
harsh conditions (100 °C, up to 60 h). Since allylic zinc halides display an enhanced 
reactivity due to a more polar carbon-zinc bond,35 it was envisioned that they could add to 
[1.1.1]propellane, allowing the formation of zincated BCPs (Scheme 10a). Subsequent 
trapping with various electrophiles (EY) would then provide double functionalized BCPs. A 
similar reactivity would be expected for zinc enolates generated from ketones and esters,42 
leading to a different class of zincated BCPs, which could also be trapped with various 
electrophiles (Scheme 10b). The objective was to optimize conditions for these additions. 
Another goal was to utilize this new protocol to synthesize a BCP-bioisostere of the synthetic 
opioid pethidine, which could then be compared to the original drug. Finally, this 
unprecedented reactivity should be rationalized via density-functional theory calculations. 
 
Scheme 10. Addition of allylic zinc halides and ketone and ester zinc enolates to 
[1.1.1]propellane, followed by trapping with electrophiles (EY). 
  
                                               
42 a) J. Dekker, A. Schouten, P. H. M. Budzelaar, J. Boersma, G. J. M. van der Kerk, 
J. Organomet. Chem. 1987, 320, 1-12; b) G. K. Jarugumilli, C. Zhu, S. P. Cook, Eur. J. Org. 
Chem. 2012, 1712-1715; c) A. Baba, M. Yasuda, Y. Nishimoto in Comprehensive Organic 




3 Results and Discussion 
3.1 Optimization of Reaction Conditions 
Reaction conditions for the addition to [1.1.1]propellane (1) were optimized using allylzinc 
bromide complexed with lithium chloride (2a). Under the conditions, that had been optimized 
for the addition of arylmagnesium halides to [1.1.1]propellane23 (1, 2.0 equiv of 
organometallic species, 50 °C, 65 h or 100 °C, 3 h, Table 1, entries 1 and 2), the desired 
functionalized BCP 4a was obtained in 95-96% yield after a copper mediated acylation with 
benzoyl chloride. This indicates that the intermediary zincated BCP of type 3 is very stable 
even at high temperatures. Further reaction temperature variation showed that the addition 
was completed after only 2 hours at 25 °C (entries 3 and 4). In comparison, the reaction of 
alkyl- and arylmagnesium halides with [1.1.1]propellane (1) requires 3-7 days at 25 °C, 
resulting in moderate yields.26-29 A reduction of the amount of zinc reagent to 1.5 equivalents 
lowered the yield to 71% (entry 5).  
 
Table 1. Screening of reaction conditions for the addition of allyl zinc bromide complexed 
with lithium chloride (2a) to [1.1.1]propellane (1) followed by copper-catalyzed acylation. 
 
entry equivalents of 2a reaction conditions yield [%][a] 
1 2.0 50 °C, 65 h   96[b] 
2 2.0 100 °C, 3 h 95 
3 2.0 25 °C, 1 h 88 
4 2.0 25 °C, 2 h   96[b] 
5 1.5 25 °C, 2 h   71[c] 
[a] GC-yields using undecane as an internal standard. [b] Isolated yield of analytically pure product. [c] No yield 
improvement was observed after an additional hour of reaction time. 
 
Interestingly, when switching to cinnamylzinc bromide complexed with lithium chloride (2b), 
only the regioisomer 4b was obtained in 93% yield (Scheme 11). The structure of this 
product was confirmed via X-ray analysis and indicates an allylic rearrangement of the 
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organozinc species 2b during the reaction. The other regioisomer 4b’ with the phenyl group 
attached to the terminal position of the allylic system was not observed.43 
 
 
Scheme 11. Addition of cinnamyl zinc bromide complexed with lithium chloride (2b) to 
[1.1.1]propellane (1) and X-ray structure of the resulting product 4b. 
 
3.2 Addition of Allylic Organozinc Halides to [1.1.1]Propellane 
With the optimized procedure in hand, a variety of BCP-derivatives were prepared using 
allylzinc bromide (4a, 4c-4g, Scheme 12), cinnamylzinc bromide (4b, 4h, 4i) and cyclohex-2-
en-1-ylzinc bromide (4j), as well as allylic zinc reagents derived from terpenoids,35f,44 such as 
prenol (4k), geraniol (4l) and ()-myrtenol (4m, 4n), in 70-97% yield. In addition, allylic zinc 
                                               
43 A test reaction with prenylmagnesium chloride showed that the reaction of allylic 
magnesium halides with [1.1.1]propellane (1) is also much quicker than the reaction of alkyl 
or aryl magnesium halides and was completed within 2 h at room temperature. The exclusive 
formation of the regioisomer that results from an allylic rearrangement was observed. This 
suggests that the reactions of allylic zinc and magnesium reagents with [1.1.1]propellane 
proceed via the same mechanism. 
44 a) G. Courtois, A. Al-Arnaout, L. Miginiac, Tetrahedron Lett. 1985, 26, 1027-1030; b) P. 
Knochel, R. Singer, Chem. Rev. 1993, 93, 2117-2188; c) M. Nakamura, A. Hirai, M. Sogi, E. 
Nakamura, J. Am. Chem. Soc. 1998, 120, 5846-5847; d) I. Marek, G. Sklute, Chem. 
Commun. 2007, 1683-1691; e) H. Ren, G. Dunet, P. Mayer, P. Knochel, J. Am. Chem. Soc. 
2007, 129, 5376-5377. 
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reagents bearing functional groups such as an ester or a nitrile35 reacted smoothly, leading to 
the corresponding functionalized BCPs 4o-4q in 55-65% yield. In all cases, only a single 
regioisomer of the product was observed. The intermediate zincated BCPs of type 3 were 
successfully trapped using Negishi-type cross-couplings45 with electron-rich (4c, 4m), 
electron-deficient (4d, 4q) and heterocyclic (4e, 4o) halides in 59-97% yield,46 as well as 
thiolations with S-aryl (4f) and S-alkyl sulfonothioates (4i)47 in 90-95% yield. A cobalt-
catalyzed electrophilic amination with N,N-diallyl-O-benzoylhydroxylamine48 provided the 
aminated BCP 4g in 91% yield. Finally, the zincated BCPs of type 3 underwent copper-
mediated allylations and acylations using various allylic halides and acid chlorides,49 leading 
to the functionalized BCPs 4a, 4b, 4h, 4j, 4k, 4l, 4n and 4p in 55-97% yield. 
                                               
45 A. O. King, N. Okukado, E.-I. Negishi, J. Chem. Soc. Chem. Commun. 1977, 19, 683-684. 
46 Without CuCN2LiCl as a cocatalyst the yields of the cross-coupling were approximately 
50% lower. CuI was a significantly less effective cocatalyst than CuCN2LiCl. 
47 K. Fujiki, N. Tanifuji, Y. Sasaki, T. Yokoyama, Synthesis 2002, 3, 343-348. 
48 a) Y.-H. Chen, S. Graßl, P. Knochel, Angew. Chem. Int. Ed. 2018, 57, 1108-1111; b) S. 
Graßl, Y.-H. Chen, C. Hamze, C. P. Tüllmann, P. Knochel, Org. Lett. 2019, 212, 494-497. 




Scheme 12. Addition of allylic zinc halides of type 2 to [1.1.1]propellane (1) yielding the 




When employing the allenic zinc reagent 2i, which is in equilibrium with the propargylic zinc 
reagent 2j,50 a separable mixture of the allenic product 4r (50% yield) and the propargylic 
product 4s (45% yield) was obtained after a copper-mediated acylation with benzoyl chloride 
(2.5 equiv, Scheme 13). This leads to the assumption, that both of the isomeric zinc reagents 
2i and 2j react with [1.1.1]propellane (1) with similar reaction rates. 
 
Scheme 13. Addition of an equilibrium mixture of the allenic zinc reagent 2i and the 
propargylic zinc reagent 2j to [1.1.1]propellane (1) yielding the functionalized BCPs 4r and 
4s. 
 
3.3 Addition of Zinc Enolates to [1.1.1]Propellane 
In order to generate zinc enolates ketones of type 5 were treated with an equimolar amount 
of LDA (6) at 78 °C, followed by the same amount of ZnCl2. The resulting zinc enolates 
added smoothly to [1.1.1]propellane (1, 0.5-2 h, 0 °C, Scheme 14). However, the newly 
generated zincated BCPs were mostly protonated before they could be trapped with 
electrophiles, probably due to the competitive deprotonation of the acidic protons in 
-position to the carbonyl group. This problem was solved by using 2 equivalents of LDA for 
1 equivalent of the ketone, followed by transmetalation with ZnCl2 (2.3 equiv), presumably 
                                               
50 a) J. A. Marshall, B. W. Gung, M. L. Grachan in Modern Allene Chemistry, Vol. 1 (Eds.: N. 
Krause, A. S. K. Hashmi), Wiley-VCH, Weinheim, 2004, pp. 493-592; b) J. A. Marshall in The 
Chemistry of Organozinc Compounds Vol. 1 (Eds.: Z. Rappoprt, I. Marek), John Wiley & 
Sons, Inc., Hoboken, 2006, pp.:421-455; c) D. R. Fandrick, J. Saha, K. R. Fandrick, S. 




leading to mixed zinc enolates coordinated with NiPr2 (7). The zincated BCPs of type 8 that 
resulted from the addition of these amidozinc enolates to [1.1.1]-propellane (1, 0.5-2 h, 0 °C, 
Scheme 14) were apparently much less prone to protonation compared to the standard 
zincated BCPs.51 Alternatively, the additional amide might also deprotonate the ketone 
products, thus removing the acidic protons. Possible trapping reactions included protonation 
(9a, 9g), copper-catalyzed allylations (9b, 9f, 9h, 9i), a palladium-catalyzed Negishi-type 
cross-coupling (9c),45 an acylation (9d) and a cyanation performed with tosyl cyanide (9e). 
The overall yield of the sequence including enolate addition and electrophilic trapping was 
46-88%. In the case of cyclohexyl acetone and dihydro--ionone a regioselective enolate 
formation was achieved and only the products 9f and 9g, in which the BCP unit is attached to 
the terminal methyl groups, were obtained in 67-71% yield. Moreover, the sterically hindered 
isobutyrophenone was added to 1, leading to the BCP-derivative 9h in 86% yield. The 
reaction with cyclohex-2-en-1-one led to the formation of the expected cyclohexenone 
derivative 9i in 75% yield. 
                                               
51 The enhanced stability of the zincated BCPs towards protonation in the presence of 
additional amide is reminiscent to the effect observed for organozinc pivalates. For reference 
see: a) C. I. Stathakis, S. Bernhardt, V. Quint, P. Knochel, Angew. Chem. Int. Ed. 2012, 51, 
9428-9432; b) A. Hernán-Gómez, E. Herd, E. Hevia, A. R. Kennedy, P. Knochel, K. 
Koszinowski, S. M. Manolikakes, R. E. Mulvey, C. Schnegelsberg, Angew. Chem. Int. Ed. 
2014, 53, 2706-2710; c) S. M. Manolikakes, M. Ellwart, C. I. Stathakis, P. Knochel, Chem. 
Eur. J. 2014, 20, 12289-12297; d) Y.-H. Chen, M. Ellwart, V. Malakhov, P. Knochel, 




Scheme 14. Addition of zinc enolates of type 7 to [1.1.1]propellane (1) yielding the 
functionalized BCPs 9a-9i after electrophile trapping. 
 
When using esters (10a-10c, 2.0 equiv) as starting materials, only a slight excess of LDA (6, 
2.1 equiv) was necessary to achieve good overall yields (Scheme 15). The zinc enolates of 
type 11, obtained after transmetalation with ZnCl2 (2.5 equiv), added to [1.1.1]propellane (1, 
1.0 equiv) within 2.5 h at 25 °C. The resulting zincated BCPs of type 12 were subsequently 
submitted to a copper-catalyzed allylation with allyl bromide (2.5 equiv). Thus, ethyl 
propionate was converted to the BCP 13a in 75% yield. When using ethyl hept-6-enoate as a 
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starting material, the expected BCP 13b was isolated in 95% yield without any traces of 
radical ring-closure side-products. The reaction was also compatible with the benzylic ester 
ethyl 2-(4-bromophenyl)acetate, leading to the BCP 13c in 94% yield. 
 
Scheme 15. Addition of zinc enolates of type 11 to [1.1.1]propellane (1) yielding the 
functionalized BCPs 13a-13c. 
 
Finally, the -deprotonation of nitriles (14a-14c, 2.0 equiv) with LDA (6, 2.1 equiv) followed 
by a transmetalation with ZnCl2 (2.5 equiv) led to the formation of nitrile-stabilized carbanions 
of type 15,52 which added to [1.1.1]propellane (1) within 1-6 h at 25 °C. The resulting 
zincated BCPs of type 16 were then submitted to a copper-catalyzed allylation with allyl 
bromide (2.5 equiv, Scheme 16). This protocol was used to prepare BCP-derivatives of 
cyclohexanecarbonitrile (17a) and 2-phenylpropanenitrile (17b) in 51-96% yield. When using 
1-cyanocyclohexene as a starting material, the BCP 17c was isolated in 96% yield. This can 
                                               
52 a) S. Arseniyadis, K. S. Kyler, D. S. Watt in Organic Reactions, Vol. 31, (Eds.: W. G. 
Dauben), John Wiley & Sons, Inc., Hoboken, 1984, pp.: 1-344; b) X. Yang, F. F. Fleming, 
Acc. Chem. Res. 2017, 50, 2556-2568. 
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be explained due to a rearrangement after the initial deprotonation in the allylic position, 
resulting in the formation of the most stabilized anion.53 
 
Scheme 16. Addition of zincated nitriles of type 15 and their addition to [1.1.1]propellane (1) 
yielding the functionalized BCPs 17a-17c. 
 
3.4 Synthesis of BCP-Pethidine 
With the optimized procedure the synthesis of the BCP-analogue of the synthetic opioid 
pethidine54 was carried out (18, Scheme 17). The deprotonation of commercially available 
ethyl 1-methylpiperidine-4-carboxylate (19, 2.0 equiv) with LDA (6, 2.1 equiv) proceeded 
smoothly within 30 min at 78 °C in THF. After the addition of ZnCl2 (2.5 equiv) the resulting 
zinc enolate was reacted with [1.1.1]propellane (1, 1.0 equiv) at 0 °C for 2 h. The generated 
zincated BCP was trapped through the addition of a saturated aqueous solution of NH4Cl. 
The crude mixture was purified using column chromatography, affording the pethidine 
analogue 20 in 95% yield on a 1.5 mmol scale in a single step. The structure of the isolated 
product was confirmed by X-ray analysis. 
                                               
53 X. Yang, D. Nath, J. Morse, C- Ogle, E. Yurtoglu, R. Altundas, F. Fleming, J. Org. Chem. 
2016, 81, 4098-4102. 




Scheme 17. Synthesis and X-ray structure of BCP-pethidine 20. 
 
The impact of the substitution of the terminal phenyl group with a BCP unit was evaluated by 
measuring some physicochemical properties of the BCP-pethidine 20. The bioisoster was 
slightly more basic than the original drug 18, with the pKa of the conjugated acid increasing 
from 8.8 to 9.0. The lipophilicity was estimated by measuring the 1-octanol/water partition 
coefficient (logP) and the distribution coefficient at pH 7.4 (logD7.4) and comparing them to 
the literature values of pethidine (18).55 The measured logP (2.9) and logD7.4 (1.3) were very 
close to the reported values for pethidine (respectively 2.7 and 1.4). This indicates that the 
lipophilicity of the bioisoster 20 is similar to that of pethidine. Contrastingly, the substitution of 
an internal para-phenyl group with a BCP unit resulted in a significant decrease of the 
lipophilicity for a number of different drug candidates.22b Overall, in this case the substitution 
of the terminal phenyl group seems to have a relatively small impact on the physicochemical 
properties of the compound. 
                                               
55 a) L. Z. Benet, F. Broccatelli, T. I. Oprea, AAPS J. 2011, 13, 519-547; b) L. Xu, L. Li, J. 




3.5 NMR Studies 
To study the influence of lithium and zinc salts on [1.1.1]propellane (a) a series of 13C-NMR-
spectra was measured (Figure 3). All of the NMR samples were prepared in a mixture of THF 
and Et2O (1:1) with a sealed capillary tube filled with deuterated benzene (d) as NMR-
standard for shimming. All samples contained traces of bromobenzene (c) and dibutyl ether 
(b), which result from the preparation and distillation of the [1.1.1]propellane.56 
 
Figure 3. 13C-NMR spectra of [1.1.1]propellane solutions containing lithium and zinc salts (a 
= [1.1.1]propellane, b = Bu2O, c = PhBr, d = C6D6, e = 1,3,5-trimethoxybenzene). 
 
As a reference a sample of [1.1.1]propellane with the NMR-standard 1,3,5-trimethoxy-
benzene (e) was measured, showing the two expected signals of [1.1.1]propellane (a) at 1.0 
and 74.0 ppm. The addition of 2 equivalents of LiCl had no effect on the [1.1.1]propellane. 
However, the addition of 2 equivalents of ZnCl2 let to a complete decomposition of the 
                                               
56 See the experimental part of this thesis for a detailed procedure. 
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[1.1.1]propellane within 1 minute at room temperature as evidenced by the disappearance of 
the initial signals. A multitude of new signals between 35-55 ppm, 100-110 ppm and 130-
160 ppm hints at the formation of a complex mixture of different products. A decomposition of 
[1.1.1]propellane in the presence of Lewis acidic transition-metal ions has been reported by 
Wiberg in the case of AgBF4 and [Rh(CO)2Cl]2, leading to mixtures of different oligomers.6 
Interestingly, no decomposition was observed when the ZnCl2 was premixed with 
4 equivalents of LiCl in THF. This observation can be explained by assuming the formation of 
a zincate (Li+ZnCl3), which significantly reduces the Lewis acidity of the zinc. In addition, this 
leads to the conclusion that the complexes present in the solutions of allylic zinc halides (with 
or without complexated LiCl) are not Lewis acidic enough to cause the decomposition of 
[1.1.1]propellane, thus allowing the formation of the respective ring-opening products in high 
yields. 
 
3.6 DOSY Spectroscopy 
In order to explore the aggregation state of the allylic zinc reagents a DOSY (Diffusion-
Ordered NMR Spectroscopy) experiment was performed (Figure 4).57 Therefore, a solution of 
allylzinc bromide coordinated with lithium chloride in THF was prepared according to the 
procedure detailed in the experimental part of this thesis. The solvent was removed under 
high vacuum using a cooling trap and a small amount of the resulting solid was transferred to 
an NMR-tube under argon. In addition, 2,2,3,3,-tetramethylbutane (TMB), anthracene and 
tetrakis(trimethylsilyl)silane (0.06 mmol each) were added as internal standards. The solids 
were dissolved in 0.5 mL of THF-d8 and the sample was submitted to the DOSY-experiment 
(measured on a Bruker AV400TR with a 5 mm PABBO BB/19F-1H/19F/D Z-GRD 
Z863001/0025 probe at 400.13 MHz using TopSpin by Bruker Biospin, Karlsruhe; pulse 
sequence: ledbpgp2s, 32 scans; transformation was performed in MestreNova 12.0 using 
Peak Heights Fit). 
                                               




Figure 4. DOSY-NMR of allylzinc bromide coordinated with lithium chloride in THF-d8. 
 
The DOSY-spectrum showed a multitude of different signals (a-e) corresponding to the allylic 
protons between 4.5 and 6.0 ppm. The diffusion coefficients D of these signals ranged from 
6.43*106 to 4.51*106 cm2/s. The signals of the internal standards were used to determine a 




Figure 5. Internal calibration curve of the DOSY-spectrum of allylzinc bromide coordinated 
with lithium chloride. 
 
The multitude of allylic signals leads to the conclusion, that the solution contains various 
clusters of allylzinc bromide in different aggregation states. The molecular weights of these 
clusters were estimated with the help of the internal calibration curve (Table 2). 
 
Table 2. Diffusion parameters and calculated molecular weights for the different clusters 
present in allylzinc bromide coordinated with lithium chloride. 







THF-d7 1,83E05 4,737549 79,1 1,88 75 
TMB 1,30E05 4,886056 114,2 2,15 141 
Anthracene 1,23E05 4,9100949 178,2 2,19 156 
Si(SiMe3)4 8,43E06 5,0741724 320,8 2,50 313 
a 6,43E06 5,1917890 - 2,71 516±124 
b 5,82E06 5,2350770 - 2,79 620±149 
c 5,60E06 5,2518120 - 2,82 665±160 
d 5,08E06 5,2941363 - 2,90 796±191 
e 4,51E06 5,3458235 - 3,00 992±238 
 
When applying the internal calibration to the diffusion parameters of the standards, the 
calculated molecular weights deviate from the actual values by 3% (Si(SiMe3)4) to 24% 
(TMB). By assuming similar margins of error for the allylic organozinc clusters, the molecular 
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weights of the clusters a-e were estimated to range from 392 to 1230 g/mol. These molecular 
weights are significantly higher than the molecular weight of a monomer of allylzinc bromide 
coordinated by one equivalent of LiCl and THF-d8 (309 g/mol). Therefore, the DOSY 
experiments confirm the existence of oligomeric aggregates. A dimeric cluster of the formula 
(allylZnBr)2(LiCl)2(THF-d8)2 possesses a molecular weight of 618 g/mol, which is in good 
accordance with the value obtained for the signal b (620±149 g/mol). When substituting one 
of the allylzinc bromides by ZnBr2, the resulting cluster (allylZnBr)(ZnBr2)(LiCl)2(THF-d8)2 
weights 657 g/mol, which is close to the molecular weight determined for the signal c 
(665±160 g/mol). The signals d and e most likely correspond to more highly aggregated 
clusters. 
 
3.7 Density Functional Theory Calculations 
In order to rationalize the exquisite regioselectivity observed in transformations with 
unsymmetrically substituted allylic zinc species, theoretical calculations have been performed 
for the reaction of propellane (1) with prenylzinc bromide complexed with lithium chloride 
(2d), whose sole reaction product is the BCP 4k (Scheme 12). Following effectively the same 
protocol used in earlier studies of organozinc reagents,58 free energies in THF solution have 
been calculated at the SMD(THF)/B2PLYP/def2-TZVPP level of theory. Calculations start 
from the cubic cluster 21 assembled from 2 equivalents of LiCl, ZnBr2,59 and prenylzinc 
bromide (2d). Complexation of propellane to one of the zinc centres in 21 displaces one of 
the cluster bromide atoms and generates the adduct 22 in a mildly exergonic first step. 
Formation of the adduct 22 is accompanied by a minor degree of charge transfer from the 
propellane unit to the cluster 21 by 0.11 e, but leads to practically no change of the 
propellane structure itself.60 Backside attack of the prenyl side chain at the bound propellane 
unit through the transition state 23 then carries the system over to the product side, whose 
ultimate end point is the cubic cluster 24 located 42.7 kJ mol1 lower than the separate 
reactants. That the barrier for this reaction amounts to only 52 kJ mol1 demonstrates the 
intrinsic flexibility of the salt cluster that thus acts as a template for the reacting 
organozinc/propellane units. As can readily be seen from the 3D presentation of the 
transition state 23 in Figure 6, formation of the C-Zn bond is almost complete at 
                                               
58 M. Ellwart, I. S. Makarov, F. Achrainer, H. Zipse, P. Knochel, Angew. Chem. Int. Ed. 2016, 
44, 10502-10506. 
59 Small amounts of ZnBr2 are present in the allylic zinc reagents as a result of partial 
homocoupling during the zinc insertion. 
60 An extensive discussion of the bonding situation and charge distribution in selected 
intermediates can be found in the appendix of this thesis. 
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r(C-Zn) = 205 pm, while formation of the C-C bond between the propellane and prenyl units 
is still underway with r(C-C) = 203 pm. From the almost perfect alignment of both reacting 
bonds along the propellane axis it is also apparent, that the cluster template exerts practically 
no external strain onto the reacting fragments. The overall reaction cycle is completed by salt 
metathesis of the product cluster 24 with one equivalent of the prenylzinc reagent 2d, 
yielding the starting cluster 21 and the product organozinc species 3d (Scheme 18). This 
reaction is almost thermoneutral at G298 = 2.5 kJ mol1. 
 
Figure 6. Calculated geometries of [1.1.1]propellane coordinated to a cubic cluster 













The activation of propellane (1) by other cluster designs or through other activation modes 
has also been studied, but all of these variations are energetically less favourable than the 
reaction pathway shown in Scheme 18. This includes the reaction with a cluster containing 
the regioisomeric form of prenylzinc bromide, in which the zinc is located at the tertiary 
carbon atom. For this cluster the calculated reaction barrier was 43.6 kJ mol1 higher than the 
one detailed in Scheme 18. Therefore, the high regioselectivity can be attributed to a kinetic 
selectivity. A reaction pathway starting with the coordination of [1.1.1]propellane to lithium 
instead of zinc resulted in a reaction barrier that was 82.5 kJ mol1 higher than the one 






For the first part of this thesis the addition of various organozinc reagents to [1.1.1]propellane 
was investigated. This was first achieved using allylic organozinc halides (Scheme 19). The 
additions proceeded with an extraordinarily high stereoselectivity, as only the products 
resulting from an allylic rearrangement were observed. The resulting zincated BCPs were 
successfully trapped using Negishi-type cross-couplings, thiolations, cobalt-catalyzed 
electrophilic aminations, as well as copper-mediated allylations and acylations. The protocol 
showed a good tolerance of functional groups, such as esters and nitriles, due to the 
relatively low reactivity of the organozinc halides. 
 
Scheme 19. Summary of the addition of allylic organozinc halides to [1.1.1]propellane. 
 
The methodology was extended to various zinc enolates, prepared from ketones, esters and 
nitriles through the deprotonation with LDA, followed by a transmetalation with ZnCl2 
(Scheme 20). Once again the resulting zincated BCPs were submitted to different 
electrophilic trapping reactions, such as protonations, copper-catalyzed allylations, 
palladium-catalyzed Negishi-type cross-couplings, acylations and cyanations. The protocol 




Scheme 20. Summary of the addition of zinc enolates to [1.1.1]propellane. 
 
The high regioselectivity of the reaction was rationalized using DFT calculations, which 
showed that the allylic rearrangement proceeds via a cyclic transition state involving ZnBr2, 











Part II: Selective Metalation of Nitrogen Containing 





1.1 Nitrogen Containing Heterocycles 
Nitrogen containing heterocycles are extremely common in both medicinal as well as 
agricultural chemistry with 59% of all unique small-molecule drugs that were approved by the 
U.S. FDA (Food and Drug Administration) in 2014 containing at least one nitrogen 
heterocycle. Among them five- and six-membered rings are by far the most prevalent, with 
39% and 59% respectively.61 The abundance of nitrogen heterocycles in pharmaceutical 
compounds results from their often favourable influence on molecular properties such as 
lipophilicity, polarity, metabolic stability and toxicity.62 Thus, the development of new 
methodologies to access large libraries of substituted nitrogen containing heterocycles for 
pharmaceutical trials is of great interest. In this work the main focus was placed on the 
aromatic five-membered 1,3,4-oxadiazole and 1,2,4-triazole as well as on the fused 
heterocycle 1H-imidazo[1,2-b]pyrazole. 
 
1.2 Selective Metalation of Heterocycles using 2,2,6,6-Tetramethylpiperidyl 
(TMP) Bases 
Selective metalations are an attractive way to generate a large variety of functionalized 
heterocycles, as the resulting metalated heterocycles can be reacted with many different 
electrophiles. This methodology takes advantage of the generally low pka-values of protons 
in aromatic heterocycles (typically between 38 and 24).63 Historically, metalations were 
mostly conducted using strong lithium-reagents like nBuLi.64 However, their high 
nucleophilicity can lead to undesired side-reactions and thus significantly reduces the scope 
of possible substrates. A solution to this problem was achieved with the introduction of the 
less nucleophilic sterically hindered lithium amide bases like LDA and TMPLi.65 Due to their 
high reactivity the resulting lithiated heterocycles are usually only stable at low temperatures 
and tend to react with many important functional groups such as esters and nitriles even 
under mild conditions. Therefore, a variety of different magnesium and zinc TMP bases have 
                                               
61 E. Vitaku, D. T. Smith, J. T. Njardarson, J. Med. Chem. 2014, 57, 10257-10274. 
62 R. D. Taylor, M. MacCoss, A. D. G. Lawson, J. Med. Chem. 2014, 57, 5845-5859. 
63 M. Balkenhohl, H. Jangra, I. S. Makarov, S.-M. Yang, H. Zipse, P. Knochel, Angew. Chem. 
Int. Ed. 2020, 59, 14992-14999. 
64 H. Gilman, R. L. Bebb, J. Am. Chem. Soc. 1939, 61, 109-112. 
65 a) V. Snieckus, Chem. Rev. 1990, 90, 879-933; b) M. Schlosser, Angew. Chem. Int. Ed. 
2005, 44, 376-393. 
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been developed by Knochel et. al. over the last years.66-69 These bases can be used at 
significantly higher temperature compared to the lithium amide bases, while tolerating many 
functional groups. In order to avoid the aggregation of the TMP bases, which leads to poor 
solubility and a low protophilicity, most of them contain a stoichiometric amount of LiCl. The 
most prominent example is TMPMgCl∙LiCl, which was prepared by reacting TMPH with 
iPrMgCl∙LiCl and can be stored at room temperature under inert gas for multiple months 
without a significant drop in reactivity.66 For less activated substrates the bis-base 
(TMP)2Mg∙2LiCl has been developed.67 Both bases enable magnesiations of various 
heterocycles with excellent regio- and chemoselectivity at convenient temperatures 
(Scheme 21).66-69 
 
Scheme 21. Regio- and chemoselective functionalizations of heterocycles using 
TMPMgCl∙LiCl or (TMP)2Mg∙2LiCl. 
 
The use of milder zinc bases, such as TMPZnCl∙LiCl68 or (TMP)2Zn∙2MgCl2∙2LiCl,69 allows 
the functionalization of even more sensitive substrates and tolerates even aldehydes or nitro 
groups (Scheme 22). 
                                               
66 a) A. Krasovskiy, V. Krasovskaya, P. Knochel, Angew. Chem. Int. Ed. 2006, 45, 2958-
2961; b) N. Boudet, J. R. Lachs, P. Knochel, Org. Lett. 2007, 9, 5525-5528; c) M. Mosrin, P. 
Knochel, Org. Lett. 2008, 10, 2497-2500. 
67 G. C. Clososki, C. J. Rohbogner, P. Knochel, Angew. Chem. Int. Ed. 2007, 46, 7681-7684. 
68 a) M. Mosrin, P. Knochel, Org. Lett. 2009, 11, 1837-1840; b) L. Klier, T. Bresser, T. A. 
Nigst, K. Karaghiosoff, P. Knochel, J. Am. Chem. Soc. 2012, 134, 13584-13587. 
69 a) S. H. Wunderlich, P. Knochel, Angew. Chem. Int. Ed. 2007, 46, 7685-7688; b) Z. Dong, 





Scheme 22. Regio- and chemoselective functionalizations of heterocycles using 
TMPZnCl∙LiCl or (TMP)2Zn∙2MgCl2∙2LiCl. 
 
1.3 1,3,4-Oxadiazole 
Over the last decades the 1,3,4-oxadiazole scaffold gained a lot of attention in 
pharmaceutical research, as it was found to improve the physicochemical and 
pharmacokinetic properties of drugs. This includes an improved metabolic stability and water 
solubility. In addition, it is a good acceptor for hydrogen bonding and thus able to efficiently 
interact with many different receptors.70 Of particular interest is the application of 
1,3,4-oxadiazoles as bioisosteres of amides and esters: The heterocyclic core maintains the 
receptor binding profile of the carbonyl derivatives, while offering a higher lipophilicity, which 
helps in transmembrane diffusion (Scheme 23a). The spectrum of biological activities 
exhibited by 1,3,4-oxadiazole derivatives is very diverse and includes antibacterial, 
antimalarial, anti-inflammatory, antidepressive, anticancer, antiviral, antifungal and analgesic 
effects.70 Among them are raltegravir, which is used in the treatment of HIV,71 and the 
experimental anticancer drug zibotentan (Scheme 23b).72 
                                               
70 a) H. Khalilullah, M. J. Ahsan, M. Hedaitullah, S. Kahn, B. Ahmed, Mini-Rev. Med. Chem. 
2012, 12, 789-801; b) S. Bajaj, V. Asati, J. Singh, P. P. Roy, Eur. J. Med. Chem. 2015, 97, 
124-141; c) A. Hoshi, T. Sakamoto, J. Takayama, M. Xuan, M. Okazaki, T. L. Hartman, R. W. 
Buckheit Jr., C. Pannecouque, M. Cushman, Bioorg. Med. Chem. 2016, 24, 3006-3022; d) T. 
Glomb, K. Szymankiewicz, P. Świątek; Molecules 2018, 26, 3361-3376. 
71 V. Summa, A. Petrocchi, F. Bonelli, B. Crescenzi, M. Donghi, M. Ferrara, F. Fiore, C. 
Gardelli, O. G. Paz, D. J. Hazuda, P. Jones, O. Kinzel, R. Laufer, E. Monteagudo, E. 
Muraglia, E. Nizi, F. Orvieto, P. Pace, G. Pescatore, R. Scarpelli, K. Stillmock, M. V. Witmer, 
M. V.; M. Rowley, J. Med. Chem. 2008, 51, 5843-5855. 
72 C. D. Morris, A. Rose, J. Curwen, A. M. Hughes, D. J. Wilson, D. J. Webb, Br. J. Cancer 




Scheme 23. 1,3,4-Oxadiazoles as bioisosteres of esters and amides and their application in 
drugs. 
 
In addition, aromatic substituted 1,3,4-oxadiazoles have been widely used as electron-
transporting/hole-blocking materials or emitting layers in electroluminescent diodes and non-
linear optic materials as they provide high photoluminescence quantum yields and excellent 
thermal and chemical stabilities.73 
1,3,4-Oxadiazoles are mainly synthesized via two different pathways: the cyclodehydration of 
diacylhydrazines (Scheme 24a) and the oxidation of arylhydrazones (Scheme 24b).74 The 
synthesis of unsubstituted 1,3,4-oxadiazole is challenging and only in 2012 Aitken was able 
to develop a reliable method to access the parent heterocycle in acceptable yield via the 
cyclodehydration of N,N’-diformylhydrazine (Scheme 24c).75 
                                               
73 a) G. Hughes, M. R. Bryce, J. Mater. Chem. 2005, 15, 94-107; b) J. Han, J. Mater. Chem. 
C 2013, 1, 7779-7797. 
74 Ž. Jakopin, M. Sollner Dolenc, Curr. Org. Chem. 2008, 15, 850-898. 




Scheme 24. Synthesis of 1,3,4-oxadiazoles. 
 
1.4 1,2,4-Triazole 
1,2,4-Triazoles have been known for a long time, with the first reports dating back to the late 
19th century.76 The unsubstituted parent heterocycle exists in two tautomeric forms, with the 
hydrogen connected to the nitrogen in the 1- and 4-position respectively. Microwave, NMR 
and ab initio quantum mechanics studies showed that the 1H tautomer is significantly more 
stable and therefore predominates in both the gas phase as well as in solution.77 
The 1,2,4-triazole core exhibits some interesting properties for pharmaceutical and 
agricultural applications. It can act as both a hydrogen bond acceptor and donor and thus 
can significantly increase the solubility of compounds in polar solvents.78 Other favourable 
properties include a moderate dipole character and good stability towards chemical and 
metabolic degradation.79 1,2,4-Triazole derivatives have been used as linkers and 
bioisosteres of amides, esters, carboxylic acids and olefinic double bonds. Their activities 
include antimicrobial, anti-inflammatory, antitubercular, antianxiety, anticancer and antiviral 
                                               
76 a) J. A. Bladin, Ber. Dtsch. Chem. Ges. 1885, 18, 1544-1551; b) J. A. Bladin, Ber. Dtsch. 
Chem. Ges. 1886, 19, 2598-2604. 
77 a) K. T. Potts, Chem. Rev. 1961, 61, 87-127; b) J. R. Cox, S. Woodcock, I. H. Hillier, M. A. 
Vincent, J. Phys. Chem. 1990, 94, 5499-5501. 
78 R. Kaur, A. R. Dwivedi, B. Kumar, V. Kumar, Anticancer Agents Med. Chem. 2016, 16, 
465-489. 
79 S. Zhang, Z. Xu, C. Gao, Q.-C. Ren, L. Chang, Z.-S. Lv, L.-S. Feng, Eur. J. Med. Chem. 
2017, 138, 501-513. 
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effects.80 Examples include maraviroc, which is used in the treatment of HIV,81 the iron 
chelator deferasirox82 and alprazolam, which is used in the medication of anxiety disorders83 
(Figure 7).  
 
Figure 7. Commercial drugs containing a 1,2,4-triazole core. 
 
1.5 1H-Imidazo[1,2-b]pyrazole 
The synthesis of a 1H-imidazo[1,2-b]pyrazole derivative was first reported in 1973 by Elguero 
et. al..84 Since then 1H-imidazo[1,2-b]pyrazoles have attracted the attention of medicinal 
chemist due to their antimicrobial,85 anti-inflammatory86 and anticancer activities87 (Figure 8). 
                                               
80 a) R. Kharb, P. C. Sharma, M. S. Yar, J. Enzyme Inhib. Med. Chem. 2011, 26, 1-21; b) M. 
S. Malik, S. A. Ahmed, I. I. Althagafi, M. A. Ansari, A. Kamal, RSC Med. Chem. 2020, 11, 
327-348. 
81 P. Dorr, M. Westby, S. Dobbs, P. Griffin, B. Irvine, M. Macartney, J. Mori, G. Rickett, C. 
Smith-Burchnell, C. Napier, R. Webster, D. Armour, D. Price, B. Stammen, A. Wood, M. 
Perros, Antimicrob. Agents Chemother. 2005, 49, 4721-4732. 
82 U. Heinz, K. Hegetschweiler, P. Acklin, B. Faller, R. Lattmann, H. P. Schnebli, Angew. 
Chem. Int. Ed. 1999, 38, 2568-2570. 
83 J. B. Hester Jr., A. D. Rudzik, B. V. Kamdar, J. Med. Chem. 1971, 14, 1078-1081. 
84 J. Elguero, R. Jacquier, S. Mignonac-Mondon, J. Heterocycl. Chem. 1973, 10, 411-412. 
85 a) A. O. Abdelhamid, E. K. A. Abdelall, Y. H. Zaki, J. Heterocycl. Chem. 2010, 47, 477-482; 
b) M. V. Murlykina, M. N. Kornet, S. M. Desenko, S. V. Shishkina, O. V. Shishkin, A. A. 
Brazhko, V. I. Musatov, E. V. Van der Eycken, V. A. Chebanov, Beilstein J. Org. Chem. 
2017, 13, 1050-1063. 
86 A. H. Shridhar, G. Banuprakash, J. H. Hoskeri, Y. T. Vijaykumar, Int. Res. J. Pharm. 2017, 
8, 25-33. 
87 a) A. T. Baviskar, C. Madaan, R. Preet, P. Mohapatra, V. Jain, A. Agarwal, S. K. Guchhait, 
C. N. Kundu, U. C. Banerjee, P. V. Bharatam, J. Med. Chem. 2011, 54, 5013-5030; b) S. 
Grosse, V. Mathieu, C. Pillard, S. Massip, M. Marchivie, C. Jarry, P. Bernard, R. Kiss, G. 
Guillaumet, Eur. J. Med. Chem. 2014, 84, 718-730; c) A. Demjén, R. Alföldi, A. Angyal, M. 
Gyuris, L. Hackler Jr., G. J. Szebeni, J. Wölfling, L. G. Puskás, I. Kanizsai, Arch. Pharm. 




Figure 8. Examples of 1H-imidazo[1,2-b]pyrazoles with biological activities. 
 
In 1994 Vanotti et. al. reported a convenient synthesis of 1H-imidazo[1,2-b]pyrazole.88 In a 
later publication, they improved their strategy to allow the synthesis of up to 70 g of the 
heterocycle in a single batch. The first step of this route is the formation of ethyl 5-amino-1-
(2,2-diethoxyethyl)-1H-pyrazole-4-carboxylate through the reaction between (2,2-diethoxy-
ethyl)hydrazine and ethyl 2-cyano-3-ethoxyacrylate. This is followed by a saponification with 
sodium hydroxide. The resulting 5-amino-1-(2,2-diethoxyethyl)-1H-pyrazole-4-carboxylic acid 
is refluxed with 20% H2SO4 in ethanol, leading to the deprotection of the aldehyde, which 
then cyclizes onto the amine. The acidic reaction conditions also lead to a complete 
decarboxylation to generate the parent heterocycle (Scheme 25).89 The general strategy of 
forming 1H-imidazo[1,2-b]pyrazoles by annulating the imidazole ring onto a preformed 
pyrazole scaffold is also used in the vast majority of all reported syntheses of substituted 
variations of this heterocycle.90 
                                               
88 E. Vanotti, F. Fiorentini, M. Villa, J. Heterocycl. Chem. 1994, 31, 737-743. 
89 P. Seneci, M. Nicola, M. Inglesi, E. Vanotti, G. Resnati, Synth. Commun. 1999, 29, 311-
341. 
90 a) R. E. Khidre, B. F. Abdel-Wahab, O. Y. Alothman, J. Chem. 2014, 1-15; b) J. Khalafy, A. 
P. Marjani, F. Salami, Tetrahedron Lett. 2014, 55, 6671-6674; c) N. N. Kolos, B. V. Kibkalo, 











Due to its highly sensitive nature no metalations of unsubstituted 1,3,4-oxadiazole have been 
reported previous to this work. In the case of N-substituted 1,2,4-triazoles only the metalation 
with the very reactive and unselective base BuLi was known from literature.91 As the 
sterically hindered TMP bases have been successfully employed in the selective 
functionalization of a range of different heterocyclic substrates, they might also be able to 
achieve a full functionalization of the 1,3,4-oxadiazole (Scheme 26a) and 1,2,4-triazole 
scaffolds (Scheme 26b). The goal of this work was to find suitable conditions for the selective 
metalations of the different heterocycles, followed by reactions with various electrophiles with 
special emphasis on palladium-catalyzed Negishi-type cross-coupling reactions45 and 
copper-catalyzed electrophilic aminations using hydroxylamino benzoates.48 
 
Scheme 26. Stepwise functionalization of 1,3,4-oxadiazole and N-substituted 1,2,4-triazoles 
using TMP bases. 
 
As the 1H-imidazo[1,2-b]pyrazole scaffold is not as easily accessible as other heterocycles 
its functionalization has not yet been explored thoroughly. All of the reported syntheses of 
functionalized 1H-imidazo[1,2-b]pyrazoles install the substituents in a precursor of the 
heterocycle before the final cyclization.90 Therefore, it is very expensive and time consuming 
to synthesize a large library of these compounds. A selective bromination, followed by a 
bromine-magnesium exchange and a series of selective metalations using TMP bases might 
                                               
91 a) R. G. Micetich, P. Spevak, T. W. Hall, B. K. Bains, Heterocycles 1985, 23, 1645-1649; 
b) S. Ohta, I. Kawasaki, A. Fukuno, M. Yamashita, T. Tada, T. Kawabata, Chem. Pharma. 
Bull. 1993, 41, 1226-1231. 
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however give access to a large variety of different substitution patterns starting from the 
N-SEM-protected heterocycle without the need to synthesize multiple different precursors 
(Scheme 27). 
 




3 Results and Discussion 
3.1 Selective Functionalization of 1,3,4-Oxadiazole 
Preliminary studies have shown that in the case of 1,3,4-oxadiazole (25), the freshly 
prepared base TMP2Zn∙2LiCl (26)92 provided the best results, leading to a complete 
conversion after 5 min at 25 °C.93 The resulting zincated 1,3,4-oxadiazole 27 was 
subsequently submitted to Negishi-type cross-coupling (Scheme 28).45 A mixture of Pd(dba)2 
(3%) and XantPhos94 (3%) provided excellent results with a variety of electron-deficient aryl 
iodides at 25 °C, producing the desired cross-coupling products 28a-28e, 28h and 28i in 
73-98% yield. When employing electron-rich aryl iodides, Pd(PPh3)4 (7.5%) was the best 
catalyst and afforded the heterocycles 28f and 28g in 63-90% yield (50 °C, 2 h). Due to the 
relatively low reactivity of the intermediate organozinc species 27 various functional groups 
were tolerated, including an ester (28b), a chloride (28c), a nitrile (28d), an amine (28g) and 
a nitro group (28h). In addition, heterocyclic iodides, such as 6-iodoquinoline and 
2-iodothiophene, have been successfully coupled, providing the heterocycles 28j and 28k in 
92% yield. 
                                               
92 The base was prepared according to the procedure detailed in the experimental part of this 
thesis and used within 3 hours. A longer storage of the base reduced the yields significantly. 
93 For a detailed summary of the optimization see the experimental part of this thesis. 
94 M. Kranenburg, Y. E. M. van der Burgt, P. C. J. Kamer, P. W. N. M. van Leeuwen, 




Scheme 28. Zincation of 1,3,4-oxadiazole (25) using TMP2Zn2LiCl (26) followed by Negishi 
coupling leading to mono-substituted 1,3,4-oxadiazoles of type 28. 
 
With the mono-substituted 1,3,4-oxadiazoles of type 28 in hand, a second metalation using 
the freshly prepared base TMP2Zn∙2MgCl2∙2LiCl (29) was performed, resulting in a complete 
zincation within 20 min at 25 °C (Scheme 29). The zincated heterocycles 30 were then 
aminated at 25 °C using hydroxylamino benzoates48 in the presence of 15% Cu(OTf)2, 
providing a variety of aminated 1,3,4-oxadiazoles of type 31 in 54-98% yield. This sequence 
proceeded well with both electron-rich (31b, 31f, 31i, 31j) as well as electron-deficient (31c, 
31d, 31h) 1,3,4-oxadiazoles. The scope of hydroxylamino benzoates was also explored, 
including reagents derived from morpholine, diallyl amine, azepane and piperazine, leading 
to the products 31a-31g in 70-98% yield. In addition, a variety of amines bearing functional 
groups such as an ester (31h), a protected ketone (31i-31j) or an amide (31k) could be 




Scheme 29. Zincation of mono-substituted 1,3,4-oxadiazoles of type 28 using 
TMP2Zn2MgCl22LiCl (29) followed by electrophilic amination leading to aminated 
1,3,4-oxadiazoles of type 31. 
 
3.2 Selective Functionalization of 1,2,4-Triazoles 
In the case of N-propyl and N-benzyl 1,2,4-triazoles (32a, 32b) a complete magnesiation was 
achieved within 30 min at 0 °C using TMPMgCl∙LiCl (33) (Scheme 30). The resulting 
magnesiated triazoles of type 34 were trapped with a variety of electrophiles such as iodine, 
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allylic bromides, benzaldehyde and benzoyl chloride, providing the 5-substituted-
1,2,4-triazoles 35a-35h in 79-95% yield. In addition, a metalation with TMPZnCl∙LiCl (36) 
under the same conditions enabled Pd-catalyzed Negishi-type cross-couplings with both 
electron-rich (35i-35j) as well as electron-deficient aryl halides (35k) in 78-94% yield. Finally, 
zincation followed by copper-catalyzed electrophilic amination with hydroxylamino benzoates 
derived from morpholine, nipecotic acid and sertraline95 led to the 5-aminated-1,2,4-triazoles 
35l, 35m and 35n in 70-95% yield. 
 
Scheme 30. Metalation of N-substituted 1,2,4-triazoles of type 32 using TMPMgCl2LiCl (33) 
followed by electrophile trapping leading to functionalized 1,2,4-triazoles of type 35. 
                                               




Two approaches have been developed to prepare fully functionalized 1,2,4-triazoles of type 
37: On one hand a double magnesiation of N-propyl 1,2,4-triazole (32a) was achieved by 
using an excess of TMPMgCl∙LiCl (7, 4.0 equiv, 0 °C, 30 min). Subsequent trapping with 
cyclohexyl bromide provided the double allylated triazole 37a in 73% yield. In addition, 
transmetalation to zinc followed by a Negishi-type cross-coupling with 4-iodoanisole led to 
the formation of the double arylated triazole 37b in 52% yield (Scheme 31a). On the other 
hand, a second metalation of 5-substituted 1,2,4-triazoles of type 35 could be achieved using 
TMPMgCl∙LiCl (33, 2.0 equiv, 0 °C, 30 min) or TMPZnCl∙LiCl (36, 1.2 equiv, 0 °C, 30 min). 
This procedure was used to allylate the 3-amino triazole 35l as well as to aminate the 
3-anisyl triazole 35i, giving access to the fully functionalized triazoles 37c and 37d in 80% 
and 87% yield (Scheme 31b). 
 
Scheme 31. Double functionalization of N-propyl 1,2,4-triazole (32a) leading to fully 




Using the N-2-iodobenzyl protected 1,2,4-triazole 32c a copper catalyzed cyclization was 
performed after a zincation with TMPZnCl∙LiCl (36, 1.5 equiv, 0 °C, 30 min, Scheme 32). The 
cyclization was completed after 18 h at 40 °C and afforded 5H-[1,2,4]triazole[5,1-a]-
isoindole96 (38) in 94% yield. 
 
Scheme 32. Copper-catalyzed cyclization of a zincated 1,2,4-triazole. 
 
3.3 Functionalization of 1H-Imidazo[1,2-b]pyrazole 
As the NH-proton represents the most acidic position in 1H-imidazo[1,2-b]pyrazole (39), it 
was necessary to install a protection group on the nitrogen before attempting any 
metalations. The SEM group has previously used to protect imidazoles, pyrazoles and 
1,2,4-triazoles during a series of metalations as it is generally easy to introduce, stable to a 
wide variety of conditions and can be removed using conditions that tolerate other functional 
groups.97 The protection was achieved by first deprotonating 1H-imidazo[1,2-b]pyrazole (39) 
with 1.5 equivalents of sodium hydride in DMF, followed by the addition of 1.5 equivalents of 
SEMCl at 0 °C. After 100 minutes the reaction was worked up and purified via column 
chromatography to yield the SEM-protected 1H-imidazo[1,2-b]pyrazole 40 in 57% yield 
(Scheme 33). 
 
Scheme 33. SEM-protection of 1H-imidazo[1,2-b]pyrazole (39). 
 
                                               
96 N. Barbero, R. SanMartin, E. Domínguez, Org. Biomol. Chem. 2010, 8, 841-645. 
97 a) J. P. Whitten, D. P. Matthews, J. R. McCarthy, J. Org. Chem. 1986, 51, 1891-1894; 
b) N. Fugina, W. Holzer, M. Wasicky, Heterocycles 1992, 34, 303-314; c) C. Despotopoulou, 
L. Klier, P. Knochel, Org. Lett. 2009, 11, 3326-3329. 
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The first functionalization of the SEM-protected 1H-imidazo[1,2-b]pyrazole 40 was achieved 
via a bromination with N-bromosuccinimide in acetonitrile (Scheme 34). The reaction was 
extremely quick, with full conversion after only 10 minutes in acetonitrile. This can be 
attributed to the highly electron-rich nature of the system. It was also important to use exactly 
1.0 equivalents of N-bromosuccinimide, as even a slight excess led to the formation of a 
double brominated side-product. The reaction was also highly regioselective and only a 
single product (41), with the bromine in the 7-position, was isolated. This selectivity is in 
accordance with the behaviour of pyrazoles, where electrophilic aromatic halogenations 
favour the 4-position.98 The product had to be protected from light and heat during the work-
up and purification to avoid decomposition. It could however be stored at −30 °C for a month 
without any signs of decomposition. 
 
Scheme 34. Selective bromination of the SEM-protected 1H-imidazo[1,2-b]pyrazole 40 in the 
7-position. 
 
In order to access a wide range of different functionalizations in the 7-position, the 
brominated 1H-imidazo[1,2-b]pyrazole 41 was treated with iPrMgCl∙LiCl (42, 2.1 equiv, 0 °C 
to 25 °C, 1 h) in THF. The resulting magnesiated 1H-imidazo[1,2-b]pyrazole was successfully 
reacted with a variety of electrophiles (Scheme 35), including S-methyl sulfonothioate 
(43a),47 tosyl cyanide (43b) and TESCl (43c) in 76-96% yield. The addition of CuCN∙2LiCl 
allowed an allylation (43d) in 94% yield and the formation of the ethyl ester 43e with ethyl 
cyanoformate in 50% yield. Additional reactions included an acylation catalyzed by 
Pd(PPh3)4 (43f) in 60% yield and a range of Kumada-type cross-couplings with electron-
deficient (43g, 43h) and electron-rich (43i) iodides catalyzed by PEPPSI-iPr99 in 68-88% 
yield. 
                                               
98 a) M. McLaughlin, K. Marcantonio, C.-Y. Chen, I. W. Davies, J. Org. Chem. 2008, 73, 
4309-4312; b) R. Goikhman, T. L. Jacques, D. Sames, J. Am. Chem. Soc. 2009, 131, 3042-
3048. 
99 M. G. Organ, M. Abdel-Hadi, S. Avola, N. Hadei, J. Nasielski, C. J. O`Brien, C. Valente, 




Scheme 35. Selective functionalization of the 1H-imidazo[1,2-b]pyrazole 41 via bromine-
magnesium exchange leading to 7-functionalized 1H-imidazo[1,2-b]pyrazoles of type 43. 
 
In order to explore the further functionalization of the 1H-imidazo[1,2-b]pyrazole scaffold the 
substrate 43b with a nitrile in the 7-position was chosen as a starting material, as it could be 
synthesized in excellent yields even at a scale of more than 1 gram. Initially, conditions for a 
second bromination using N-bromosuccinimide in acetonitrile were explored (Scheme 36). 
This time the bromination was significantly slower and 2.0 equivalents of NBS were 
necessary to achieve a full conversion after 80 minutes at 25 °C. The bromination was highly 
selective, as only a single product 44 was isolated in 70% yield. The structure of 44 was 
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explored via 2D-NMR spectroscopy, which showed that the bromine was introduced in the 
3-position. 
 
Scheme 36. Selective bromination of the 1H-imidazo[1,2-b]pyrazole 43b using NBS. 
 
As the second bromination was significantly slower than the first one and required a large 
excess of NBS, the use of TMPMgCl∙LiCl (33, 1.5 equiv, −20 °C, 2 h) to achieve the second 
functionalization without needing to handle a sensitive bromide was explored instead 
(Scheme 37). The TMP base resulted in a selective magnesiation in the 3-position. The 
metalated 1H-imidazo[1,2-b] pyrazole was successfully reacted with a variety of electrophiles 
in 57-89% yield (45a-45j). This included a copper-catalyzed allylation (45a) in 65% yield, a 
thiolation with S-phenyl sulfonothioate (45b)47 in 69% yield and the reaction with ethyl 
cyanoformate (45c) in 65% yield. A transmetalation with ZnCl2 allowed a series of Negishi-
type cross-couplings45 in 57-89% yield (45d-45j). When electron-rich iodides where 
employed (45d, 45e), a mixture of Pd(OAc)2 (5%) and SPhos100 (10%) yielded the best 
results. For electron-deficient halides (45f-45i) the NHC catalyst PEPPSI-iPr (2%) performed 
significantly better. By increasing the reaction temperature from 40 °C to 60 °C, it was even 
possible to conduct the cross-coupling with a less reactive bromide instead of an iodide (45i). 
The use of the more active catalyst PEPPSI-iPent101 (3%) at 60 °C allowed the reaction with 
a highly functionalized iodide containing an α,β-unsaturated amide and an amine in 57% 
yield (45j). 
                                               
100 T. E. Barder, S. D. Walker, J. R. Martinelli, S. L. Buchwald, J. Am. Chem. Soc. 2005, 127, 
4685-4696. 





Scheme 37. Selective metalation of the 1H-imidazo[1,2-b]pyrazoles 43b using 
TMPMgCl∙LiCl (33) followed by electrophile trapping leading to 3-substituted 1H-imidazo-
[1,2-b]pyrazoles of type 45. 
 
The third functionalization was optimized using ethyl 7-cyano-1-((2-(trimethylsilyl)ethoxy)-
methyl)-1H-imidazo[1,2-b]pyrazole-3-carboxylate (45c) as a substrate (Scheme 38). An initial 
screening showed, that the bis-base (TMP)2Zn∙MgCl2∙2LiCl (46, 0.65 equiv), prepared from 
TMPLi through the addition of half an equivalent each of a freshly prepared MgCl2 and ZnCl2 
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solution in THF, yielded the best results. The metalation targeted selectively the 2-position 
and was completed after 30 minutes at 0 °C. The zincated 1H-imidazo[1,2-b]pyrazole was 
reacted in a copper-catalyzed allylation, yielding 72% of the corresponding product 47a. In 
addition, a series of copper-catalyzed acylations with aromatic (47b, 47c), aliphatic (47d) and 
heteroaromatic (47e) acyl chlorides was conducted in 61-81% yield. Finally, a range of 
Negishi-type cross-couplings catalyzed by Pd(PPh3)4 (5%) gave access to the products 47f-
47j in 50-69% yield. The scope of possible substrates included electron-deficient (47f, 47g), 
electron-rich (47h, 47i) and heterocyclic (47j) iodides. The low reactivity of the intermediate 
zinc species allowed the use of electrophiles containing sensitive functional groups, such as 




Scheme 38. Selective metalation of the 1H-imidazo[1,2-b]pyrazoles 45c using 
(TMP)2Zn∙MgCl2∙2LiCl (46) followed by electrophile trapping leading to 2-substituted 
1H-imidazo[1,2-b]pyrazoles of type 47. 
 
When attempting the final functionalization of a series of 2,3,7-trifunctionalized 1H-imidazo-
[1,2-b]pyrazoles of type 47 using (TMP)2Zn∙MgCl2∙2LiCl (46, 0.65 equiv), the starting 
materials were fully consumed within 30-150 minutes at 0 °C, without the addition of any 
electrophile (Scheme 39). TLC analysis of hydrolysed aliquots showed the formation of a 
single highly polar new spot in all cases. The new products of type 48 were purified via 
column chromatography on Florisil® and analysed via ESI mass spectrometry and NMR 
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spectroscopy. The data hinted at the presence of a previously unknown 1H,1'H,5H,5'H-6,6'-
biimidazo[1,2-b]pyrazolylidene core. The formation of this unusual new class of products can 
be explained through the attack of a zincated 1H-imidazo[1,2-b]pyrazole molecule on the 
6-position of a second 1H-imidazo[1,2-b]pyrazole unit. A second deprotonation then leads to 
the formation of the central double bond.102 A final aqueous work-up leads to the formation of 
the products 48a-48e in 67-96% yield. The reaction was successfully performed with 
1H-imidazo[1,2-b]pyrazoles containing aryl substituents with electron withdrawing (48a, 48b) 
and electron donating (48c) groups in the 2-position. Other substituents included a 3-thienyl 
(48d) and a benzoyl group (48e). 
 
Scheme 39. Treatment of 2,3,7-trifunctionalized 1H-imidazo [1,2-b]pyrazoles of type 47 with 
(TMP)2Zn∙MgCl2∙2LiCl (46) leading to 1H,1'H,5H,5'H-6,6'-biimidazo[1,2-b]pyrazolylidenes of 
type 48. 
 
Most of these novel 1H,1'H,5H,5'H-6,6'-biimidazo[1,2-b]pyrazolylidenes of type 48 exhibited 
fluorescence in solution when irradiated by UV-light (366 nm, Figure 9). The colour of the 
emitted light correlated with the structure of the substituents in the 2-positions: The electron 
                                               
102 The exact configuration of the central double bond remains to be determined. NMR-
spectroscopy confirms the presence of only a single conformer. 
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donating substituents in 48c and 48d led to the emission of blue light. The inductively 
electron withdrawing CF3-groups in 48b resulted in a green light, while the inductive and 
mesomeric electron withdrawal of the esters in 48a led to the emission of orange light. A 
solution of the compound 48e with benzoyl substituents in the 2-positions did not exhibit any 
fluorescence under the 366 nm UV-lamp. However, it showed a very intense yellow colour, 
hinting at a strong absorption in the blue range of visible light. 
 
Figure 9. Fluorescence of 1H,1'H,5H,5'H-6,6'-biimidazo[1,2-b]pyrazolylidenes of type 48 in 







The topic of the second part of this thesis was the metalation of various nitrogen containing 
heterocycles using TMP bases. This was first achieved in the case of 1,3,4-oxadiazole using 
the base TMP2Zn∙2LiCl (Scheme 40). The resulting zincated 1,3,4-oxadiazole was reacted in 
a series of Negishi-type cross-couplings with electron-deficient, electron-rich and heterocyclic 
iodides. The mono substituted 1,3,4-oxadiazoles were then metalated a second time using 
TMP2Zn∙2MgCl2∙2LiCl, followed by a series of copper-catalyzed electrophilic aminations 
using hydroxylamino benzoates. 
 
Scheme 40. Summary of the functionalization of 1,3,4-oxadiazole. 
 
N-propyl and N-benzyl 1,2,4-triazole were investigated as a second heterocyclic system 
(Scheme 41). In this case the first metalation was achieved using TMPMgCl∙LiCl or 
TMPZnCl∙LiCl. The metalated 1,2,4-triazoles were subsequently submitted to a variety of 
electrophilic trapping reactions, including copper-catalyzed allylations and acylations, as well 
as Negishi-type cross-couplings and copper-catalyzed electrophilic aminations. A second 




Scheme 41. Summary of the functionalization of 1,2,4-triazoles. 
 
Finally, the functionalization of 1H-imidazo[1,2-b]pyrazole was explored (Scheme 42). The 
free NH-group of the heterocycle was protected with a SEM-group. The first functionalization 
was achieved via a selective bromination in the 7-position using NBS, followed by a bromine-
magnesium exchange and different electrophilic trapping reactions. A second selective 
metalation in the 3-position was performed using TMPMgCl∙LiCl. The metalated 
intermediates could once again be reacted with a variety of electrophiles. The third 
metalation with (TMP)2Zn∙MgCl2∙2LiCl went selectively in the 2-position and allowed the 




Scheme 42. Summary of the functionalization of 1H-imidazo[1,2-b]pyrazole. 
 
The treatment of 2,3,7-trifunctionalized 1H-imidazo[1,2-b]pyrazoles with 
(TMP)2Zn∙MgCl2∙2LiCl let to the formation of a series of novel 1H,1'H,5H,5'H-6,6'-biimidazo-




















Part III: Experimental Section 
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1 General Considerations 
Unless otherwise stated all reactions were carried out under an argon atmosphere in flame-
dried glassware. Syringes which were used to transfer anhydrous solvents or reagents were 
purged with argon prior to use. Reactions at high temperatures containing volatile 
compounds were conducted in BIOTAGE microwave vials sealed with the appropriate caps 
(up to 3 mL total volume) or Ace pressure vials. Yields refer to isolated yields of compounds 
estimated to be >95% pure as determined by 1H-NMR (25 °C) and capillary GC. All reagents 
were obtained from commercial sources and used without further purification unless 
otherwise stated. Reaction mixtures were cooled using an acetone / dry ice bath and heated 
using an oil bath on a magnetic stirrer. The suspension formed during the work-up of 
reactions containing CuCN∙2LiCl was dissolved by adding appropriate amounts of 
concentrated aqueous ammonia solution. 
 
1.1 Solvents 
CH2Cl2 was predried over CaCl2 and distilled from CaH2 under nitrogen atmosphere. 
Et2O was predried over CaCl2 and passed through activated aluminium oxide (solvent 
purification system SPS-400-2 from Innovative Technologies Inc.) 
THF was continuously refluxed and freshly distilled from sodium benzophenone ketyl under 
nitrogen and stored over molecular sieves. 
All other solvents were purchased from chemical suppliers (Merck, Acros Organics) and 
used without further purification. 
Solvents for reaction workups and column chromatography were distilled prior to use. 
 
1.2 Reagents 
nBuLi and PhLi solutions in hexane or dibutyl ether were purchased from Albemarle or 
Merck and the concentration was determined by titration against N-benzylbenzamide in THF 
at 40 °C or 0 °C respectively.103 
                                               
103 A. F. Burchat, J. M. Chong, N. Nielsen, J. Organomet. Chem. 1997, 542, 281-283. 
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TMPH was purchased from Albemarle (Frankfurt, Germany), freshly distilled over CaH2 and 
stored under argon. 
Diisopropylamine was purchased from Acros Organics, freshly distilled over CaH2 and 
stored under argon. 
CuCN∙2LiCl solution (1.00 M in THF) was prepared by drying CuCN (8.96 g, 100 mmol, 
1.00 equiv) and LiCl (8.48 g, 200 mmol, 2.00 equiv) in a Schlenk-flask under vacuum for 5 h 
at 150 °C. After cooling to 25 °C, dry THF (100 mL) was added and the resulting mixture was 
stirred until the salts were dissolved. 
ZnCl2 solution (1.00 M in THF) was prepared by drying ZnCl2 (27.3 g, 200 mmol) in a 
Schlenk-flask under vacuum for 5 h at 150 °C. After cooling to 25 °C, dry THF (200 mL) was 
added and the resulting mixture was stirred until the salts were dissolved. 
iPrMgCl∙LiCl in THF was prepared by flame drying magnesium turnings (24 g, 1.0 mol, 
2.0 equiv) and anhydrous LiCl (25 g, 0.60 mol, 1.2 equiv) in a Schlenk-flask under vacuum at 
450 °C. After the addition of anhydrous THF (500 mL), iPrCl (39 g, 0.50 mol, 1.0 equiv) was 
added dropwise at 25 °C using a dropping funnel until the reaction started. Then the reaction 
mixture was cooled to 0 °C and the addition was continued overnight while allowing the flask 
to warm up to 25 °C. The remaining solids were filtered off and the iPrMgCl∙LiCl solution was 
titrated against iodine. 
TMPH was purchased from Albemarle (Frankfurt, Germany), freshly distilled over CaH2 and 
stored under argon. 
 
1.3 Chromatography 
Flash column chromatography was performed using silica gel 60 (40-63 μm, 230-400 
mesh ASTM), alumina 90 active acidic (63-200 μm, 70-230 mesh ASTM), or Florisil® PR 
grade (149-250 μm, 60-100 mesh) from Merck. The activity of the alumina was set to grade 
III by adding 4.5% distilled water and stirring at 40 °C for 2 h. 
Thin layer chromatography (TLC) was performed using aluminium plates covered with 
SiO2 (Merck 60, F–254). Spots were visualized by UV light irradiation and/or by staining of 
the TLC plate with one of the reagents below, followed by heating with a heat gun if 
necessary. 
• KMnO4 (0.3 g), K2CO3 (20 g) and KOH (0.3 g) in water (300 mL). 
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• Ce(SO4)2 (5.0 g), (NH4)6Mo7O24•4H2O (25 g) and conc. H2SO4 (50 mL) in water 
(450 mL). 
• Neat iodine absorbed on silica gel (no heating required). 
• Vanillin (15 g) and conc. H2SO4 (2.5 mL) in EtOH (250 mL). 
• p-Anisaldehyde (3.7 mL), conc. H2SO4 (5 mL) and acetic acid (1.5 mL) in EtOH 
(135 mL). 
Preparative HPLC purification was performed on an Agilent Technologies 1260 Infinity 
HPLC-System, consisting of two prep-pumps (acetonitrile/water, no additives), a MWD-
detector (210 nm wavelength, 40 nm bandwidth, ref-wavelength 400 nm, ref-bandwidth 100 
nm) and a fraction collector. Three different columns were used: 1) Kinetix EVO C18 5 μm 
column (length: 150 mm, diameter: 10 mm), 2) Kinetix EVO C18 5 μm column (length: 150 
mm, diameter: 21.2 mm) and 3) Waters XBridge Prep C8 5 μm column (length: 150 mm, 
diameter: 30 mm). 
 
1.4 Analytical Data 
NMR spectra were recorded on Bruker ARX 200, AC 300, WH 400 or AMX 600 instruments. 
Chemical shifts are reported as δ-values in ppm relative to the deuterated solvent peak: 
CDCl3 (δH: 7.26; δC: 77.16), DMSO-d6 (δH: 2.50; δC: 39.52), C6D6 (δH: 7.16; δC: 128.06) 
Acetone-d6 (δH: 2.05; δC: 206.26 / 29.84). For the observation of the observed signal 
multiplicities, the following abbreviations and combinations thereof were used: s (singlet), d 
(doublet), t (triplet), q (quartet) and m (multiplet). If not otherwise noted, the coupling 
constants given are either H-H or H-F coupling constants for proton signals and C-F coupling 
constants for carbon signals. In the cases where a steric centre is located next to a 
bicyclopentane core, the protons of the methylene groups in the BCP unit are diastereotopic 
and show the splitting pattern expected for the resulting [AB]3-system.  
Melting points are uncorrected and were measured on a Büchi B.540 apparatus.  
Infrared spectra were recorded from 4000-400 cm−1 on a Perkin Elmer Spectrum BX-59343 
instrument. For detection a Smiths Detection DuraSampl IR II Diamond ATR sensor was 
used. The main absorption peaks are reported in cm−1. 
Gas chromatographical analysis (GC) was performed with instruments of the type Hewlett-
Packard 6890 or 5890 Series II, using a column of the type HP 5 (Hewlett-Packard, 5% 
phenylmethylpolysiloxane; length: 10 m, diameter: 0.25 mm, film thickness 0.25 μm). The 
detection was accomplished using a flame ionization detector. Mass spectra (MS) and high 
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resolution mass spectra (HRMS) were recorded on a Finnigan MAT 95Q or Finnigan MAT 90 
instrument for electron impact ionization (EI). For the combination of gas chromatography 
with mass spectroscopic detection, a GC–MS of the type Hewlett-Packard 6890/MSD 5793 
networking was used (column: HP 5–MS, Hewlett–Packard; 5% phenylmethylpolysiloxane; 
length: 15 m, diameter: 0.25 mm, film thickness: 0.25 μm).  
Single crystals of compounds suitable for X-ray diffraction were obtained by slow 
evaporation of either EtOAc or CDCl3 solutions. The crystals were introduced into 
perfluorinated oil and a suitable single crystal was carefully mounted on the top of a thin 
glass wire. Data collection was performed with an Oxford Xcalibur 3 diffractometer equipped 
with a Spellman generator (50 kV, 40 mA) and a Kappa CCD detector, operating with Mo-Kα 
radiation (λ = 0.71071 Ǻ).  
Data collection was performed with the CrysAlis CCD software;104 CrysAlis RED software105 
was used for data reduction. Absorption correction using the SCALE3 ABSPACK multiscan 
method106 was applied. The structures were solved with SHELXS-97,107 refined with 
SHELXL-97108 and finally checked using PLATON.109 Details for data collection and structure 
refinement are summarized in the tables at the end of this document. 
The 1-octanol/water partitioning coefficient (logP) was determined using a miniaturized 
Shake-Flask equilibrium method. Prior to start the experiment the two phases were pre-
saturated, so “water-saturated 1-octanol” and “1-octanol-saturated water” were used. The 
samples were initially dissolved in DMSO as a 10 mM stock concentration. The samples and 
an internal standard were dispensed in a 1ml deepwell plate and DMSO is evaporated prior 
to be dissolved in 1-octanol at a target concentration of 150 µM by shaking at 1000 rpm for 
8 hours. The pH 7.4 buffer was added with a phase ratio K of 1 (where K = Vwater/Voctanol) and 
then the samples were shaken 4 hours on a shaker at 1000 rpm. The deepwell plate was 
centrifuged at 3000rpm prior to phase separation. A x10 dilution for the aqueous phase and a 
                                               
104 CrysAlis CCD, Oxford Diffraction Ltd., Version 1.171.27p5 beta (release 01-04-2005 
CrysAlis171.NET) (compiled Apr 1 2005, 17:53:34). 
105 CrysAlis RED, Oxford Diffraction Ltd., Version 1.171.27p5 beta (release 01-04-2005 
CrysAlis171.NET) (compiled Apr 1 2005, 17:53:34). 
106 SCALE3 ABSPACK – An Oxford Diffraction Program (1.0.4, gui:1.0.3) (C), Oxford 
Diffraction, Ltd., 2005. 
107 G. M. Sheldrick (1997) SHELXS-97: Program for Crystal Structure Solution, University of 
Göttingen, Germany. 
108 G. M. Sheldrick (1997) SHELXS-97: Program for the Refinement of Crystal Structures, 
University of Göttingen, Germany. 
109 A. L. Spek (1999) PLATON: A Multipurpose Crystallographic Tool, Utrecht University, 
Utrecht, the Netherlands. 
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x1000 dilution for the octanol phase are prepared and quantified by LC-HRMS against an 
internal standard (Dexamethasone) with a known logD = 1.9 with the following equation 3:110 




𝐴𝑛𝑎𝑙𝑦𝑡𝑒 𝑝𝑒𝑎𝑘 𝑎𝑟𝑒𝑎 𝑖𝑛 𝑜𝑐𝑡𝑎𝑛𝑜𝑙 ∗ 1000
𝐼𝑆 𝑝𝑒𝑎𝑘 𝑎𝑟𝑒𝑎 𝑖𝑛 𝑜𝑐𝑡𝑎𝑛𝑜𝑙
0.794⁄
⁄
𝐴𝑛𝑎𝑙𝑦𝑡𝑒 𝑝𝑒𝑎𝑘 𝑎𝑟𝑒𝑎 𝑖𝑛 𝑎𝑞𝑢𝑒𝑜𝑢𝑠 ∗ 10








Column used: Zorbax_SB_AQ 50 x 2.1 mm 1.8 µm – Column oven temperature = 50 °C 
Mobile phase: A= 100% water UHPLC grade + 0.08% formic acid. B = 100% ACN + 0.08% 
Formic acid. Flow rate = 0.5 ml/min. Gradient mode: starting at 95% A up to 95% B in 
0.5 min and kept constant during 1min before to restore initial conditions within 0.1 min. 
Vinj = 5 µl. Full MS acquisition mode – Full scan 130 to 1800 m/z and resolution = 35’000. 
[M+H]+ ion chromatogram was extracted for each compounds. 
Potentiometric ionization constants were determined on the commercial SiriusT3 
instruments (Pion-inc.com) as described by Takács-Novák et. al. 1997. Briefly, 0.3 to 1 mM of 
test solutions were titrated from pH 2 to 12 for bases or 12 to 2 for acids. Titrations were 
conducted at 25 °C and in 0.15 M ionic strength. Aqueous titrations were performed in 
triplicate in 0.15 M KCl, while sparingly soluble test compounds were titrated in 10-60 %wt 
methanol, 1,4-dioxane, or dimethyl sulfoxide co-solvent. A minimum of three titrations in 
varying amounts of cosolvent were performed for extrapolation to the aqueous pKa. For each 
titration, initial estimates of pKa values were obtained from Bjerrum difference plots (number 
of bound protons versus pH) and then were refined by a weighted non-linear least-squares 
procedure (Avdeef 1992, 1993) available in the instrument software. Experimental variability 
was determined from 389 duplicate measurements from different days and experimentalists, 
with a standard deviation of 0.28. 
  
                                               
110 Y. W. Low, F. Blasco, P. Vachaspati, Eur. J. Pharm. Sci. 2016, 92, 110-116. 
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2 Experimental Section Part I: Highly Regio-
selective Addition of Organozinc Reagents to 
[1.1.1]Propellane 
2.1 Preparation of Starting Materials 
The following reagents were prepared according to literature procedures: 1,1-dibromo-2,2-
bis(chloromethyl)cyclopropane,111 N,N-diallyl-O-benzoylhydroxylamine,48 S-phenyl benzene-
sulfonothioate , S-methyl benzenesulfonothioate,112 ethyl 2-(bromomethyl)acrylate,113 ethyl 6-
chlorocyclohex-1-ene-1-carboxylate114, (1R)-myrtenyl bromide115 and 5-bromocyclopent-1-
enecarbonitrile.116 
 
Preparation of the solution of [1.1.1]propellane (1) in diethyl ether 
 
In a dry Schlenk-flask 1,1-dibromo-2,2-bis(chloromethyl)cyclopropane (5.9 g, 20 mmol, 
1.0 equiv) was dissolved in Et2O (20 mL) and cooled to 45 °C. Phenyllithium (1.8 M in 
dibutyl ether, 22 mL, 40 mmol, 2.0 equiv) was added dropwise over 15 min using a syringe 
pump. The resulting mixture was stirred for 5 min at 45 °C and 2 h at 0 °C. Then an argon 
flushed distillation head connected to a collector Schlenk-tube immersed into an acetone/ dry 
ice bath (T = 78 °C) was attached and the distillation was started at 200 mbar. The reaction 
flask was removed from the ice bath and the pressure was gradually lowered to 45 mbar. 
After approximately 30 min the distillation was stopped and the system was filled with argon. 
An aliquot (0.1 mL) of the solution was analysed by NMR spectroscopy with 
1,3,5-trimethoxybenzene (16.8 mg, 0.10 mmol) as a standard to determine the concentration. 
                                               
111 K. R. Mondanaro, W. P. Dailey, Org. Synth. 1998, 75, 98-101. 
112 K. Fujiki, N. Tanufuji, Y. Sasaki, T. Yokoyama, Synthesis 2002, 3, 343-348. 
113 J. Caillé, M. Pantin, F. Boeda, M. S. M. Pearson-Long, P. Bertus, Synthesis 2019, 51, 
1329-1341. 
114 Z. Peng, T. D. Blümke, P. Mayer, P. Knochel, Angew. Chem. Int. Ed. 2010, 49, 8516-
8519. 
115 R. K. de Richter, M. Bonato, M. Follet, J.-M. Kamenka, J. Org. Chem. 1990, 55, 2855-
2860 




The average concentration of the [1.1.1]propellane solution was 0.5-0.7 M. The solution was 
stored at 25 °C under argon. 
 
General procedure for the preparation of allylic organozinc reagents of type 2 in THF 
A Schlenk-flask was loaded with zinc dust (2.0 equiv) and lithium chloride (1.2 equiv) and 
flame dried with a heat gun under vacuum at 450 °C. Once the flask was cooled down it was 
filled with argon and THF (1 mL/mmol halide). The zinc was activated by adding a drop of 
1,2-dibromoethane and heating until a slight gas evolution started. Then the reaction mixture 
was cooled to 0 °C and the respective organohalide (1.0 equiv) was added dropwise. The 
reaction mixture was stirred over night while slowly warming up to room temperature. The 
remaining zinc dust was removed using a syringe filter and the concentration was 
determined via titration against iodine.117 
 
2.2 Typical Procedures 
TP1: Typical procedure for the reaction of allylic organozinc reagents of type 2 with 
[1.1.1]propellane (1) followed by electrophile addition 
 
A BIOTAGE Microwave vial under argon was loaded with the allylic organozinc reagent in 
THF (0.40 mmol, 2.0 equiv), followed by [1.1.1]propellane in diethyl ether (0.20 mmol, 
1.0 equiv). The vial was sealed and stirred at the respective temperature (25 °C / 50 °C / 
100 °C) for the indicated amount of time. Then the reaction mixture was cooled down to room 
temperature and the electrophile was added. The reaction was stirred until GCMS analysis 
showed full conversion. Afterwards a saturated aqueous solution of NH4Cl (1 mL) was added 
and the reaction mixture was extracted with EtOAc (3 times), washed with brine, dried over 
MgSO4 and concentrated in vacuo. The crude product was purified via silica gel column 
chromatography using an appropriate mixture of i-hexane and EtOAc as eluent. 
                                               
117 A. Krasovskiy, P. Knochel, Synthesis 2006, 890-891. 
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TP2: Typical procedure for the reaction of zinc enolates of type 7 with 
[1.1.1]propellane (1) followed by electrophile addition 
 
Diisopropylamine (63 mg, 0.62 mmol, 3.1 equiv) was dissolved in THF (0.6 mL) and BuLi 
(2.55 M in hexane, 0.24 mL, 0.62 mmol, 3.1 equiv) was added dropwise at 0 °C. The mixture 
was stirred for 5 min and cooled to 78 °C. Then the ketone (0.30 mmol, 1.5 equiv) was 
added. After 30 min a solution of ZnCl2 in THF (1.0 M, 0.70 mL, 0.70 mmol, 3.5 equiv) was 
added and the mixture was stirred at 0 °C for 5 min before adding [1.1.1]propellane in diethyl 
ether (0.20 mmol, 1.0 equiv). After stirring at 0 °C or 25 °C for the indicated time the 
electrophile was added and the mixture was stirred until GCMS analysis showed full 
conversion. Then a saturated aqueous solution of NH4Cl (1 mL) was added and the reaction 
mixture was extracted with EtOAc (3 times), washed with brine, dried over MgSO4 and 
concentrated in vacuo. The crude product was purified via silica gel column chromatography 
using an appropriate mixture of i-hexane and EtOAc as eluent. 
 
TP3: Typical procedure for the reaction of zinc ester enolates of type 11 with 
[1.1.1]propellane (1) followed by electrophile addition 
 
Diisopropylamine (43 mg, 0.42 mmol, 2.1 equiv) was dissolved in THF (0.5 mL) and BuLi 
(2.55 M in hexane, 0.16 mL, 0.42 mmol, 2.1 equiv) was added dropwise at 0 °C. The mixture 
was stirred for 5 min and cooled to 78 °C. Then the ester (0.40 mmol, 2.0 equiv) was 
added. After 30 min a solution of ZnCl2 in THF (1.0 M, 0.50 mL, 0.50 mmol, 2.5 equiv) was 
added and the mixture was stirred at 0 °C for 5 min before adding [1.1.1]propellane in diethyl 
ether (0.20 mmol, 1.0 equiv). After stirring at 0 °C for 3 h the electrophile was added and the 
mixture was stirred until GCMS analysis showed full conversion. Then a saturated aqueous 
solution of NH4Cl (1 mL) was added and the reaction mixture was extracted with EtOAc 
(3 times), washed with brine, dried over MgSO4 and concentrated in vacuo. The crude 
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product was purified via silica gel column chromatography using an appropriate mixture of 
i-hexane and EtOAc as eluent. 
 
TP4: Typical procedure for the reaction of nitrile-stabilized zinc enolates of type 15 
with [1.1.1]propellane (1) followed by copper-catalyzed allylation 
 
Diisopropylamine (43 mg, 0.42 mmol, 2.1 equiv) was dissolved in THF (0.5 mL) and BuLi 
(2.55 M in hexane, 0.16 mL, 0.42 mmol, 2.1 equiv) was added dropwise at 0 °C. The mixture 
was stirred for 5 min and cooled to 78 °C. Then the nitrile (0.40 mmol, 2.0 equiv) was 
added. After 30 min a solution of ZnCl2 in THF (1.0 M, 0.50 mL, 0.50 mmol, 2.5 equiv) was 
added and the mixture was stirred at 0 °C for 5 min before adding [1.1.1]propellane in diethyl 
ether (0.20 mmol, 1.0 equiv). After stirring at 25 °C for the indicated time CuCN2LiCl in THF 
(1.0 M, 0.04 mL, 0.04 mmol, 20%) and allyl bromide (61 mg, 0.50 mmol, 2.5 equiv) were 
added and the mixture was stirred for 20 min at 25 °C. Then a saturated aqueous solution of 
NH4Cl (1 mL) was added and the reaction mixture was extracted with EtOAc (3 times), 
washed with brine, dried over MgSO4 and concentrated in vacuo. The crude product was 
purified via silica gel column chromatography using an appropriate mixture of i-hexane and 





(3-Allylbicyclo[1.1.1]pentan-1-yl)(phenyl)methanone was prepared according to TP1 using 
allylzinc bromide coordinated with lithium chloride (0.90 M, 0.44 mL, 0.40 mmol, 2.0 equiv). 
The reaction was stirred at 25 °C for 2 h before adding CuCN2LiCl in THF (1.0 M, 0.20 mL, 
0.20 mmol, 1.0 equiv) and benzoyl chloride (70 mg, 0.50 mmol, 2.5 equiv). The resulting 
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mixture was stirred at 25 °C for 4 h. Workup according to TP1 and purification via column 
chromatography (iHex / EtOAc = 49 / 1) afforded the desired compound 4a (41 mg, 
0.19 mmol, 96%) as a colorless liquid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 7.5, 1.2 Hz, 2 H), 7.53 (tt, J = 7.5, 1.2 Hz, 1 H), 7.43 (t, 
J = 7.5 Hz, 2 H), 5.82 – 5.68 (m, 1 H), 5.10 – 5.00 (m, 2 H), 2.30 (dt, J = 7.2, 1.2 Hz, 2 H), 
2.15 (s, 6 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 197.9, 136.8, 134.7, 132.9, 129.0, 128.5, 116.7, 53.4, 
45.0, 39.8, 36.5. 
MS (70 eV, EI) m/z (%): 212 (1) [M]+, 197 (11), 171 (23), 153 (11), 143 (10), 141 (11), 
128 (19), 105 (100), 91 (20), 79 (13), 77 (43). 
IR (ATR) ~ (cm-1): 3074, 2974, 2910, 2874, 1719, 1662, 1641, 1598, 1579, 1510, 1447, 
1340, 1302, 1289, 1267, 1204, 1176, 1086, 1070, 1025, 992, 912, 867, 759, 712, 692, 675. 




Phenyl(3-(1-phenylallyl)bicyclo[1.1.1]pentan-1-yl)methanone was prepared according to TP1 
using cinnamylzinc bromide coordinated with lithium chloride (0.53 M, 0.75 mL, 0.40 mmol, 
2.0 equiv). The reaction was stirred at 50 °C for 7 h before adding CuCN2LiCl in THF (1.0 M, 
0.20 mL, 0.20 mmol, 1.0 equiv) and benzoyl chloride (70 mg, 0.50 mmol, 2.5 equiv). The 
resulting mixture was stirred at 25 °C for 3 h. Workup according to TP1 and purification via 
column chromatography (iHex / EtOAc = 99 / 1) afforded the desired compound 4b (54 mg, 
0.19 mmol, 93%) as colorless crystals. The structure was confirmed via single crystal X-ray 
diffraction studies. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 7.96 (d, J = 7.1 Hz, 2 H), 7.53 (tt, J = 7.5, 2.0 Hz, 1 H), 
7.42 (t, J = 7.7 Hz, 2 H), 7.34 (t, J = 7.4 Hz, 2 H), 7.28 – 7.22 (m, 1 H), 7.18 (d, J = 6.8 Hz, 
2 H), 6.12 (ddd, J = 17.0, 10.3, 8.4 Hz, 1 H), 5.21 – 5.07 (m, 2 H), 3.50 (d, J = 8.4 Hz, 1 H), 
2.15 (A part of an [AB]3-system, 3 H), 2.09 (B part of an [AB]3-system, 3 H). 
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13C-NMR (CDCl3, 101 MHz, ppm): δ = 197.9, 141.3, 137.6, 136.7, 132.9, 129.0, 128.6, 
128.5, 128.0, 126.6, 116.6, 52.3, 51.7, 45.0, 43.5. 
MS (70 eV, EI) m/z (%): 287 (3) [MH]+, 183 (14), 171 (20), 168 (17), 167 (23), 165 (12), 155 
(20), 153 (30), 152 (12), 143 (15), 141 (38), 129 (14), 128 (55), 117 (33), 115 (61), 105 (100), 
91 (22), 77 (38). 
IR (ATR) ~ (cm-1): 2978, 1661, 1636, 1595, 1577, 1488, 1447, 1331, 1277, 1203, 1175, 
1069, 1022, 998, 931, 877, 839, 784, 759, 730, 699, 676. 
HRMS (EI) calculated for C21H19O+: 287.1430, found 287.1432 [MH]+. 




1-Allyl-3-(4-methoxyphenyl)bicyclo[1.1.1]pentane was prepared according to TP1 using 
allylzinc bromide coordinated with lithium chloride (0.90 M, 0.44 mL, 0.40 mmol, 2.0 equiv). 
The reaction was stirred at 50 °C for 3 h before adding 4-iodoanisole (117 mg, 0.50 mmol, 
2.5 equiv), PdCl2(dppf)CH2Cl2 (8.2 mg, 0.010 mmol, 5%) and CuCN2LiCl in THF (1.0 M, 
0.020 mL, 0.020 mmol, 10%). The resulting mixture was stirred at 45 °C for 3 h. Workup 
according to TP1 and purification via column chromatography (iHex / EtOAc = 99 / 1) and 
HPLC afforded the desired compound 4c (39 mg, 0.18 mmol, 92%) as a colorless liquid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 7.14 (d, J = 8.6 Hz, 2 H), 6.84 (d, J = 8.6 Hz, 2 H), 
5.79 (ddt, J = 17.3, 10.1, 7.2 Hz, 1 H), 5.09 – 4.97 (m, 2 H), 3.79 (s, 3 H), 2.30 (dt, J = 7.3, 
1.2 Hz, 2 H), 1.88 (s, 6 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 158.3, 135.8, 134.0, 127.2, 115.9, 113.6, 55.4, 52.2, 
41.9, 37.8, 36.9. 
MS (70 eV, EI) m/z (%): 214 (18) [M]+, 199 (42), 186 (97), 185 (34), 184 (33), 173 (43), 
171 (66), 159 (20), 158 (99), 155 (29), 148 (64), 145 (18), 144 (17), 141 (30), 133 (100), 




IR (ATR) ~ (cm-1): 2956, 2903, 2865, 2834, 1641, 1610, 1578, 1519, 1503, 1463, 1441, 
1413, 1353, 1294, 1263, 1243, 1172, 1132, 1098, 1037, 991, 908, 832, 801, 791, 666. 
HRMS (EI) calculated for C15H18O+: 214.1352, found 214.1350 [M]+. 
 
Ethyl 4-(3-allylbicyclo[1.1.1]pentan-1-yl)benzoate (4d) 
 
Ethyl 4-(3-allylbicyclo[1.1.1]pentan-1-yl)benzoate was prepared according to TP1 using 
allylzinc bromide coordinated with lithium chloride (0.90 M, 0.44 mL, 0.40 mmol, 2.0 equiv). 
The reaction was stirred at 50 °C for 3 h before adding 4-iodobenzoate (138 mg, 0.50 mmol, 
2.5 equiv), PdCl2(dppf)CH2Cl2 (8.2 mg, 0.010 mmol, 5%) and CuCN2LiCl in THF (1.0 M, 
0.020 mL, 0.020 mmol, 10%). The resulting mixture was stirred at 45 °C for 19 h. Workup 
according to TP1 and purification via column chromatography (iHex / EtOAc = 99 / 1) and 
HPLC afforded the desired compound 4d (50 mg, 0.19 mmol, 97%) as a colorless liquid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 7.96 (d, J = 8.3 Hz, 2 H), 7.25 (d, J = 8.3 Hz, 2 H), 
5.77 (ddt, J = 17.3, 10.2, 7.2 Hz, 1 H), 5.12 – 4.96 (m, 2 H), 4.36 (q, J = 7.1 Hz, 2 H), 2.31 
(dt, J = 7.2, 1.2 Hz, 2 H), 1.93 (s, 6 H), 1.38 (t, J = 7.1 Hz, 3 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 166.8, 146.6, 135.4, 129.6, 128.5, 126.2, 116.2, 60.9, 
52.2, 42.3, 38.2, 36.7, 14.5. 
MS (70 eV, EI) m/z (%): 256 (1) [M]+, 228 (20), 211 (11), 200 (13), 183 (16), 169 (10), 
168 (15), 167 (16), 165 (10), 156 (12), 155 (100), 154 (15), 153 (31), 152 (11), 145 (23), 
143 (30), 142 (20), 141 (94), 129 (27), 128 (60), 117 (11), 115 (52), 91 (24), 77 (11). 
IR (ATR) ~ (cm-1): 2964, 2906, 2868, 1713, 1641, 1610, 1445, 1407, 1367, 1307, 1266, 
1174, 1156, 1104, 1093, 1020, 991, 907, 857, 780, 755, 700. 






2-(3-Allylbicyclo[1.1.1]pentan-1-yl)pyridine was prepared according to TP1 using allylzinc 
bromide coordinated with lithium chloride (0.90 M, 0.44 mL, 0.40 mmol, 2.0 equiv). The 
reaction was stirred at 25 °C for 2 h before adding 2-bromopyridine (79 mg, 0.50 mmol, 
2.5 equiv), PdCl2(dppf)CH2Cl2 (8.2 mg, 0.010 mmol, 5%) and CuCN2LiCl in THF (1.0 M, 
0.020 mL, 0.020 mmol, 10%). The resulting mixture was stirred at 45 °C for 19 h. Workup 
according to TP1 and purification via column chromatography (iHex / EtOAc = 19 / 1) and 
HPLC afforded the desired compound 4e (26 mg, 0.14 mmol, 70%) as a colorless liquid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 8.54 (ddd, J = 4.9, 1.8, 0.9 Hz, 1 H), 7.60 (td, J = 7.7, 
1.8 Hz, 1 H), 7.17 (dt, J = 7.8, 1.1 Hz, 1 H), 7.11 (ddd, J = 7.6, 4.9, 1.2 Hz, 1 H), 5.78 (ddt, 
J = 17.2, 10.2, 7.2 Hz, 1 H), 5.10 – 4.98 (m, 2 H), 2.32 (dt, J = 7.2, 1.3 Hz, 2 H), 2.00 (s, 7 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 160.1, 149.3, 136.4, 135.4, 121.5, 120.8, 116.2, 51.9, 
43.1, 38.3, 36.7. 
MS (70 eV, EI) m/z (%): 184 (22) [MH]+, 170 (16), 168 (15), 158 (10), 156 (15), 154 (10), 
145 (10), 144 (100), 143 (32), 142 (15), 130 (13), 117 (17). 
IR (ATR) ~ (cm-1): 3076, 2967, 2907, 2869, 1641, 1589, 1567, 1514, 1474, 1432, 1362, 
1289, 1265, 1169, 1050, 992, 912, 788, 753, 698. 




(3-Allylbicyclo[1.1.1]pentan-1-yl)(phenyl)sulfane was prepared according to TP1 using 
allylzinc bromide coordinated with lithium chloride (0.90 M, 0.44 mL, 0.40 mmol, 2.0 equiv). 
The reaction was stirred at 50 °C for 3 h before adding S-phenyl benzenesulfonothioate 
(125 mg, 0.50 mmol, 2.5 equiv). The resulting mixture was stirred at 25 °C for 4 h. Workup 
according to TP1 and purification via column chromatography (iHex) afforded the desired 
compound 4f (41 mg, 0.19 mmol, 95%) as a colorless liquid. 
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1H-NMR (CDCl3, 400 MHz, ppm): δ = 7.39 – 7.32 (m, 2 H), 7.25 – 7.16 (m, 3 H), 5.65 – 5.49 
(m, 1 H), 4.96 – 4.78 (m, 2 H), 2.15 (d, J = 7.2 Hz, 2 H), 1.71 (s, 6 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 135.0, 134.3, 133.6, 128.8, 127.5, 116.4, 54.1, 42.4, 
40.3, 36.5. 
MS (70 eV, EI) m/z (%): 216 (10) [M]+, 188 (22), 173 (22), 147 (16), 142 (11), 141 (11), 
135 (31), 134 (14), 123 (11), 111 (10), 110 (21), 109 (16), 107 (35), 105 (27), 91 (100), 
79 (87), 77 (16), 10 (65). 
IR (ATR) ~ (cm-1): 3075, 2975, 2907, 2870, 1640, 1583, 1473, 1438, 1272, 1188, 1131, 
1091, 1066, 1024, 1011, 991, 912, 891, 741, 690. 




N,N,3-Triallylbicyclo[1.1.1]pentan-1-amine was prepared according to TP1 using allylzinc 
bromide coordinated with lithium chloride (0.90 M, 0.44 mL, 0.40 mmol, 2.0 equiv). The 
reaction was stirred at 50 °C for 3 h before adding CoCl2 (0.78 mg, 0.0060 mmol, 3%.) and 
N,N-diallyl-O-benzoylhydroxylamine (109 mg, 0.50 mmol, 2.5 equiv). The resulting mixture 
was stirred at 45 °C for 17 h. Workup according to TP1 and purification via column 
chromatography (iHex / EtOAc = 9 / 1) afforded the desired compound 4g (37 mg, 
0.18 mmol, 91%) as a colorless liquid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 5.85 (ddt, J = 16.8, 10.1, 6.5 Hz, 2 H), 5.70 (ddt, 
J = 17.2, 10.1, 7.1 Hz, 1 H), 5.18 – 5.04 (m, 4 H), 5.04 – 4.92 (m, 2 H), 3.15 (dt, J = 6.5, 
1.4 Hz, 4 H), 2.26 (dt, J = 7.1, 1.3 Hz, 2 H), 1.65 (s, 6 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 136.5, 135.9, 117.0, 115.8, 57.8, 53.0, 50.1, 35.6, 
34.9. 
MS (70 eV, EI) m/z (%): 202 (46) [MH]+, 188 (43), 174 (57), 172 (10), 163 (11), 162 (93), 
160 (62), 157 (10), 148 (23), 147 (16), 146 (53), 136 (22), 134 (55), 132 (54), 122 (36), 
121 (21), 120 (100), 118 (31), 106 (31), 105 (25), 94 (32), 93 (26), 91 (75), 81 (21), 80 (28), 
79 (84), 77 (42), 67 (21), 41 (71). 
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IR (ATR) ~ (cm-1): 3075, 2961, 2923, 2867, 1858, 1783, 1722, 1641, 1446, 1418, 1379, 
1277, 1237, 1113, 1047, 993, 913, 807, 712. 
HRMS (EI) calculated for C14H20N+: 202.1590, found 202.1590 [MH]+. 
 
Ethyl 2-((3-(1-phenylallyl)bicyclo[1.1.1]pentan-1-yl)methyl)acrylate (4h) 
 
Ethyl 2-((3-(1-phenylallyl)bicyclo[1.1.1]pentan-1-yl)methyl)acrylate was prepared according to 
TP1 using cinnamylzinc bromide coordinated with lithium chloride (0.53 M, 0.75 mL, 
0.40 mmol, 2.0 equiv). The reaction was stirred at 50 °C for 7 h before adding CuCN2LiCl in 
THF (1.0 M, 0.040 mL, 0.040 mmol, 20%) and ethyl 2-(bromomethyl)acrylate (97 mg, 
0.50 mmol, 2.5 equiv). The resulting mixture was stirred at 25 °C for 16 h. Workup according 
to TP1 and purification via column chromatography (iHex / EtOAc = 99 / 1) and HPLC 
afforded the desired compound 4h (54 mg, 0.19 mmol, 93%) as a colorless liquid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 7.28 (t, J = 7.3 Hz, 2 H), 7.19 (tt, J = 7.3, 2.1 Hz, 1 H), 
7.12 (d, J = 6.7 Hz, 2 H), 6.12 (d, J = 1.7 Hz, 1 H), 6.05 (ddd, J = 17.0, 10.3, 8.3 Hz, 1 H), 
5.42 (dt, J = 1.8, 1.0 Hz, 1 H), 5.11 – 4.97 (m, 2 H), 4.17 (q, J = 7.1 Hz, 2 H), 3.38 (d, J = 
8.3 Hz, 1 H), 2.48 (d, J = 0.9 Hz, 2 H), 1.46 (A part of an [AB]3-system, 3 H), 1.41 (B part of 
an [AB]3-system, 3 H), 1.28 (t, J = 7.1 Hz, 3 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 167.3, 142.2, 138.6, 138.5, 128.3, 128.0, 126.1, 
125.8, 115.6, 60.7, 52.0, 49.2, 42.5, 39.5, 34.9, 14.3. 
MS (70 eV, EI) m/z (%): 223 (5) [MCO2Et]+, 207 (19), 193 (14), 192 (11), 184 (11), 
183 (79), 181 (25), 179 (22), 178 (16), 168 (38), 167 (40), 166 (15), 165 (33), 155 (56), 
154 (10), 153 (26), 142 (19), 141 (86), 133 (35), 131 (23), 129 (42), 128 (59), 117 (65), 
116 (10), 115 (100), 107 (11), 105 (97), 103 (13), 91 (83), 79 (30), 77 (15). 
IR (ATR) ~ (cm-1): 2964, 2905, 2867, 1715, 1631, 1601, 1493, 1445, 1368, 1308, 1251, 
1234, 1155, 111, 1094, 1027, 943, 914, 859, 821, 755, 699. 






Methyl(3-(1-phenylallyl)bicyclo[1.1.1]pentan-1-yl)sulfane was prepared according to TP1 
using cinnamylzinc bromide coordinated with lithium chloride (0.53 M, 0.75 mL, 0.40 mmol, 
2.0 equiv). The reaction was stirred at 50 °C for 7 h before adding S-methyl benzene-
sulfonothioate (94 mg, 0.50 mmol, 2.5 equiv). The resulting mixture was stirred at 25 °C for 
16 h. Workup according to TP1 and purification via column chromatography (iHex / EtOAc = 
99 / 1) afforded the desired compound 4i (41 mg, 0.18 mmol, 90%) as a colorless liquid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 7.31 (t, J = 7.3 Hz, 2 H), 7.22 (tt, J = 7.3, 2.1 Hz, 1 H), 
7.14 (d, J = 6.8 Hz, 2 H), 6.06 (ddd, J = 17.0, 10.2, 8.3 Hz, 1 H), 5.17 – 5.02 (m, 2 H), 
3.47 (d, J = 8.4 Hz, 1 H), 2.03 (s, 3 H), 1.77 (A part of an [AB]3-system, 3 H), 1.72 (B part of 
an [AB]3-system, 3 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 141.6, 137.9, 128.4, 127.9, 126.4, 116.3, 51.8, 51.6, 
43.6, 41.8, 13.7. 
MS (70 eV, EI) m/z (%): 215 (17), 202 (30), 187 (12), 183 (21), 181 (24), 168 (18), 167 (89), 
166 (17), 165 (28), 156 (12), 155 (100), 154 819), 153 (33), 152 (19), 142 (11), 141 (95), 
129 (15), 128 (30), 117 (12), 115 (59), 91 (37). 
IR (ATR) ~ (cm-1): 3027, 2975, 2906, 2870, 1637, 1601, 1492, 1451, 1317, 1259, 1195, 
1131, 1070, 1030, 990, 960, 915, 895, 840, 754, 715, 698, 660. 




1-(3-(Cyclohex-2-en-1-yl)bicyclo[1.1.1]pentan-1-yl)propan-1-one was prepared according to 
TP1 using cyclohex-2-en-1-ylzinc bromide coordinated with lithium chloride (0.34 M, 1.18 mL, 
0.40 mmol, 2.0 equiv). The reaction was stirred at 50 °C for 6 h before adding CuCN2LiCl in 
THF (1.0 M, 0.20 mL, 0.20 mmol, 1.0 equiv) and propionyl chloride (46 mg, 0.50 mmol, 
2.5 equiv). The resulting mixture was stirred at 25 °C for 1 h. Workup according to TP1 and 
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purification via column chromatography (iHex / EtOAc = 49 / 1) and HPLC afforded the 
desired compound 4j (38 mg, 0.19 mmol, 94%) as a colorless liquid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 5.73 (dtd, J = 10.0, 3.7, 2.6 Hz, 1 H), 5.54 – 5.46 (m, 
1 H), 2.46 (q, J = 7.3 Hz, 2 H), 2.22 – 2.13 (m, 1 H), 1.98 – 1.91 (m, 2 H), 1.89 – 1.80 (([AB]3-
system, 6 H), 1.71 – 1.64 (m, 2 H), 1.55 – 1.44 (m, 1 H), 1.31 – 1.20 (m, 1 H), 1.02 (t, J = 
7.3 Hz, 3 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 209.7, 128.4, 127.5, 49.6, 43.9, 42.4, 36.1, 32.0, 25.5, 
25.1, 21.3, 7.5. 
MS (70 eV, EI) m/z (%): 203 (2) [MH]+, 189 (12), 176 (41), 175 (45), 161 (65), 143 (33), 
133 (18), 117 (51), 105 (76), 91 (100), 77 (94). 
IR (ATR) ~ (cm-1): 3349, 2977, 2913, 2876, 1694, 1653, 1509, 1449, 1408, 1361, 1268, 
1170, 1020, 957, 890, 823, 733, 702. 




(3-(2-Methylbut-3-en-2-yl)bicyclo[1.1.1]pentan-1-yl)(phenyl)methanone was prepared 
according to TP1 using prenylzinc bromide coordinated with lithium chloride (0.61 M, 
0.66 mL, 0.40 mmol, 2.0 equiv). The reaction was stirred at 50 °C for 17 h before adding 
CuCN2LiCl in THF (1.0 M, 0.20 mL, 0.20 mmol, 1.0 equiv) and benzoyl chloride (70 mg, 
0.50 mmol, 2.5 equiv). The resulting mixture was stirred at 25 °C for 1 h. Workup according 
to TP1 and purification via column chromatography (iHex / EtOAc = 99 / 1) and HPLC 
afforded the desired compound 4k (47 mg, 0.19 mmol, 97%) as a colorless liquid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 8.02 – 7.94 (m, 2 H), 7.54 (tt, J = 7.4, 1.3 Hz, 1 H), 
7.44 (t, J = 7.6 Hz, 2 H), 5.81 (dd, J = 17.3, 10.9 Hz, 1 H), 5.03 – 4.93 (m, 2 H), 2.07 (s, 6 H), 
1.00 (s, 6 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 198.5, 144.6, 136.8, 132.9, 129.0, 128.5, 111.8, 50.2, 
47.3, 42.7, 36.0, 22.9. 
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MS (70 eV, EI) m/z (%): 225 (14) [MCH3]+, 171 (41), 153 (12), 143 (15), 128 (22), 
105 (100), 93 (10), 91 (18), 77 (41). 
IR (ATR) ~ (cm-1): 2965, 2910, 2874, 1663, 1638, 1598, 1579, 1509, 1461, 1448, 1414, 
1377, 1360, 1331, 1280, 1205, 1177, 1134, 1055, 1025, 1001, 913, 872, 820, 765, 694, 676. 





red according to TP1 using geranylzinc bromide coordinated with lithium chloride (0.40 M, 5.0 
mL, 2.0 mmol, 2.0 equiv) and [1.1.1]propellane dissolved in diethyl ether (0.43 M, 2.3 mL, 1.0 
mmol, 1.0 equiv). The reaction was stirred at 50 °C for 6 h before adding CuCN2LiCl in THF 
(1.0 M, 1.0 mL, 1.0 mmol, 1.0 equiv) and benzoyl chloride (353 mg, 2.5 mmol, 2.5 equiv). The 
resulting mixture was stirred at 25 °C for 17 h. Workup according to TP1 and purification via 
column chromatography (iHex / EtOAc = 49 / 1) and HPLC afforded the desired compound 4l 
(216 mg, 0.70 mmol, 70%) as a colorless liquid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 7.99 (d, J = 7.0 Hz, 2 H), 7.54 (tt, J = 7.5, 2.0 Hz, 1 H), 
7.43 (t, J = 7.6 Hz, 2 H), 5.67 (dd, J = 17.5, 10.8 Hz, 1 H), 5.16 – 5.04 (m, 2 H), 4.96 (dd, 
J = 17.5, 1.4 Hz, 1 H), 2.08 ([AB]3-system, 6 H), 1.94 – 1.78 (m, 2 H), 1.69 (d, J = 1.5 Hz, 
3 H), 1.59 (d, J = 1.4 Hz, 3 H), 1.41 – 1.24 (m, 2 H), 0.98 (s, 3 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 198.5, 142.9, 136.8, 132.9, 131.5, 129.0, 128.5, 
124.9, 113.5, 50.3, 47.5, 43.0, 39.2, 36.9, 25.9, 23.1, 17.8, 17.7. 
MS (70 eV, EI) m/z (%): 211 (7), 171 (10), 128 (10), 119 (12), 105 (100), 93 (9), 91 (19), 
77 (30). 
IR (ATR) ~ (cm-1): 2970, 2913, 2874, 1664, 1598, 1579, 1508, 1448, 1412, 1373, 1205, 
1176, 1143, 1025, 1001, 912, 873, 843, 765, 694, 676. 







clo[3.1.1]heptane was prepared according to TP1 using myrtenylzinc bromide coordinated 
with lithium chloride (0.43 M, 0.93 mL, 0.40 mmol, 2.0 equiv). The reaction was stirred at 
50 °C for 8 h before adding 4-iodoanisole (117 mg, 0.50 mmol, 2.5 equiv), 
PdCl2(dppf)CH2Cl2 (8.2 mg, 0.010 mmol, 5%) and CuCN2LiCl in THF (1.0 M, 0.020 mL, 
0.020 mmol, 10%). The resulting mixture was stirred at 45 °C for 15 h. Workup according to 
TP1 and purification via column chromatography (iHex / EtOAc = 99 / 1) and HPLC afforded 
the desired compound 4m (46 mg, 0.15 mmol, 75%) as colorless crystals. The structure was 
confirmed via single crystal X-ray diffraction studies. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 7.17 (d, J = 8.6 Hz, 2 H), 6.85 (d, J = 8.6 Hz, 2 H), 
4.71 (dt, J = 22.0, 1.9 Hz, 2 H), 3.80 (s, 3 H), 2.72 – 2.66 (m, 1 H), 2.42 (t, J = 5.4 Hz, 1 H), 
2.33 – 2.24 (m, 1 H), 2.05 – 1.95 (m, 2 H), 1.90 (s, 6 H), 1.78 (dt, J = 14.2, 3.5 Hz, 1 H), 1.26 
(s, 3 H), 1.19 (d, J = 9.9 Hz, 1 H), 0.77 (s, 3 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 158.2, 152.1, 134.1, 127.2, 113.6, 109.0, 55.4, 52.1, 
51.1, 43.5, 41.7, 40.5, 40.4, 36.2, 27.6, 27.4, 26.0, 21.7. 
MS (70 eV, EI) m/z (%): 308 (2) [M]+, 265 (12), 237 (18), 223 (13), 211 (11), 209 (12), 
197 (11), 185 (12), 173 (26), 171 (12), 165 (12), 159 (11), 158 (24), 157 (71), 148 (15), 
147 (13), 145 (13), 143 (20), 142 (36), 141 (13), 135 (54), 134 (10), 133 (40), 131 (41), 
130 (10), 129 (100), 128 (18), 121 (86), 117 (20), 115 (32), 105 (19), 91 (33), 79 (11), 
77 (10). 
IR (ATR) ~ (cm-1): 2948, 1918, 2865, 1636, 1608, 1578, 1519, 1501, 1455, 1380, 1366, 
1345, 1293, 1259, 1244, 1175, 1159, 1132, 1098, 1034, 934, 878, 857, 835, 822, 791, 697. 
HRMS (EI) calculated for C22H28O+: 308.2135, found 308.2136 [MH]+. 







tan-1-yl)methyl)acrylate was prepared according to TP1 using myrtenylzinc bromide 
coordinated with lithium chloride (0.43 M, 0.93 mL, 0.40 mmol, 2.0 equiv). The reaction was 
stirred at 50 °C for 8 h before adding CuCN2LiCl in THF (1.0 M, 0.040 mL, 0.040 mmol, 
20%) and ethyl 2-(bromomethyl)acrylate (97 mg, 0.50 mmol, 2.5 equiv). The resulting 
mixture was stirred at 25 °C for 2 h. Workup according to TP1 and purification via column 
chromatography (iHex / EtOAc = 99 / 1) and HPLC afforded the desired compound 4n 
(60 mg, 0.19 mmol, 95%) as a colorless liquid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 6.13 (d, J = 1.7 Hz, 1 H), 5.47 – 5.44 (m, 1 H), 4.65 (t, 
J = 1.9 Hz, 1 H), 4.57 (t, J = 1.9 Hz, 1 H), 4.19 (q, J = 7.1 Hz, 2 H), 2.58 – 2.52 (m, 1 H), 2.51 
(d, J = 0.9 Hz, 2 H), 2.33 (t, J = 5.4 Hz, 1 H), 2.20 (dtd, J = 9.9, 5.9, 2.1 Hz, 1 H), 1.94 – 1.85 
(m, 2 H), 1.65 (ddd, J = 14.1, 4.0, 2.8 Hz, 1 H), 1.47 (s, 6 H), 1.29 (t, J = 7.1 Hz, 3 H), 1.21 
(s, 3 H), 1.09 (d, J = 9.8 Hz, 1 H), 0.70 (s, 3 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 167.5, 152.2, 138.8, 125.7, 108.8, 60.7, 52.9, 52.1, 
49.3, 44.5, 40.4, 39.1, 36.3, 35.0, 27.5, 27.3, 26.0, 21.7, 14.4. 
MS (70 eV, EI) m/z (%): 225 (13), 207 (32), 197 (62), 185 (12), 183 (19), 182 (11), 181 (14), 
171 (32), 169 (54), 167 (13), 161 (20), 159 (59), 157 (72), 156 (24), 155 (79), 145 (71), 
143 (71), 142 (27), 141 (57), 133 (27), 131 (77), 130 (11), 129 (86), 128 (42), 119 (50), 
117 (100), 115 (38), 107 (15), 105 (85), 93 (25), 91 (84), 79 (30), 77 (18). 
IR (ATR) ~ (cm-1): 2959, 2906, 2865, 1717, 1663, 1534, 1455, 1383, 1367, 1300, 1255, 
1236, 1174, 1154, 1097, 1027, 940, 881, 856, 820, 729, 696. 




Ethyl 6-(3-(quinolin-2-yl)bicyclo[1.1.1]pentan-1-yl)cyclohex-1-ene-1-carboxylate (4o) 
 
Ethyl 6-(3-(quinolin-2-yl)bicyclo[1.1.1]pentan-1-yl)cyclohex-1-ene-1-carboxylate was prepa-
red according to TP1 using (2-(ethoxycarbonyl)cyclohex-2-en-1-yl)zinc chloride coordinated 
with lithium chloride (0.74 M, 0.54 mL, 0.40 mmol, 2.0 equiv). The reaction was stirred at 
50 °C for 15 h before adding 2-bromoquinoline (104 mg, 0.50 mmol, 2.5 equiv), 
PdCl2(dppf)CH2Cl2 (8.2 mg, 0.010 mmol, 5%) and CuCN2LiCl in THF (1.0 M, 0.020 mL, 
0.020 mmol, 10%). The resulting mixture was stirred at 45 °C for 7 h. Workup according to 
TP1 and purification via column chromatography (iHex / EtOAc = 9 / 1) and HPLC afforded 
the desired compound 4o (45 mg, 0.13 mmol, 65%) as a colorless liquid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 8.07 (t, J = 8.8 Hz, 2 H), 7.75 (dd, J = 8.1, 1.5 Hz, 
1 H), 7.66 (ddd, J = 8.4, 6.9, 1.5 Hz, 1 H), 7.47 (ddd, J = 8.0, 6.8, 1.2 Hz, 1 H), 7.32 (d, 
J = 8.4 Hz, 1 H), 7.01 (t, J = 3.9 Hz, 1 H), 4.28 – 4.12 (m, 2 H), 2.99 – 2.88 (m, 1 H), 2.30 – 
2.03 (m, 8 H), 1.95 – 1.86 (m, 1 H), 1.74 – 1.53 (m, 3 H), 1.31 (t, J = 7.1 Hz, 3 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 168.3, 160.4, 147.9, 140.1, 136.3, 131.7, 129.5, 
129.2, 127.6, 127.0, 126.0, 119.2, 60.4, 52.2, 42.4, 42.2, 33.2, 25.7, 25.1, 18.0, 14.4. 
MS (70 eV, EI) m/z (%): 347 (1) [M]+, 274 (5), 195 (14), 194 (100), 193 (8), 192 (8), 180 (8), 
167 (10). 
IR (ATR) ~ (cm-1): 2967, 2905, 2868, 1707, 1643, 1618, 1599, 1559, 1514, 1501, 1446, 
1425, 1373, 1345, 1328, 1296, 1253, 1235, 1181, 1139, 1114, 1091, 1061, 1049, 1017, 941, 
929, 913, 875, 837, 802, 786, 749, 735, 702, 675. 





red according to TP1 using (2-cyanocyclopent-2-en-1-yl)zinc bromide coordinated with 
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lithium chloride (0.54 M, 0.74 mL, 0.40 mmol, 2.0 equiv). The reaction was stirred at 25 °C for 
17 h before adding CuCN2LiCl in THF (1.0 M, 0.040 mL, 0.040 mmol, 20%) and 
3-bromocyclohex-1-ene (81 mg, 0.50 mmol, 2.5 equiv). The resulting mixture was stirred at 
25 °C for 1 h. Workup according to TP1 and purification via column chromatography (iHex / 
EtOAc = 49 / 1) and HPLC afforded the desired compound 4p (26 mg, 0.11 mmol, 55%) as a 
colorless liquid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 6.65 (td, J = 2.7, 1.7 Hz, 1 H), 5.75 – 5.67 (m, 1 H), 
5.52 (dq, J = 10.1, 2.3 Hz, 1 H), 3.02 – 2.94 (m, 1 H), 2.49 – 2.41 (m, 2 H), 2.20 – 2.12 (m, 
1 H), 2.06 – 1.98 (m, 1 H), 1.97 – 1.91 (m, 2 H), 1.81 – 1.74 (m, 1 H), 1.61 – 1.49 (m, 8 H), 
1.31 – 1.20 (m, 2 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 149.6, 128.3, 127.9, 117.5, 117.0, 48.3, 47.1, 42.9, 
40.8, 36.4, 32.9, 26.7, 25.7, 25.2, 21.4. 
MS (70 eV, EI) m/z (%): 238 (19) [MH]+, 224 (10), 210 (11), 196 (16), 182 (16), 170 (10), 
168 (12), 156 (15), 147 (21), 131 (11), 130 (16), 129 13), 119 (29), 117 (16), 116 (13), 
115 (16), 107 (32), 105 (86), 93 (18), 92 (15), 91 (100), 81 (12), 79 (99), 78 (11), 77 (22), 65 
(12). 
IR (ATR) ~ (cm-1): 3425, 2957, 2924, 2865, 2216, 1727, 1653, 1612, 1446, 1433, 1409, 
1304, 1257, 1227, 1171, 1142, 1020, 950, 895, 869, 822, 740, 721, 668. 




5-(3-(4-Methoxyphenyl)bicyclo[1.1.1]pentan-1-yl)cyclopent-1-ene-1-carbonitrile was prepared 
according to TP1 using (2-cyanocyclopent-2-en-1-yl)zinc bromide coordinated with lithium 
chloride (0.54 M, 0.74 mL, 0.40 mmol, 2.0 equiv). The reaction was stirred at 25 °C for 17 h 
before adding 4-iodobenzoate (138 mg, 0.50 mmol, 2.5 equiv), PdCl2(dppf)CH2Cl2 (8.2 mg, 
0.010 mmol, 5%) and CuCN2LiCl in THF (1.0 M, 0.020 mL, 0.020 mmol, 10%). The resulting 
mixture was stirred at 45 °C for 5 h. Workup according to TP1 and purification via column 
chromatography (iHex / EtOAc = 19 / 1) afforded the desired compound 4q (36 mg, 
0.12 mmol, 59%) as a colorless solid. 
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1H-NMR (CDCl3, 400 MHz, ppm): δ = 7.97 (d, J = 8.3 Hz, 2 H), 7.26 (d, J = 8.3 Hz, 2 H), 
6.71 (q, J = 2.6 Hz, 1 H), 4.36 (q, J = 7.1 Hz, 2 H), 3.13 – 3.05 (m, 1 H), 2.56 – 2.47 (m, 2 H), 
2.15 – 1.97 (m, 7 H), 1.89 – 1.79 (m, 1 H), 1.38 (t, J = 7.1 Hz, 3 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 166.7, 150.0, 145.8, 129.6, 128.7, 126.2, 117.3, 
116.5, 61.0, 51.0, 47.9, 42.1, 40.5, 32.9, 26.6, 14.5. 
MS (70 eV, EI) m/z (%): 307 (1) [M]+, 281 (27), 262 (17), 261 (36), 253 (13), 246 (18), 
234 (47), 233 (19), 232 (10), 225 (16), 219 (11), 218 (15), 215 (23), 208 (13), 207 (100), 206 
(13), 191 (18), 177 (32), 169 (17), 162 (34), 145 (55), 143 (55), 142 (19), 141 (36), 131 (10), 
129 (18), 128 (47), 117 (11), 115 (40), 91 (18). 
IR (ATR) ~ (cm-1): 2968, 2945, 2906, 2868, 2214, 1714, 1608, 1467, 1451, 1428, 1407, 
1367, 1307, 1294, 1268, 1212, 1176, 1146, 1130, 1104, 1092, 1045, 1017, 978, 944, 923, 
904, 875, 860, 850, 815, 800, 761, 719, 700. 
HRMS (EI) calculated for C20H21NO2+: 307.1567, found 307.1568 [M]+. 





         
Phenyl(3-(1-(triisopropylsilyl)propa-1,2-dien-1-yl)bicyclo[1.1.1]pentan-1-yl)methanone and 
phenyl(3-(3-(triisopropylsilyl)prop-2-yn-1-yl)bicyclo[1.1.1]pentan-1-yl)methanone were prepa-
red according to TP1 using (3-(triisopropylsilyl)prop-2-yn-1-yl)zinc bromide coordinated with 
lithium chloride (0.24 M, 1.67 mL, 0.40 mmol, 2.0 equiv). The reaction was stirred at 50 °C for 
19 h before adding CuCN2LiCl in THF (1.0 M, 0.20 mL, 0.20 mmol, 1.0 equiv) and benzoyl 
chloride (70 mg, 0.50 mmol, 2.5 equiv). The resulting mixture was stirred at 25 °C for 1 h. 
Workup according to TP1 and purification via column chromatography (iHex / EtOAc = 99 / 1) 
and HPLC afforded phenyl(3-(1-(triisopropylsilyl)propa-1,2-dien-1-yl)bicyclo-[1.1.1]pentan-1-
yl)methanone 4r (37 mg, 0.10 mmol, 50%) as a colorless solid and phenyl(3-(3-
(triisopropylsilyl)-prop-2-yn-1-yl)bicyclo[1.1.1]pentan-1-yl)methanone 4s (33 mg, 0.09 mmol, 





1H-NMR (CDCl3, 400 MHz, ppm): δ = 8.02 – 7.95 (m, 2 H), 7.54 (tt, J = 7.3, 1.3 Hz, 1 H), 
7.44 (t, J = 7.6 Hz, 2 H), 4.44 (s, 2 H), 2.35 (s, 6 H), 1.28 – 1.15 (m, 3 H), 1.13 – 1.04 (m, 
18 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 212.7, 198.1, 136.8, 133.0, 129.0, 128.6, 91.1, 69.5, 
56.3, 44.6, 39.8, 18.8, 12.0. 
MS (70 eV, EI) m/z (%): 324 (17), 323 (82) [MC3H7]+, 281 (16), 253 (12), 225 (21), 
209 (11), 208 (10), 207 (70), 193 (31), 191 (15), 179 (15), 178 (100), 165 (21), 152 (14), 
131 (19), 115 (11), 105 (11), 103 (55), 77 (12), 75 (87), 73 (16), 61 (14), 59 (10). 
IR (ATR) ~ (cm-1): 2955, 2940, 2863, 2176, 1922, 1665, 1598, 1578, 1505, 1460, 1446, 
1381, 1364, 1332, 1312, 1268, 1209, 1176, 1070, 1018, 990, 941, 920, 882, 839, 822, 805, 
766, 699, 674. 
HRMS (EI) calculated for C24H33OSi+: 365.2295, found 365.2298 [MH]+. 
mp: 77.7 – 79.2 °C. 
Phenyl(3-(3-(triisopropylsilyl)prop-2-yn-1-yl)bicyclo[1.1.1]pentan-1-yl)methanone (4s): 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 8.02 – 7.95 (m, 2 H), 7.55 (tt, J = 7.4, 1.2 Hz, 1 H), 
7.44 (t, J = 7.6 Hz, 2 H), 2.54 (s, 2 H), 2.24 (s, 6 H), 1.11 – 1.02 (m, 21 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 197.7, 136.7, 133.0, 129.0, 128.6, 104.8, 82.1, 53.5, 
44.3, 38.4, 23.7, 18.8, 11.4. 
MS (70 eV, EI) m/z (%): 324 (23), 323 (100) [MC3H7]+, 295 (29), 281 (11), 233 (12), 
207 (20), 193 (44), 191 (17), 179 (16), 178 (79), 165 (24), 153 (10), 152 (11), 145 (10), 
129 (13), 128 (13), 115 (17), 105 (30), 91 (13), 77 (17), 75 (36), 61 (11). 
IR (ATR) ~ (cm-1): 2941, 2864, 2172, 1728, 1666, 1598, 1580, 1511, 1462, 1448, 1419, 
1382, 1338, 1297, 1266, 1205, 1176, 1086, 1070, 1027, 1011, 994, 926, 881, 760, 694, 675, 
659. 






2-(Bicyclo[1.1.1]pentan-1-yl)cyclohexan-1-one was prepared according to TP2 using 
cyclopentanone (29 mg, 0.30 mmol, 1.5 equiv). The reaction was stirred at 0 °C for 30 min 
before adding a saturated aqueous solution of NH4Cl (1 mL). The resulting mixture was 
stirred at 25 °C for 10 min. Workup according to TP2 and purification via column 
chromatography (iHex / EtOAc = 49 / 1) afforded the desired compound 9a (29 mg, 
0.17 mmol, 87%) as a colorless liquid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 2.48 (s, 1 H), 2.36 (dd, J = 8.4, 5.8 Hz, 1 H), 2.27 (dd, 
J = 7.3, 5.8 Hz, 2 H), 1.97 – 1.72 (m, 10 H), 1.66 – 1.56 (m, 2 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 212.3, 51.6, 50.2, 45.0, 42.2, 30.3, 28.0, 27.3, 23.6. 
MS (70 eV, EI) m/z (%): 163 (3) [MH]+, 149 (42), 135 (43), 131 (13), 121 (11), 117 (10), 107 
(15), 105 (54), 95 (17), 93 (89), 92 (22), 91 (80), 81 (12), 79 (100), 77 (42), 67 (32). 
IR (ATR) ~ (cm-1): 2958, 2939, 2865, 2175, 2006, 1921, 1708, 1665, 1598, 1578, 1447, 
1365, 1333, 1265, 1196, 1125, 1070, 1018, 990, 941, 883, 837, 805, 766, 699, 674. 




2-(3-Allylbicyclo[1.1.1]pentan-1-yl)cyclohexan-1-one was prepared according to TP2 using 
cyclopentanone (29 mg, 0.30 mmol, 1.5 equiv). The reaction was stirred at 0 °C for 30 min 
before adding CuCN2LiCl in THF (1.0 M, 0.040 mL, 0.040 mmol, 20%) and allyl bromide 
(85 mg, 0.70 mmol, 3.5 equiv). The resulting mixture was stirred at 25 °C for 2 h. Workup 
according to TP2 and purification via column chromatography (iHex / EtOAc = 49 / 1) 
afforded the desired compound 9b (36 mg, 0.18 mmol, 88%) as a colorless liquid. 
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1H-NMR (CDCl3, 400 MHz, ppm): δ = 5.70 (ddt, J = 16.7, 10.4, 7.2 Hz, 1 H), 5.01 – 4.93 (m, 
2 H), 2.38 (dd, J = 8.7, 5.8 Hz, 1 H), 2.27 (dd, J = 7.1, 6.0 Hz, 2 H), 2.20 (dt, J = 7.1, 1.3 Hz, 
2 H), 1.97 – 1.70 (m, 4 H), 1.64 – 1.53 (m, 8 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 212.3, 135.8, 115.8, 51.0, 50.0, 42.2, 40.0, 39.1, 36.9, 
30.5, 27.4, 23.7. 
MS (70 eV, EI) m/z (%): 189 (11) [MCH3]+, 164 (12), 163 (100), 145 (13), 143 (13), 135 
(13), 133 (10), 129 (12), 119 (21), 117 (18), 107 (24), 106 (11), 105 (52), 93 (20), 91 (86), 
79 (44), 77 (21), 67 (10). 
IR (ATR) ~ (cm-1): 2937, 2866, 1705, 1640, 1447, 1425, 1370, 1316, 1255, 1218, 1146, 
1124, 1066, 991, 946, 910, 652. 




2-(3-(4-Methoxyphenyl)bicyclo[1.1.1]pentan-1-yl)cyclohexan-1-one was prepared according 
to TP2 using cyclopentanone (29 mg, 0.30 mmol, 1.5 equiv). The reaction was stirred at 0 °C 
for 30 min before adding 4-iodoanisole (164 mg, 0.70 mmol, 3.5 equiv), PdCl2(dppf)CH2Cl2 
(8.2 mg, 0.010 mmol, 5%) and CuCN2LiCl in THF (1.0 M, 0.020 mL, 0.020 mmol, 10%). The 
resulting mixture was stirred at 40 °C for 3 h. Workup according to TP2 and purification via 
column chromatography (iHex / EtOAc = 19 / 1) afforded the desired compound 9c (42 mg, 
0.16 mmol, 78%) as a colorless solid. The structure was confirmed via single crystal X-ray 
diffraction studies. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 7.14 (d, J = 8.7 Hz, 2 H), 6.83 (d, J = 8.8 Hz, 2 H), 
3.78 (s, 3 H), 2.49 (dd, J = 9.2, 5.6 Hz, 1 H), 2.32 (dd, J = 7.4, 5.7 Hz, 2 H), 2.06 – 1.58 (m, 
12 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 212.2, 158.3, 133.6, 127.2, 113.6, 55.4, 51.9, 50.7, 
42.4, 41.8, 38.5, 30.6, 27.4, 24.0. 
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MS (70 eV, EI) m/z (%): 270 (1) [M]+, 256 (19), 255 (100), 199 (8), 173 (51), 172 (18), 
171 (10), 163 (8), 158 (39), 141 (7), 133 (9), 128 (7), 115 (7). 
IR (ATR) ~ (cm-1): 2934, 2867, 1704, 1608, 1576, 1518, 1503, 1460, 1442, 1373, 1343, 
1315, 1292, 1266, 1243, 1211, 1185, 1172, 1163, 1148, 1133, 1123, 1067, 1034, 953, 923, 
905, 889, 862, 846, 829, 791, 783, 720, 702, 659. 
HRMS (EI) calculated for C18H22O2+: 270.1614, found 270.1617 [M]+. 




2-(3-Benzoylbicyclo[1.1.1]pentan-1-yl)cyclohexan-1-one was prepared according to TP2 
using cyclopentanone (29 mg, 0.30 mmol, 1.5 equiv). The reaction was stirred at 0 °C for 
30 min before adding CuCN2LiCl in THF (1.0 M, 0.020 mL, 0.020 mmol, 10%) and benzoyl 
chloride (141 mg, 1.0 mmol, 5.0 equiv). The resulting mixture was stirred at 25 °C for 1 h. 
Workup according to TP2 and purification via column chromatography (iHex / EtOAc = 9 / 1) 
and HPLC afforded the desired compound 9d (30 mg, 0.15 mmol, 73%) as a colorless solid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 8.04 – 7.98 (m, 2 H), 7.54 (tt, J = 7.3, 1.2 Hz, 1 H), 
7.44 (t, J = 7.5 Hz, 2 H), 2.46 (dd, J = 10.9, 5.6 Hz, 1 H), 2.36 – 2.25 (m, 8 H), 2.11 – 1.96 
(m, 2 H), 1.91 – 1.83 (m, 1 H), 1.78 – 1.62 (m, 2 H), 1.59 – 1.47 (m, 1 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 211.7, 197.7, 136.6, 133.0, 129.1, 128.5, 53.0, 50.3, 
45.0, 42.5, 40.2, 30.6, 27.5, 24.4. 
MS (70 eV, EI) m/z (%): 198 (19) [MC4H6O]+, 179 (12), 171 (17), 163 (15), 123 (47), 
105 (100), 91 (19), 77 (37). 
IR (ATR) ~ (cm-1): 2981, 2928, 2875, 1706, 1659, 1595, 1578, 1509, 1446, 1374, 1333, 
1313, 1284, 1203, 1171, 1123, 1106, 1071, 1041, 1018, 967, 931, 875, 848, 815, 766, 712, 
699, 679. 
HRMS (EI) calculated for C18H20O2+: 268.1458, found 268.1460 [M]+. 
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3-(2-Oxocyclohexyl)bicyclo[1.1.1]pentane-1-carbonitrile was prepared according to TP2 
using cyclopentanone (29 mg, 0.30 mmol, 1.5 equiv). The reaction was stirred at 0 °C for 
30 min before adding CuCN2LiCl in THF (1.0 M, 070 mL, 0.70 mmol, 3.5 equiv) and tosyl 
cyanide (145 mg, 0.80 mmol, 4.0 equiv). The resulting mixture was stirred at 25 °C for 18 h. 
Workup according to TP2 and purification via column chromatography (iHex / EtOAc = 
85 / 15) afforded the desired compound 9e (17 mg, 0.09 mmol, 46%) as a colorless solid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 2.37 (dd, J = 11.9, 5.5 Hz, 1 H), 2.23 (s, 8 H), 2.07 – 
1.93 (m, 2 H), 1.91 – 1.78 (m, 1 H), 1.68 – 1.54 (m, 2 H), 1.44 – 1.31 (m, 1 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 210.7, 117.9, 53.6, 49.6, 43.9, 42.4, 30.6, 27.4, 24.5, 
24.4. 
MS (70 eV, EI) m/z (%): 174 (10) [MCH3]+, 161 (10), 160 (100), 146 (21), 145 (11), 144 
(100), 133 (13), 132 (24), 130 (69), 118 (31), 117 (36), 116 (20), 115 (10), 105 (15), 104 (40), 
93 (13), 91 (46), 79 (38), 78 (11), 77 (27), 67 (17). 
IR (ATR) ~ (cm-1): 2936, 2861, 2228, 1706, 1446, 1430, 1377, 1338, 1303, 1272, 1256, 
1225, 1211, 1145, 1124, 1105, 1081, 1068, 1041, 1009, 963, 931, 914, 892, 847, 793, 771, 
705, 660. 
HRMS (EI) calculated for C12H14NO+: 188.1070, found 188.1069 [MH]+. 






1-(3-Allylbicyclo[1.1.1]pentan-1-yl)-3-cyclohexylpropan-2-one was prepared according to TP2 
using cyclohexyl acetone (42 mg, 0.30 mmol, 1.5 equiv). The reaction was stirred at 0 °C for 
2 h before adding CuCN2LiCl in THF (1.0 M, 0.040 mL, 0.040 mmol, 20%) and allyl bromide 
(85 mg, 0.70 mmol, 3.5 equiv). The resulting mixture was stirred at 25 °C for 2 h. Workup 
according to TP2 and purification via column chromatography (iHex / EtOAc = 99 / 1) 
afforded the desired compound 9f (35 mg, 0.14 mmol, 71%) as a colorless liquid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 5.76 – 5.62 (m, 1 H), 5.02 – 4.93 (m, 2 H), 2.53 (s, 
2 H), 2.24 (d, J = 6.8 Hz, 2 H), 2.19 (d, J = 7.2 Hz, 2 H), 1.86 – 1.75 (m, 1 H), 1.71 – 1.61 (m, 
5 H), 1.59 (s, 6 H), 1.29 – 1.21 (m, 2 H), 1.18 – 1.09 (m, 1 H), 0.96 – 0.83 (m, 2 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 209.5, 135.6, 115.9, 51.4, 51.4, 46.3, 39.7, 36.8, 36.5, 
33.7, 33.4, 26.4, 26.3. 
MS (70 eV, EI) m/z (%): 205 (0.5) [MC3H5]+, 125 (20), 98 (7), 97 (100), 91 (7), 79 (7), 
69 (12), 55 (29). 
IR (ATR) ~ (cm-1): 3076, 2921, 2852, 1711, 1640, 1611, 1447, 1404, 1354, 1293, 1255, 
1206, 1148, 1047, 991, 965, 909, 803, 708. 




1-(Bicyclo[1.1.1]pentan-1-yl)-4-(2,6,6-trimethylcyclohex-1-en-1-yl)butan-2-one was prepared 
according to TP2 using dihydro--ionone (58 mg, 0.30 mmol, 1.5 equiv). The reaction was 
stirred at 0 °C for 2 h before adding a saturated aqueous solution of NH4Cl (1 mL). The 
resulting mixture was stirred at 25 °C for 10 min. Workup according to TP2 and purification 
via column chromatography (iHex / EtOAc = 99 / 1) afforded the desired compound 9g 
(35 mg, 0.14 mmol, 67%) as a colorless liquid. 
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1H-NMR (CDCl3, 400 MHz, ppm): δ = 2.54 (s, 2 H), 2.50 – 2.41 (m, 3 H), 2.27 – 2.19 (m, 
2 H), 1.89 (t, J = 6.2 Hz, 2 H), 1.78 (s, 6 H), 1.60 – 1.51 (m, 5 H), 1.44 – 1.36 (m, 2 H), 0.97 
(s, 6 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 209.5, 136.1, 127.8, 51.6, 46.5, 44.4, 41.4, 39.8, 35.2, 
32.9, 28.6, 28.5, 22.1, 19.9, 19.6. 
MS (70 eV, EI) m/z (%): 260 (8) [M]+, 245 (12), 242 (18), 227 (11), 179 (13), 163 (15), 
161 (35), 145 (12), 137 (29), 136 (52), 135 (16), 123 (38), 122 (14), 121 (100), 109 (14), 104 
(10), 95 (25), 67 (14). 
IR (ATR) ~ (cm-1): 2962, 2926, 2906, 2868, 1711, 1472, 1457, 1407, 1360, 1279, 1256, 
1195, 1147, 1116, 1083, 1066, 1041, 1020, 970, 953, 873. 




2-(3-Allylbicyclo[1.1.1]pentan-1-yl)-2-methyl-1-phenylpropan-1-one was prepared according 
to TP2 using isobutyrophenone (44 mg, 0.30 mmol, 1.5 equiv). The reaction was stirred at 
0 °C for 2 h before adding CuCN2LiCl in THF (1.0 M, 0.040 mL, 0.040 mmol, 20%) and allyl 
bromide (85 mg, 0.70 mmol, 3.5 equiv). The resulting mixture was stirred at 25 °C for 2 h. 
Workup according to TP2 and purification via column chromatography (iHex / EtOAc = 49 / 1) 
afforded the desired compound 9h (44 mg, 0.17 mmol, 86%) as a colorless liquid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 7.62 – 7.56 (m, 2 H), 7.45 – 7.41 (m, 1 H), 7.40 – 7.34 
(m, 2 H), 5.68 (ddt, J = 16.4, 10.9, 7.2 Hz, 1 H), 5.02 – 4.92 (m, 2 H), 2.19 (dt, J = 7.3, 
1.3 Hz, 2 H), 1.53 (s, 6 H), 1.27 (s, 6 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 208.1, 140.3, 135.5, 130.7, 127.9, 127.7, 115.8, 48.2, 
47.8, 45.6, 37.1, 36.6, 23.4. 
MS (70 eV, EI) m/z (%): 253 (1) [MH]+, 239 (3), 148 (3), 147 (4), 119 (6), 107 (5), 106 (8), 
105 (100), 93 (5), 91 (12), 79 (5), 77 (28). 
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IR (ATR) ~ (cm-1): 3075, 2963, 2906, 1921, 1668, 1641, 1597, 1578, 1467, 1445, 1385, 
1362, 1331, 1258, 1209, 1168, 1126, 1077, 1018, 991, 967, 909, 883, 806, 795, 767, 739, 
698, 676. 




6-(3-Allylbicyclo[1.1.1]pentan-1-yl)cyclohex-2-en-1-one was prepared according to TP2 using 
cyclohex-2-en-1-one (29 mg, 0.30 mmol, 1.5 equiv). The reaction was stirred at 0 °C for 
30 min before adding CuCN2LiCl in THF (1.0 M, 0.040 mL, 0.040 mmol, 20%) and allyl 
bromide (85 mg, 0.70 mmol, 3.5 equiv). The resulting mixture was stirred at 0 °C for 30 min. 
Workup according to TP2 and purification via column chromatography (iHex / EtOAc = 19 / 1) 
afforded the desired compound 9i (30 mg, 0.15 mmol, 75%) as a colorless liquid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 6.89 (dt, J = 10.1, 4.0 Hz, 1 H), 5.93 (dt, J = 10.1, 
2.1 Hz, 1 H), 5.69 (ddt, J = 16.5, 10.5, 7.2 Hz, 1 H), 5.01 – 4.91 (m, 2 H), 2.48 – 2.35 (m, 
2 H), 2.32 – 2.22 (m, 1 H), 2.19 (d, J = 7.2 Hz, 2 H), 2.05 (ddt, J = 13.0, 7.6, 5.3 Hz, 1 H), 
1.87 (td, J = 13.3, 5.9 Hz, 1 H), 1.65 – 1.55 ([AB]3-system, 6 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 200.0, 149.6, 135.7, 130.0, 115.8, 50.3, 47.2, 40.3, 
38.8, 36.8, 25.7, 24.3. 
MS (70 eV, EI) m/z (%): 187 (8) [MCH3]+, 161 (57), 159 (16), 143 (15), 131 (14), 128 (15), 
119 (37), 117 (25), 115 (13), 105 (33), 96 (13), 95 (17), 93 (24), 91 (100), 79 (22), 77 (23). 
IR (ATR) ~ (cm-1): 3075, 2961, 2904, 1673, 1640, 1620, 1448, 1428, 1411, 1386, 1352, 
1307, 1286, 1252, 1170, 1118, 1019, 991, 946, 909, 835, 763, 713, 686. 




Ethyl 2-(3-allylbicyclo[1.1.1]pentan-1-yl)propanoate (11a) 
 
Ethyl 2-(3-allylbicyclo[1.1.1]pentan-1-yl)propanoate was prepared according to TP3 using 
ethyl propionate (41 mg, 0.40 mmol, 2.0 equiv). After stirring at 0 °C for 3 h, CuCN2LiCl in 
THF (1.0 M, 0.040 mL, 0.040 mmol, 20%) and allyl bromide (61 mg, 0.50 mmol, 2.5 equiv) 
were added. Workup according to TP3 and purification via column chromatography 
(iHex / EtOAc = 49 / 1) afforded the desired compound 11a (31 mg, 0.15 mmol, 75%) as a 
colorless liquid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 5.77 – 5.62 (m, 1 H), 5.02 – 4.93 (m, 2 H), 4.19 – 4.03 
(m, 2 H), 2.54 (q, J = 7.0 Hz, 1 H), 2.20 (dt, J = 7.2, 1.3 Hz, 2 H), 1.51 (s, 6 H), 1.24 (t, 
J = 7.1 Hz, 3 H), 1.05 (d, J = 7.0 Hz, 3 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 174.6, 135.7, 115.9, 60.2, 49.1, 41.15, 41.1, 37.9, 
36.8, 14.6, 13.5. 
MS (70 eV, EI) m/z (%): 167 (8) [MC3H5]+, 139 (73), 135 (17), 133 (11), 119 (50), 107 (77), 
106 (10), 105 (53), 93 (52), 91 (100), 79 (60), 77 (26), 44 (18). 
IR (ATR) ~ (cm-1): 2962, 2907, 2869, 1733, 1641, 1456, 1409, 1374, 1336,1289, 1255, 
1227, 1183, 1148, 1096, 1053, 1019, 1009, 911, 859, 822, 791, 708, 668. 
HRMS (EI) calculated for C10H15O2+: 167.1067, found 167.1066 [MC3H5]+. 
 
Ethyl 2-(3-allylbicyclo[1.1.1]pentan-1-yl)hept-6-enoate (11b) 
 
Ethyl 2-(3-allylbicyclo[1.1.1]pentan-1-yl)hept-6-enoate was prepared according to TP3 using 
ethyl hept-6-enoate (156 mg, 1.0 mmol, 2.0 equiv) and [1.1.1]propellane in diethyl ether 
(0.50 mmol, 1.0 equiv). After stirring at 0 °C for 3 h, CuCN2LiCl in THF (1.0 M, 0.10 mL, 
0.10 mmol, 20%) and allyl bromide (151 mg, 1.3 mmol, 2.5 equiv) were added. Workup 
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according to TP3 and purification via column chromatography (iHex / EtOAc = 99 / 1) and 
HPLC afforded the desired compound 11b (125 mg, 0.48 mmol, 95%) as a colorless liquid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 5.85 – 5.62 (m, 2 H), 5.03 – 4.90 (m, 4 H), 4.12 (qd, 
J = 7.1, 3.8 Hz, 2 H), 2.47 – 2.39 (m, 1 H), 2.20 (dt, J = 7.2, 1.3 Hz, 2 H), 2.08 – 1.99 (m, 
2 H), 1.63 – 1.58 (m, 1 H), 1.53 (A part of an [AB]3-system, 3 H), 1.49 (B part of an [AB]3-
system, 3 H), 1.42 – 1.29 (m, 3 H), 1.25 (t, J = 7.1 Hz, 3 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 174.0, 138.7, 135.7, 115.9, 114.7, 60.1, 49.5, 47.4, 
40.6, 38.1, 36.8, 33.8, 28.5, 27.2, 14.6. 
MS (70 eV, EI) m/z (%): 221 (2) [MC3H5]+, 193 (10), 165 (10), 147 (57), 145 (18), 137 (61), 
133 (24), 131 (32), 125 (16), 121 (10), 119 (61), 117 (23), 107 (61), 93 (34), 91 (100), 
81 (15), 79 (67), 77 (23), 67 (13). 
IR (ATR) ~ (cm-1): 3077, 2963, 2905, 2868, 1732, 1641, 1444, 1370, 1344, 1254, 1174, 
1124, 1027, 991, 909, 805. 
HRMS (EI) calculated for C14H21O2+: 221.1536, found 221.1535 [MC3H5]+. 
 
Ethyl 2-(3-allylbicyclo[1.1.1]pentan-1-yl)-2-(4-bromophenyl)acetate (11c) 
 
Ethyl 2-(3-allylbicyclo[1.1.1]pentan-1-yl)-2-(4-bromophenyl)acetate was prepared according 
to TP3 using ethyl 2-(4-bromophenyl)acetate (97 mg, 1.0 mmol, 2.0 equiv). After stirring at 
0 °C for 3 h, CuCN2LiCl in THF (1.0 M, 0.10 mL, 0.10 mmol, 20%) and allyl bromide 
(151 mg, 1.3 mmol, 2.5 equiv) were added. Workup according to TP3 and purification via 
column chromatography (iHex / EtOAc = 49 / 1) afforded the desired compound 11c (66 mg, 
0.19 mmol, 94%) as a colorless liquid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 7.42 (d, J = 8.4 Hz, 2 H), 7.17 (d, J = 8.5 Hz, 2 H), 
5.73 – 5.57 (m, 1 H), 5.00 – 4.90 (m, 2 H), 4.22 – 4.05 (m, 2 H), 3.68 (s, 1 H), 2.18 (dt, 
J = 7.2, 1.3 Hz, 2 H), 1.52 (s, 6 H), 1.24 (t, J = 7.1 Hz, 3 H). 
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13C-NMR (CDCl3, 101 MHz, ppm): δ = 171.7, 136.0, 135.4, 131.4, 130.4, 121.2, 116.0, 60.8, 
53.0, 49.7, 41.0, 39.3, 36.7, 14.4. 
MS (70 eV, EI) m/z (%): 307 (6) [MC3H5]+, 281 (41), 279 (41), 215 (13), 214 (13), 196 (58), 
195 (20), 182 (14), 181 (100), 180 (19), 179 (27), 172 (13), 171 (43), 169 (43), 168 (25), 
167 (47), 166 (32), 165 (45), 155 (32), 154 (63), 153 (72), 152 (28), 151 (78), 141 (25), 
135 (15), 134 (16), 129 (21), 128 (47), 116 (16), 115 (50), 107 (29), 105 (22), 91 (34), 
89 (20), 79 (33), 77 (18). 
IR (ATR) ~ (cm-1): 3075, 2965, 2905, 2868, 1732, 1640, 1488, 1464, 1445, 1408, 1367, 
1336, 1302, 1248, 1197, 1156, 1121, 1073, 1011, 991, 911, 880, 835, 757, 737, 712, 683. 




1-(3-Allylbicyclo[1.1.1]pentan-1-yl)cyclohexane-1-carbonitrile was prepared according TP4 
using cyclohexanecarbonitrile (44 mg, 0.40 mmol, 2.0 equiv). The reaction mixture was 
stirred 6 h at 25 °C. Trapping and workup according to TP4 and purification via column 
chromatography (iHex / EtOAc = 49 / 1) afforded the desired compound 17a (22 mg, 
0.10 mmol, 51%) as a colorless solid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 5.70 (ddt, J = 16.4, 11.0, 7.2 Hz, 1 H), 5.05 – 4.93 (m, 
2 H), 2.25 (dt, J = 7.2, 1.3 Hz, 2 H), 1.87 – 1.69 (m, 5 H), 1.56 (s, 8 H), 1.21 – 1.06 (m, 3 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 135.2, 122.4, 116.3, 47.1, 43.8, 39.7, 37.3, 36.5, 32.0, 
25.3, 23.1. 
MS (70 eV, EI) m/z (%): 214 (6) [MH]+, 186 (13), 172 (18), 160 (19), 158 (13), 146 (29), 
144 (21), 132 (14), 131 (11), 130 (11), 118 (11), 117 (13), 107 (40), 105 (33), 93 (12), 92 
(14), 91 (67), 81 (14), 79 (100), 77 (16), 67 (15). 
IR (ATR) ~ (cm-1): 3076, 2963, 2933, 2907, 2861, 2227, 1641, 1447, 1286, 1265, 1249, 
1213, 1179, 1136, 991, 937, 910, 870, 811, 713. 
HRMS (EI) calculated for C15H20N+: 214.1590, found 214.1588 [MH]+. 
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2-(3-Allylbicyclo[1.1.1]pentan-1-yl)-2-phenylpropanenitrile was prepared according TP4 using 
-methylbenzyl cyanide (52 mg, 0.40 mmol, 2.0 equiv). The reaction mixture was stirred 3 h 
at 25 °C. Trapping and workup according to TP4 and purification via column chromatography 
(iHex / EtOAc = 49 / 1) afforded the desired compound 17b (46 mg, 0.19 mmol, 96%) as a 
colorless liquid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 7.39 – 7.27 (m, 5 H), 5.72 – 5.58 (m, 1 H), 5.02 – 4.92 
(m, 2 H), 2.21 (dt, J = 7.2, 1.3 Hz, 2 H), 1.70 (s, 3 H), 1.51 (s, 6 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 137.7, 134.9, 128.6, 127.8, 126.0, 122.3, 116.4, 47.6, 
45.1, 43.3, 37.7, 36.4, 21.9. 
MS (70 eV, EI) m/z (%): 236 (5) [MH]+, 222 (6), 194 (6), 181 (10), 180 (11), 167 (9), 
154 (12), 153 (10), 141 (12), 131 (51), 130 (34), 129 (22), 128 (21), 127 (11), 116 (14), 115 
(21), 107 (51), 105 (26), 104 (16), 103 (53), 102 (10), 92 (11), 91 (79), 79 (100), 78 (18), 77 
(63), 67 (15), 65 (22), 53 (14), 51 (22). 
IR (ATR) ~ (cm-1): 2970, 2909, 2872, 2235, 1641, 1601, 1493, 1446, 1378, 1325, 1247, 
1174, 1134, 1076, 1026, 992, 913, 801, 744, 697, 657. 






1-(3-Allylbicyclo[1.1.1]pentan-1-yl)cyclohex-2-ene-1-carbonitrile was prepared according TP4 
using 1-cyanocyclohexene (43 mg, 0.40 mmol, 2.0 equiv). The reaction mixture was stirred 
2 h at 25 °C. Trapping and workup according to TP4 and purification via column 
chromatography (iHex / EtOAc = 49 / 1) afforded the desired compound 17c (41 mg, 
0.19 mmol, 96%) as a colorless liquid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 5.92 (ddd, J = 9.9, 4.6, 2.9 Hz, 1 H), 5.76 – 5.63 (m, 
1 H), 5.52 – 5.46 (m, 1 H), 5.04 – 4.96 (m, 2 H), 2.25 (dt, J = 7.2, 1.3 Hz, 2 H), 2.13 – 2.03 
(m, 1 H), 2.02 – 1.91 (m, 2 H), 1.82 – 1.73 (m, 2 H), 1.64 – 1.55 ([AB]3-system, 6 H), 1.55 – 
1.48 (m, 1 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 134.9, 131.8, 123.4, 121.8, 116.3, 47.3, 42.9, 38.1, 
38.0, 36.4, 29.7, 24.4, 19.2. 
MS (70 eV, EI) m/z (%): 212 (4) [MH]+, 184 (9), 170 (16), 156 (23), 145 (16), 144 (15), 
143 (15), 142 (11), 131 (12), 130 (30), 129 (29), 128 (16), 117 (24), 116 (15), 115 (22), 
107 (21), 105 (32), 103 (12), 92 (10), 91 (81), 80 (10), 79 (100), 77 (36), 65 (11). 
IR (ATR) ~ (cm-1): 3028, 2966, 2908, 2870, 2230, 1641, 1446, 1432, 1257, 1230, 1194, 
1144, 1019, 992, 912, 884, 845, 730, 695, 668. 
HRMS (EI) calculated for C15H18N+: 212.1434, found 212.1433 [MH]+. 
 
Ethyl 4-(bicyclo[1.1.1]pentan-1-yl)-1-methylpiperidine-4-carboxylate (20) 
 
Diisopropylamine (320 mg, 3.2 mmol, 2.1 equiv) was dissolved in THF (3.5 mL) and BuLi 
(2.3 M in hexane, 1.4 mL, 3.2 mmol, 2.1 equiv) was added dropwise at 0 °C. The mixture was 
stirred for 5 min and cooled to 78 °C. Then ethyl 1-methylpiperidine-4-carboxylate (510 mg, 
3.0 mmol, 2.0 equiv) was added dropwise. After 30 min a solution of ZnCl2 in THF (1.0 M, 
3.8 mL, 3.8 mmol, 2.5 equiv) was added and the mixture was stirred at 0 °C for 5 min before 
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adding the [1.1.1]propellane in diethyl ether (0.53 M, 2.8 mL, 1.5 mmol, 1.0 equiv). After 
stirring at 0 °C for 2 h a saturated aqueous solution of NH4Cl (5 mL) was added. The reaction 
mixture was stirred for another 10 min at 25 °C, extracted with EtOAc (3 times), washed with 
brine, dried over MgSO4 and concentrated in vacuo. Purification via column chromatography 
(alumina, grade III, iHex / NEt3 = 19 / 1) afforded the desired compound 20 (340 mg, 
1.4 mmol, 95%) as colorless crystals. The structure was confirmed via single crystal X-ray 
diffraction studies. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 4.16 (q, J = 7.1 Hz, 2 H), 2.75 (d, J = 11.8 Hz, 2 H), 
2.44 (s, 1 H), 2.22 (s, 3 H), 2.06 (d, J = 13.5 Hz, 2 H), 1.84 (t, J = 12.2 Hz, 2 H), 1.62 (s, 6 H), 
1.45 (td, J = 13.2, 3.8 Hz, 2 H), 1.26 (t, J = 7.1 Hz, 3 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 173.8, 60.3, 53.6, 49.3, 47.9, 46.4, 46.1, 30.1, 25.3, 
14.7. 
MS (70 eV, EI) m/z (%): 237 (28) [M]+, 236 (21), 222 (11), 208 (42), 192 (19), 168 (26), 
165 (12), 164 (100), 162 (42), 148 (13), 140 (20), 136 (24), 122 (14), 120 (11), 105 (10), 
96 (22), 94 (27), 91 (19), 79 (13), 71 (14), 70 (35), 42 (15). 
IR (ATR) ~ (cm-1): 2964, 2935, 2908, 2872, 2840, 2739, 1723, 1467, 1441, 1427, 1378, 
1365, 1315, 1290, 1229, 1208, 1199, 1183, 1155, 1142, 1094, 1058, 1024, 1004, 966, 949, 
891, 863, 852, 789, 762, 701. 
HRMS (EI) calculated for C14H23NO2+: 237.1723, found 237.1725 [M]+. 




3 Experimental Section Part II: Selective 
Metalation of Nitrogen Containing Heterocycles 
Using 2,2,6,6-Tetramethylpiperidyl Bases 
3.1 Preparation of Starting Materials 
1,3,4-Oxadiazole (25) 
 
1,3,4-Oxadiazole was prepared according to a literature procedure.75 Polyphosphoric acid 
(108 g) was heated to 100 °C before adding P2O5 (12 g, 42 mmol, 0.31 equiv). After stirring 
for 15 min N,N’-diformylhydrazine (12 g, 136 mmol, 1.0 equiv) was added, the resulting 
mixture was stirred at 100 °C for 4 h and then poured on ice (100 g). Neutralization with solid 
NaHCO3, extraction with DCM, drying over MgSO4 and evaporation of the solvents in vacuo 
yielded 1,3,4-oxadiazole 25 (2.5 g, 36 mmol, 26%) as a colorless liquid. The product was 
protected from light and stored at 5 °C. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 8.51 (s, 2 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 152.9. 
 
N-Substituted 1H-1,2,4-triazoles (32) 
N-Substituted 1H-1,2,3-triazoles were prepared according to a literature procedure.118 A dry 
and argon-flushed 250mL round-bottom flask equipped with a magnetic stirrer and a septum 
was charged with 1H-1,2,4-triazole (6.91 g, 100 mmol), the respective bromide (105 mmol) 
and THF (100 mL). After cooling to 4 °C 1,8-diazabicyclo(5.4.0)undec-7-ene (17.9 ml, 18.3 g, 
120 mmol) was added to the solution. The mixture was stirred for 18 h at room temperature, 
quenched with water (100 mL) and extracted with DCM (3 × 80 mL). The combined organic 
phases were washed with brine (80 mL) and dried over MgSO4. Evaporation of the solvents 
in vacuo and purification via column chromatography on silica gel or vacuum distillation 
afforded the desired N-substituted 1H-1,2,3-triazole 32. 
                                               






1-Propyl-1H-1,2,4-triazole was prepared using 1-bromopropane (9.6 ml, 13 g, 110 mmol). 
Purification via column chromatography (silica gel, ihexane / EtOAc = 1:1) yielded the title 
compound 32a (6.8 g, 61 mmol, 56%) as a colorless liquid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 8.01 (s, 1 H), 7.88 (s, 1 H), 4.12 – 4.03 (m, 2 H), 1.93 
– 1.79 (m, 2 H), 0.92 – 0.82 (m, 3 H). 




1-Benzyl-1H-1,2,4-triazole was prepared using benzyl bromide (18.0 g, 105 mmol). 
Purification via column chromatography (silica gel, ihexane / EtOAc = 1:1) yielded the title 
compound 32b (7.98 g, 50.1 mmol, 48%) as a colorless solid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 8.06 (s, 1 H), 7.98 (s, 1 H), 7.46 – 7.30 (m, 3 H), 7.30 
– 7.23 (m, 2 H), 5.35 (s, 2 H). 




1-(2-Iodobenzyl)-1H-1,2,4-triazole was prepared using 2-iodobenzyl bromide (9.57 mL, 
12.9 g, 105 mmol). Purification via vacuum distillation (2 mbar, 111-114 °C) yielded the title 
compound 32c (5.98 g, 53.8 mmol, 54%) as a colorless oil. 
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1H-NMR (CDCl3, 400 MHz, ppm): δ = 8.18 (s, 1 H), 8.01 (s, 1 H), 7.90 (dd, J = 8.0, 1.3 Hz, 
1 H), 7.37 (td, J = 7.6, 1.3 Hz, 1 H), 7.13 (dd, J = 7.7, 1.7 Hz, 1 H), 7.07 (td, J = 7.7, 1.6 Hz, 
1 H), 5.43 (s, 2 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 152.33, 143.76, 139.91, 137.10, 130.40, 129.80, 




1H-Imidazo[1,2-b]pyrazole was synthesized using a slightly modified literature procedure89: A 
solution of N2H4H2O (77 mL, 500 mmol) in absolute ethanol (250 mL) was heated to reflux 
before adding bromoacetaldehyde diethyl acetal (121 mL, 2.5 mol) dropwise over 45 min. 
The resulting solution was refluxed for an additional 3 h and the solvents were removed in 
vacuo. The residue was taken up in aqueous NaOH (35%, 60 mL) and a saturated aqueous 
solution of NaCl (50 mL) and the mixture was extracted with toluene (2x250 mL). 
The resulting solution of (2,2-diethoxyethyl)hydrazine in toluene was treated with ethyl 
2-cyano-3-ethoxyacrylate (85 g, 500 mmol) under argon atmosphere and stirred at 25 °C 
over night. Then the reaction mixture was heated for 3.5 h while distilling of an azeotrope of 
toluene, ethanol and water at around 73 °C. The remaining toluene was removed in vacuo 
and the residue containing ethyl 5-amino-1-(2,2-diethoxyethyl)-1H-pyrazole-4-carboxylate 
was treated with NaOH (4 M, 1 L) and heated to 110 °C for 2 h. The mixture was cooled 
down, extracted with DCM (2x200mL) and the organic phase was washed with brine 
(50 mL). The combined aqueous phases were cooled to 0 °C and treated with HCl (6 M) until 
pH 4.5. The resulting solid was filtered off, washed with cold water and dried to obtain pure 
5-amino-1-(2,2-diethoxyethyl)-1H-pyrazole-4-carboxylic acid (97 g, 400 mmol, 80% over 
3 steps) as a colorless solid. 
The 5-amino-1-(2,2-diethoxyethyl)-1H-pyrazole-4-carboxylic acid was dissolved in absolute 
ethanol (100 mL) and H2SO4 (20%, 700 mL) and heated to 75 °C for 75 min. After cooling to 
25 °C the mixture was poured on crushed ice (1 L) and slowly treated with solid NaHCO3 
until pH 9. The formed solid was filtered off and washed with cold water. The aqueous phase 
was extracted with EtOAc (3x500 mL), the combined organic phase was dried over MgSO4 
and evaporated. The resulting solid was combined with the solid from the filtration and 
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purified via flash column chromatography (silica gel, EtOAc/MeOH = 49:1) to yield 
1H-imidazo[1,2-b]pyrazole (39, 25 g, 240 mmol, 60%) as a slightly yellow solid. 
1H-NMR (DMSO-d6, 400 MHz, ppm): δ = δ 10.96 (brs, 1 H), 7.48 (dd, J = 2.1, 0.7 Hz, 1 H), 
7.44 (dd, J = 2.1, 1.3 Hz, 1 H), 7.13 (dd, J = 2.1, 1.3 Hz, 1 H), 5.61 (dd, J = 2.2, 0.7 Hz, 1 H). 
13C-NMR (DMSO-d6, 101 MHz, ppm): δ = 141.9, 141.0, 117.9, 107.3, 78.3. 
MS (70 eV, EI) m/z (%): 107 (100) [M]+, 106 (17), 80 (27), 79 (15), 44 (21). 
IR (ATR) ~ (cm-1): 3157, 3132, 3051, 3005, 2741, 2691, 1594, 1463, 1441, 1393, 1348, 
1282, 1171, 1097, 1074, 1045, 957, 914, 867, 831, 789, 763, 697, 677. 
HRMS (EI) calculated for C5H5N3+: 107.0478, found 107.0478 [M]+. 




To a solution of 1H-imidazo[1,2-b]pyrazole (2.1 g, 20 mmol, 1.0 equiv) in DMF (40 mL) was 
slowly added sodium hydride (0.71 g, 30 mmol, 1.5 equiv) at 0 °C. The resulting mixture was 
stirred at 0 °C for 1 h before adding SEMCl (5.3 mL, 30 mmol, 1.5 equiv). The reaction was 
warmed to 25 °C and stirred for 2 h before slowly adding a concentrated aqueous solution of 
NH4Cl (20 mL). The reaction mixture was extracted with EtOAc (3x30 mL), washed with brine 
(3x30 mL), dried over MgSO4 and concentrated in vacuo. Purification via column 
chromatography (silica gel, iHex/EtOAc = 2:1 to pure EtOAc) yielded 
1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[1,2-b]pyrazole (40, 2.7 g, 11 mmol, 57%) as a 
slightly yellow liquid alongside unreacted 1H-imidazo[1,2-b]pyrazole (39, 0.47 g, 4.4 mmol, 
22%). 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 7.65 – 7.60 (m, 1 H), 7.33 (d, J = 1.9 Hz, 1 H), 6.83 – 
6.80 (m, 1 H), 5.75 (d, J = 1.8 Hz, 1 H), 5.22 (s, 2 H), 3.52 (t, J = 8.2 Hz, 2 H), 0.90 (t, J = 
8.2 Hz, 2 H), 0.04 (s, 9 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 144.5, 143.7, 120.6, 110.4, 80.6, 78.3, 68.1, 19.1, 0.0. 
MS (70 eV, EI) m/z (%): 237 (16) [M]+, 179 (70), 151 (10), 121 (33), 120 (56), 103 (11), 93 
(16), 73 (100). 
107 
 
IR (ATR) ~ (cm-1): 3131, 2952, 2892, 1589, 1547, 1463, 1412, 1379, 1315, 1282, 1247, 
1229, 1210, 1193, 1178, 1070, 1032, 973, 936, 917, 856, 831, 758, 690. 




To a solution of 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[1,2-b]pyrazole (1.7 g, 
5.0 mmol, 1.0 equiv) in MeCN (20 mL) was added N-bromosuccinimide (1.3 g, 5.0 mmol, 
1.0 equiv) and the resulting mixture was stirred at 25 °C for 10 min. The solvent was 
removed in vacuo at 30 °C and the crude product was directly purified via column 
chromatography (silica gel, iHex/EtOAc = 4:1) to yield 7-bromo-1-((2-
(trimethylsilyl)ethoxy)methyl)-1H-imidazo[1,2-b]pyrazole (41, 1.9 g, 6.0 mmol, 86%) as a 
colorless liquid. The compound was stored in the dark as a solid at 30 °C to prevent 
decomposition. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 7.55 (s, 1 H), 7.34 – 7.31 (m, 1 H), 6.86 (s, 1 H), 5.41 
(s, 2 H), 3.60 (t, J = 8.2 Hz, 2 H), 0.91 (t, J = 8.2 Hz, 2 H), 0.03 (s, 9 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 143.2, 138.3, 120.1, 109.7, 75.5, 66.7, 64.8, 17.9, 
1.3. 
MS (70 eV, EI) m/z (%): 317 (13), 315 (13) [M]+, 259 (53), 257 (53), 200 (31), 198 (33), 178 
(25), 151 (13), 119 (33), 73 (100). 
IR (ATR) ~ (cm-1): 3133, 2952, 2895, 1736, 1606, 1551, 1463, 1412, 1378, 1324, 1294, 
1276, 1247, 1210, 1194, 1177, 1153, 1081, 1069, 1027, 1003, 972, 916, 857, 833, 758, 689. 
HRMS (EI) calculated for C11H18BrN3OSi+: 315.0397, found 315.0397 [M]+. 
 
(TMP)2Zn∙2LiCl (26) 
TMPH (1.7 mL, 10 mmol, 1.0 equiv) was dissolved in THF (10 mL) and cooled to −40 °C 
before adding a solution of BuLi in hexanes (2.3 M, 4.4 mL, 10 mL, 1.0 equiv). The resulting 
mixture was stirred at 0 °C for 30 min, a solution of ZnCl2 in THF (1.0 M, 5.0 mL, 5.0 mmol, 
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0.50 equiv) was added, the reaction was protected from light using aluminium foil and stirred 
at 25 °C for 1-2 h. The formed solids were removed using a syringe filter and the base was 
titrated against benzoic acid using 4-(phenylazo)-diphenylamine as an indicator. 
 
(TMP)2Zn∙2MgCl2∙2LiCl (29) 
Freshly titrated TMPMgCl∙LiCl (10 mmol, 1.0 equiv) was added dropwise to a solution of 
ZnCl2 in THF (1.0 M, 5.3 mL, 5.3 mmol, 0.53 equiv). The resulting mixture was protected from 
light using aluminium foil and stirred at 25 °C for 2 h before titrating the base against benzoic 
acid using 4-(phenylazo)-diphenylamine as an indicator. 
 
TMPMgCl∙LiCl (33) 
TMPH (14.8 g, 105 mmol, 1.05 equiv) was slowly added to a solution of iPrMgCl∙LiCl in dry 
THF (1.05 M, 95 mL, 1.0 equiv). The resulting mixture was stirred under argon at 25 °C for 




TMPH (1.7 mL, 10 mmol, 1.0 equiv) was dissolved in THF (10 mL) and cooled to −40 °C 
before adding a solution of BuLi in hexanes (2.3 M, 4.4 mL, 10 mL, 1.0 equiv). The resulting 
mixture was stirred at 0 °C for 30 min, a solution of ZnCl2 in THF (1.0 M, 10 mL, 10 mmol, 
1.0 equiv) was added, the reaction was stirred at 25 °C for 1-2 h before titrating the base 
against benzoic acid using 4-(phenylazo)-diphenylamine as an indicator. 
 
(TMP)2Zn∙MgCl2∙2LiCl (46) 
Magnesium shavings (182 mg, 7.5 mmol) were placed in a Schlenk-flask under vacuum and 
dried with a heat gun at 650 °C for 5 min. After the flask was cooled down it was filled with 
argon and THF (15 mL). 1,2-Dichloroethane (0.59 mL, 7.5 mmol) was added dropwise over 
20 min, leading to gas evolution. The reaction was stirred for at least 1 h, leading to the 
formation of a 0.50 M solution of MgCl2 in THF. In a second Schlenk-flask TMPH (1.9 mL, 
11 mmol, 1.0 equiv) was dissolved in THF (11 mL) and cooled to 40 °C. Then freshly 
titrated BuLi (1.40 M in hexane, 7.86 mL, 11 mmol, 1.0 equiv) was added and the resulting 
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solution was stirred for 30 min. Then the freshly prepared MgCl2 solution (0.50 M in THF, 
11 mL, 5.5 mmol, 0.50 equiv) and ZnCl2 solution (1.0 M in THF, 5.5 mL, 5.5 mmol, 
0.50 equiv) were added. The resulting mixture was brought to room temperature, protected 
from light with aluminium foil and stirred for at least 1 h before titration against benzoic acid 
using 4-(phenylazo)-diphenylamine as an indicator. The base was stored in a closed 
Schlenk-flask covered with aluminium foil at room temperature for up to one week without a 
significant change in reactivity. 
 
3.2 Typical Procedures 
TP5: Metalation of 1,3,4-oxadiazole (25) with (TMP)2Zn∙2LiCl (26) followed by cross-
coupling 
1,3,4-Oxadiazole (25, 137 mg, 0.30 mmol, 1.0 equiv) was dissolved in THF (0.90 mL) and 
freshly prepared (TMP)2Zn∙2LiCl (26, 0.24 M, 0.68 mL, 0.17 mmol, 0.55 equiv) was added 
dropwise. The resulting suspension was stirred at 25 °C for 5 min before adding Pd(dba)2 
(14 mg, 0.0060 mmol, 3%), XantPhos (3.5 mg, 0.0060 mmol, 3%) and the respective aryl 
iodide (0.20 mmol, 0.67 equiv). After stirring for 2 h a saturated aqueous solution of NH4Cl 
(1 mL) was added. Extraction with EtOAc, drying over MgSO4, evaporation of the solvents in 
vacuo and purification via silica gel column chromatography yielded the desired mono-
substituted 1,3,4-oxadiazole 28. 
 
TP6: Metalation of mono-substituted 1,3,4-oxadiazoles of type 28 with 
(TMP)2Zn∙MgCl2∙2LiCl (29) followed by copper catalysed electrophilic amination 
Mono-substituted 1,3,4-oxadiazole of type (28, 0.50 mmol, 1.0 equiv) was dissolved in THF 
(1.0 mL) and freshly prepared (TMP)2Zn∙MgCl2∙2LiCl (29, 0.34 M, 0.81 mL, 0.28 mmol, 
0.55 equiv) was added dropwise. After stirring at 25 °C for 20 min the mixture was added to a 
solution of the respective hydroxyamino benzoate (0.35 mmol, 0.70 equiv) and copper(II) 
triflate (27 mg, 0.075 mmol, 15%) in THF (1 mL) and stirred for additional 2 h at 25 °C. Then 
a saturated aqueous solution of NH4Cl (1 mL) was added,. Extraction with EtOAc, drying 
over MgSO4, evaporation of the solvents in vacuo and purification via silica gel column 




TP7: Metalation of N-substituted 1H-1,2,4-triazoles (32) with TMPMgCl∙LiCl (33) 
followed by electrophilic trapping 
N-Substituted 1H-1,2,4-triazole (32, 0.50 mmol, 1.0 equiv) was dissolved in THF (1.5 mL) 
and cooled to 0 °C. TMPMgCl∙LiCl solution (33, 0.60 mmol, 1.2 equiv) was slowly added to 
the vigorously stirred solution. After 30 min the respective electrophile (0.60 mmol, 1.2 equiv) 
was added and the ice bath was removed. After stirring for 30 min the mixture was quenched 
with sat. aq. NH4Cl solution (15 mL), extracted with DCM (3×15 mL) and dried over 
anhydrous MgSO4. The crude product 35 was purified by flash column chromatography. 
 
TP8: Metalation of N-substituted 1H-1,2,4-triazoles (32) with TMPZnCl∙LiCl (36) 
followed by cross-coupling 
N-Substituted 1H-1,2,4-triazole (32, 0.50 mmol, 1.0 equiv) was dissolved in THF (1.5 mL) 
and cooled to 0 °C. TMPZnCl∙LiCl solution (36, 0.65 mmol, 1.3 equiv) was slowly added to 
the stirred solution. A dry, argon flushed Schlenk-flask equipped with a magnetic stirring bar 
and a septum was charged with the respective aromatic bromide or iodide (0.6 mmol, 
1.2 equiv), Pd(OAc)2 (5.6 mg, 0.025 mmol, 5%), SPhos (20.5 mg, 0.050 mmol, 10%) and 
THF (1.0 mL). After 30 min the metalated species was slowly added to the vigorously stirred 
solution. The reaction mixture was stirred at 40 °C for 18 h, quenched with sat. aq. NH4Cl 
solution (15 mL), extracted with DCM (3×15 mL) and dried over anhydrous MgSO4. The 
crude product 35 was purified by flash column chromatography. 
 
TP9: Metalation of N-substituted 1H-1,2,4-triazoles (32) with TMPZnCl∙LiCl (36) 
followed by copper-catalyzed electrophilic amination  
N-Substituted 1H-1,2,4-triazole (32, 0.50 mmol, 1.0 equiv) was dissolved in THF (1.5 mL) 
and cooled to 0 °C. TMPZnCl∙LiCl solution (36, 1 mmol, 2.0 equiv) was slowly added to the 
stirred solution. A dry, argon flushed Schlenk-flask equipped with a magnetic stirring bar and 
a septum was charged with amine benzoate (0.6 mmol, 1.2 equiv), copper (II) triflate (36 mg, 
0.1 mmol, 20%) and THF (2.0 mL). After 30 min the metalated species was slowly added to 
the vigorously stirred solution. After 2 h the mixture was quenched with sat. aq. NH4Cl 
solution (15 mL), extracted with DCM (3×15 mL) and dried over anhydrous MgSO4. The 




TP10: Double functionalization of N-substituted 1H-1,2,4-triazoles (32) with 
TMPMgCl∙LiCl (33) 
N-Substituted 1H-1,2,4-triazole (32, 0.50 mmol, 1.0 equiv) was dissolved in THF (1.5 mL) 
and cooled down to 0 °C. TMPMgCl∙LiCl solution (33, 2.0 mmol, 4.0 equiv) was slowly added 
to the vigorously stirred solution. After 30 min the respective electrophile (2.2 mmol, 
4.1 equiv) was added and the ice bath was removed. After 30 min the mixture was quenched 
with sat. aq. NH4Cl solution (15 mL), extracted with DCM (3×15 mL) and dried over 
anhydrous MgSO4. The crude product 37 was purified by flash column chromatography. 
 
TP11: Bromine-magnesium exchange of 7-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-
1H-imidazo[1,2-b]pyrazole (41) followed by electrophile trapping 
To a solution of 7-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[1,2-b]pyrazole (41, 
1.0 equiv) in THF (0.5 M) was added iPrMgClLiCl (42, 2.1 equiv) dropwise at 0 °C. The 
reaction mixture was warmed up to 25 °C and stirred for 1 h before adding the respective 
electrophile. After stirring for the indicated time a saturated aqueous solution of NH4Cl was 
added. The reaction was extracted with EtOAc (3x), washed with brine, dried over MgSO4, 
concentrated in vacuo and purified via silica gel column chromatography to yield the desired 
7-substituted 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[1,2-b]pyrazole of type 43. 
 
TP12: Metalation of 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[1,2-b]pyrazole-7-
carbonitrile (43b) with TMPMgCl∙LiCl (33) followed by electrophile trapping 
To a solution of 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[1,2-b]pyrazole-7-carbonitrile 
(43b, 1.0 equiv) in THF (0.5 M) was added a solution of TMPMgClLiCl (33, typically 0.95-
1.05 M in THF, 1.5 equiv) dropwise at 20 °C. The mixture was stirred at 20 °C for 2 h 
before adding the respective electrophile. After stirring for the indicated time a saturated 
aqueous solution of NH4Cl was added. The reaction was extracted with EtOAc (3x), washed 
with brine, dried over MgSO4, concentrated in vacuo and purified via silica gel column 
chromatography to yield the desired 3-substituted 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-




TP13: Metalation of ethyl 7-cyano-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo-
[1,2-b]pyrazole-3-carboxylate (45c) with (TMP)2Zn∙MgCl2∙2LiCl (46) followed by 
electrophile trapping 
To a solution of 7-cyano-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[1,2-b]pyrazole-3-
carboxylate (45c, 1.0 equiv) in THF (0.20 mL) was added a solution of (TMP)2Zn∙MgCl2∙2LiCl 
(46, typically 0.14-0.16 M in THF, 0.65 equiv for allylations and acylations, 0.55 equiv for 
cross-couplings) dropwise at 0 °C. The mixture was stirred at 0 °C for 30 min before adding 
the respective electrophile. After stirring for the indicated time a saturated aqueous solution 
of NH4Cl was added. The reaction was extracted with EtOAc (3x), washed with brine, dried 
over MgSO4, concentrated in vacuo and purified via silica gel column chromatography to 
yield the desired 2-substituted ethyl 7-cyano-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-
imidazo[1,2-b]pyrazole-3-carboxylate of type 47. 
 
TP14: Dimerization of 2-functionalized ethyl 7-cyano-1-((2-(trimethylsilyl)-
ethoxy)methyl)-1H-imidazo[1,2-b]pyrazole-3-carboxylates of type 47 with 
(TMP)2Zn∙MgCl2∙2LiCl (46) 
To a solution of the respective 7-cyano-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[1,2-b]-
pyrazole-3-carboxylate of type 47 (1.0 equiv) in THF (0.5 M) was added a solution of 
(TMP)2Zn∙MgCl2∙LiCl (46, typically 0.14-0.16 M in THF, 0.65 equiv) dropwise at 0 °C. The 
mixture was stirred at 0 °C for the indicated time before adding a saturated aqueous solution 
of NH4Cl. The reaction was extracted with EtOAc (3x), washed with brine, dried over MgSO4, 
concentrated in vacuo and purified via column chromatography on Florisil® (iHex/EtOAc = 
4:1, then iHex/ EtOAc = 1:1, then EtOAc, then EtOAc/MeOH = 10:1) to yield the desired 
1H,1'H,5H,5'H-6,6'-biimidazo[1,2-b]pyrazolylidene of type 48. 
 
3.3 Optimization of the Conditions for the Metalation of 1,3,4-Oxadiazole 
The conditions for the metalation of 1,3,4-oxadiazole were screened via GC chromatography 
after a copper-catalyzed allylation with 3-bromocyclohexene (Scheme 44). Magnesium bases 
yielded only traces of the desired product. A significant improvement was achieved by 
switching to zinc bases, with the bis-base (TMP)2Zn∙2LiCl giving the best results. The yields 
were significantly higher if the solid formed during the preparation of the base was filtered off 
before the use. The optimal amount of base was determined to be 0.55 equivalents, which 











2-Phenyl-1,3,4-oxadiazole was prepared according to TP5 using phenyl iodide (41 mg, 
0.20 mmol). Purification via column chromatography (silica gel, ihexane / EtOAc = 4:1) 
yielded the title compound 28a (25 mg, 0.17 mmol, 86%) as colorless crystals. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 8.48 (s, 1 H), 8.12 – 8.02 (m, 2 H), 7.60 – 7.46 (m, 
3 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 164.8, 152.7, 132.0, 129.1, 127.1, 123.5. 
MS (70 eV, EI) m/z (%): 146 (100) [M]+, 105 (42), 91 (11), 90 (32), 89 (19), 77 (16). 
IR (ATR) ~ (cm-1): 3231, 3131, 1706, 1663, 1609, 1589, 1555, 1514, 1481, 1449, 1340, 
1288, 1234, 1179, 1105, 1077, 1063, 1025, 1002, 955, 944, 927, 849, 777, 709, 687. 
HRMS (EI) calculated for C8H6N2O+: 146.0475, found 146.0475 [M]+. 
mp: 33.8 – 35.1 °C. 
 
Ethyl 4-(1,3,4-oxadiazol-2-yl)benzoate (28b) 
 
Ethyl 4-(1,3,4-oxadiazol-2-yl)benzoate was prepared according to TP5 using ethyl 
4-iodobenzoate (55 mg, 0.20 mmol). Purification via column chromatography (silica gel, 
ihexane / EtOAc = 3:1) yielded the title compound 28b (43 mg, 0.197 mmol, 98%) as a 
colorless solid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 8.53 (s, 1 H), 8.21 – 8.13 (m, 4 H), 4.41 (q, J = 7.1 Hz, 
2 H), 1.42 (t, J = 7.1 Hz, 3 H). 




MS (70 eV, EI) m/z (%): 218 (7) [M]+, 190 (64), 174 (10), 173 100), 149 (14), 145 (14), 
118 (8), 90 (8). 
IR (ATR) ~ (cm-1): 3124, 1701, 1553, 1477, 1414, 1370, 1310, 1277, 1178, 1131, 1105, 
1069, 1013, 955, 874, 847, 779, 714. 
HRMS (EI) calculated for C11H11N2O3+: 218.0686, found 218.0688 [M]+. 




2-(4-Chlorophenyl)-1,3,4-oxadiazole was prepared according to TP5 using 1-chloro-4-
iodobenzene (48 mg, 0.20 mmol). Purification via column chromatography (silica gel, 
ihexane / EtOAc = 4:1) yielded the title compound 28c (31 mg, 0.17 mmol, 86%) as a slightly 
brown solid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 8.48 (s, 1 H), 8.02 (d, J = 8.6 Hz, 2 H), 7.50 (d, 
J = 8.6 Hz, 2 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 164.0, 152.7, 138.4, 129.6, 128.4, 121.9. 
MS (70 eV, EI) m/z (%): 182 (35), 181 (13), 180 (100) [M]+, 141 (24), 139 (95), 137 (20), 125 
(17), 124 (20), 111 (22), 89 (29), 85 (14), 75 (21), 71 (19), 69 (10), 57 (21), 43 (17). 
IR (ATR) ~ (cm-1): 3148, 2921, 1983, 1716, 1605, 1583, 1549, 1513, 1480, 1406, 1332, 
1278, 1215, 1172, 1114, 1091, 1062, 1009, 971, 959, 951, 941, 859, 830, 741, 730, 693. 
HRMS (EI) calculated for C8H5ClN2O+: 180.0085, found 180.0081 [M]+. 






4-(1,3,4-Oxadiazol-2-yl)benzonitrile was prepared according to TP5 using 4-iodobenzonitrile 
(46 mg, 0.20 mmol). Purification via column chromatography (silica gel, ihexane / EtOAc = 
6:4) yielded the title compound 28d (25 mg, 0.15 mmol, 73%) as a colorless solid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 8.50 (s, 1 H), 8.15 (d, J = 8.7 Hz, 2 H), 7.77 (d, 
J = 8.7 Hz, 2 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 163.3, 153.3, 133.0, 127.6, 127.3, 117.8, 115.6. 
MS (70 eV, EI) m/z (%): 171 (69) [M]+, 130 (57), 128 (16), 116 (37), 115 (100), 114 (36), 
91 (11), 88 (13), 76 (17), 75 (20), 62 (10). 
IR (ATR) ~ (cm-1): 3154, 2922, 2228, 1581, 1551, 1501, 1489, 1405, 1282, 1225, 1091, 
1068, 1015, 956, 867, 839, 736, 698. 
HRMS (EI) calculated for C9H5N3O+: 171.0427, found 171.0425 [M]+. 




2-(4-(trifluoromethyl)phenyl)-1,3,4-oxadiazole was prepared according to TP5 using 1-iodo-4-
(trifluoromethyl)benzene (55 mg, 0.20 mmol). Purification via column chromatography (silica 
gel, ihexane / EtOAc = 4:1) yielded the title compound 28e (35 mg, 0.16 mmol, 82%) as a 
colorless solid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 8.54 (s, 1 H), 8.22 (d, J = 7.7 Hz, 2 H), 7.79 (d, 
J = 8.4 Hz, 2 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 163.7, 153.1, 133.7 (q, J = 33.0 Hz), 127.5, 126.7, 
126,2 (q, J = 3.8 Hz), 123.5 (q, J = 273.1 Hz). 
117 
 
MS (70 eV, EI) m/z (%): 214 (100) [M]+, 195 (13), 173 (69), 167 (10), 158 (71), 145 (38), 138 
(9). 
IR (ATR) ~ (cm-1): 3153, 2923, 1562, 1516, 1414, 1319, 1224, 1186, 1157, 1111, 1071, 
1056, 1010, 947, 867, 847, 748, 705. 
HRMS (EI) calculated for C9H5F3N2O+: 214.0348, found 214.0348 [M]+. 




2-(4-Methoxyphenyl)-1,3,4-oxadiazole was prepared according to TP5 using 1-iodo-4-
methoxybenzene (47 mg, 0.20 mmol). The cross-coupling was conducted at 50 °C using 
Pd(PPh3)4 (17 mg, 0.015 mmol, 7.5%) as a catalyst. Purification via column chromatography 
(silica gel, ihexane / EtOAc = 6:4) yielded the title compound 14f (32 mg, 0.18 mmol, 90%) 
as a colorless solid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 8.41 (s, 1 H), 8.01 (d, J = 8.9 Hz, 2 H), 7.01 (d, 
J = 8.9 Hz, 2 H), 3.88 (s, 3 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 164.7, 162.5, 152.2, 128.9, 116.0, 114.5, 55.5. 
MS (70 eV, EI) m/z (%): 176 (100) [M]+, 136 (8), 135 (95), 91 (6), 77 (7). 
IR (ATR) ~ (cm-1): 3126, 2922, 2851, 1718, 1612, 1587, 1559, 1517, 1494, 1456, 1438, 
1422, 1302, 1257, 1179, 1122, 1110, 1097, 1066, 1017, 973, 959, 939, 860, 832, 818, 797, 
738, 702. 
HRMS (EI) calculated for C9H8N2O2+: 176.0580, found 176.0580 [M]+. 






N,N-Dimethyl-4-(1,3,4-oxadiazol-2-yl)aniline was prepared according to TP5 using 4-iodo-
N,N-dimethylaniline (49 mg, 0.20 mmol). The cross-coupling was conducted at 50 °C using 
Pd(PPh3)4 (17 mg, 0.015 mmol, 7.5%) as a catalyst. Purification via column chromatography 
(silica gel, ihexane / EtOAc = 7:3) yielded the title compound 28g (24 mg, 0.13 mmol, 63%) 
as a colorless solid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 8.35 (s, 1 H), 7.91 (d, J = 9.0 Hz, 2 H), 6.74 (d, 
J = 9.0 Hz, 2 H), 3.05 (s, 6 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 165.5, 152.5, 151.7, 128.6, 111.7, 110.6, 40.2. 
MS (70 eV, EI) m/z (%): 189 (100) [M]+, 188 (60), 161 (7), 148 (30), 145 (13), 132 (13), 
118 (7). 
IR (ATR) ~ (cm-1):  
HRMS (EI) calculated for C10H11N3O+: 189.0897, found 189.0896 [M]+. 




2-(3-Nitrophenyl)-1,3,4-oxadiazole was prepared according to TP5 using 1-iodo-3-
nitrobenzene (50 mg, 0.20 mmol). Purification via column chromatography (silica gel, 
ihexane / EtOAc = 6:4) yielded the title compound 28h (37 mg, 0.19 mmol, 97%) as a 
colorless solid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 8.91 (t, J = 2.0 Hz, 1 H), 8.58 (s, 1 H), 8.45 (ddd, 
J = 7.8, 1.6, 1.0 Hz, 1 H), 8.42 (ddd, J = 8.3, 2.3, 1.1 Hz, 1 H), 7.76 (t, J = 8.0 Hz, 1 H). 




MS (70 eV, EI) m/z (%): 191 (86) [M]+, 150 (49), 145 (15), 118 (21), 117 (14), 104 (13), 
90 (77), 89 (100), 88 (14), 87 (18), 86 (16), 76 (42), 75 (39), 74 (26), 63 (47), 62 (19), 
50 (12), 46 (12). 
IR (ATR) ~ (cm-1): 3160, 3092, 2923, 2853, 1620, 1591, 1556, 1530, 1508, 1475, 1352, 
1253, 1238, 1166, 1122, 1104, 1061, 1001, 976, 963, 953, 906, 883, 871, 856, 812, 753, 
739, 711, 668. 
HRMS (EI) calculated for C8H5N3O3+: 191.0325, found 191.0324 [M]+. 




2-(2-Fluorophenyl)-1,3,4-oxadiazole was prepared according to TP5 using 1-fluoro-2-
iodobenzene (44 mg, 0.20 mmol). Purification via column chromatography (silica gel, 
ihexane / EtOAc = 4:1) yielded the title compound 28i (29 mg, 0.18 mmol, 88%) as a slightly 
brown liquid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 8.54 (s, 1 H), 8.08 (ddd, J = 7.9, 7.1, 1.8 Hz, 1 H), 7.59 
– 7.51 (m, 1 H), 7.31 (td, J = 7.6, 1.1 Hz, 1 H), 7.26 (ddd, J = 10.5, 8.3, 1.1 Hz, 1 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 161.7 (d, J = 4.9 Hz), 160.1 (d, J = 258.6 Hz), 153.0 
(d, J = 1.2 Hz), 133.9 (d, J = 8.5 Hz), 129.9, 124.8 (d, J = 3.8 Hz), 117.1 (d, J = 20.8 Hz), 
112.0 (d, J = 11.7 Hz). 
MS (70 eV, EI) m/z (%): 164 (100) [M]+, 123 (36), 109 (20), 108 (57), 107 (24). 
IR (ATR) ~ (cm-1): 3117, 1621, 1591, 1550, 1515, 1492, 1472, 1442, 1405, 1346, 1272, 
1262, 1223, 1159, 1102, 1069, 1053, 1027, 955, 856, 820, 765, 740, 700, 663. 






2-(Quinolin-6-yl)-1,3,4-oxadiazole was prepared according to TP5 using 6-iodoquinoline 
(51 mg, 0.20 mmol). Purification via column chromatography (silica gel, EtOAc) yielded the 
title compound 28j (36 mg, 0.19 mmol, 92%) as a slightly yellow solid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 9.01 (dd, J = 4.3, 1.7 Hz, 1 H), 8.57 (d, J = 1.9 Hz, 
1 H), 8.55 (s, 1 H), 8.37 (dd, J = 8.8, 1.9 Hz, 1 H), 8.28 (d, J = 8.4 Hz, 1 H), 8.23 (d, 
J = 8.9 Hz, 1 H), 7.50 (dd, J = 8.3, 4.2 Hz, 1 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 164.5, 153.1, 152.5, 149.4, 137.0, 130.9, 128.0, 
127.7, 127.1, 122.4, 121.6. 
MS (70 eV, EI) m/z (%): 197 (98) [M]+, 157 (10), 156 (100), 141 (10), 140 (12), 128 (27). 
IR (ATR) ~ (cm-1): 3351, 3080, 2923, 2852, 1628, 1578, 1549, 1509, 1495, 1438, 1367, 
1331, 1310, 1249, 1187, 1127, 1089, 1059, 1037, 977, 958, 939, 911, 889, 850, 834, 798, 
768, 723. 
HRMS (EI) calculated for C11H7N3O+: 197.0584, found 197.0582 [M]+. 




2-(Thiophen-2-yl)-1,3,4-oxadiazole was prepared according to TP5 using 2-iodothiophene 
(42 mg, 0.20 mmol). Purification via column chromatography (silica gel, ihexane / EtOAc = 
4:1) yielded the title compound 28k (28 mg, 0.18 mmol, 92%) as a slightly brown liquid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 8.40 (s, 1 H), 7.79 (dd, J = 3.8, 1.2 Hz, 1 H), 7.57 (dd, 
J = 5.0, 1.2 Hz, 1 H), 7.18 (dd, J = 5.0, 3.7 Hz, 1 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 161.0, 152.0, 130.6, 130.3, 128.3, 124.7. 
MS (70 eV, EI) m/z (%): 152 (100) [M]+, 110 (49), 96 (22), 70 (6). 
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IR (ATR) ~ (cm-1): 3228, 3106, 3000, 1703, 1652, 1593, 1578, 1520, 1490, 1419, 1372, 
1355, 1297, 1233, 1214, 1096, 1061, 1010, 953; 919, 851, 720. 




4-(5-Phenyl-1,3,4-oxadiazol-2-yl)morpholine was prepared according to TP6 using 2-phenyl-
1,3,4-oxadiazole 28a (73 mg, 0.50 mmol) and morpholino benzoate (73 mg, 0.35 mmol). 
Purification via column chromatography (silica gel, ihexane / EtOAc = 3:1) yielded the title 
compound 31a (79 mg, 0.34 mmol, 98%) as a colorless oil. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 7.88 – 7.78 (m, 2 H), 7.38 (dq, J = 6.6, 2.8, 1.8 Hz, 
3 H), 3.82 – 3.73 (m, 4 H), 3.53 (dd, J = 5.8, 3.9 Hz, 4 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 164.0, 159.6, 130.7, 128.9, 125.9, 124.4, 66.0, 46.2. 
MS (70 eV, EI) m/z (%): 231 (80) [M]+, 207 (25), 135 (100), 70 (6). 
IR (ATR) ~ (cm-1): 2398, 2377, 1798, 1721, 1355, 1348, 1250, 688. 




N,N-Dimethyl-4-(5-morpholino-1,3,4-oxadiazol-2-yl)aniline was prepared according to TP6 
using N,N-dimethyl-4-(1,3,4-oxadiazol-2-yl)aniline 28g (95 mg, 0.50 mmol) and morpholino 
benzoate (73 mg, 0.35 mmol). Purification via column chromatography (silica gel, ihexane / 
EtOAc = 3:1) yielded the title compound 31b (71 mg, 0.26 mmol, 74%) as a colorless oil. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 7.83 – 7.63 (m, 2 H), 6.78 – 6.62 (m, 2 H), 3.88 – 3.72 
(m, 4 H), 3.66 – 3.48 (m, 4 H), 3.01 (s, 6 H). 
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13C-NMR (CDCl3, 101 MHz, ppm): δ = 163.6, 160.5, 151.8, 127.3, 111.7, 66.1, 46.4, 40.2. 
MS (70 eV, EI) m/z (%): 274 (86) [M]+, 207 (35), 135 (100), 120 (12). 
IR (ATR) ~ (cm-1): 2972, 2917, 2893, 2857, 1605, 1572, 1510, 1452, 1445, 1432, 1364, 
1272, 1258, 1228, 1192, 1170, 1117, 1071, 1062, 951, 945, 909, 820, 761, 725, 704. 




4-(5-(4-Chlorophenyl)-1,3,4-oxadiazol-2-yl)morpholine was prepared according to TP6 using 
2-(4-chlorophenyl)-1,3,4-oxadiazole 28c (90 mg, 0.50 mmol) and morpholino benzoate 
(73 mg, 0.35 mmol). Purification via column chromatography (silica gel, ihexane / EtOAc = 
3:1) yielded the title compound 31c (74 mg, 0.28 mmol, 80%) as a colorless oil. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 7.86 – 7.71 (m, 2 H), 7.45 – 7.31 (m, 2 H), 3.84 – 3.70 
(m, 4 H), 3.65 – 3.48 (m, 4 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 164.2, 158.9, 136.8, 129.4, 127.2, 123.0, 66.1, 46.3. 
MS (70 eV, EI) m/z (%): 265 (78) [M]+, 207 (29), 135 (100), 70 (9). 
IR (ATR) ~ (cm-1): 2922, 1706, 1637, 1618, 1614, 1603, 1577, 1485, 1440, 1434, 1421, 
1396, 1390, 1359, 1273, 1258, 1221, 1120, 1114, 1092, 1060, 1012, 912, 837, 732. 




4-(5-(4-(Trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)morpholine was prepared according to 
TP6 using 2-(4-(trifluoromethyl)phenyl)-1,3,4-oxadiazole 28e (107 mg, 0.50 mmol) and 
morpholino benzoate (73 mg, 0.35 mmol). Purification via column chromatography (silica gel, 
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ihexane / EtOAc = 3:1) yielded the title compound 31d (73 mg, 0.25 mmol, 70%) as a 
colorless oil. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 8.01 (d, J = 8.1 Hz, 2 H), 7.70 (d, J = 8.3 Hz, 2 H), 
3.84 (dd, J = 6.0, 3.8 Hz, 4 H), 3.61 (dd, J = 5.8, 3.9 Hz, 4 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 164.3, 158.4, 132.2 (d, J = 32.8 Hz), 127.6, 126.0, 
126.0 (d, J = 3.9 Hz, 2C), 123.7 (d, J = 272.4 Hz), 65.9, 46.2. 
MS (70 eV, EI) m/z (%): 299 (43) [M]+, 242 (65), 173 (100), 145 (79), 114 (45). 
IR (ATR) ~ (cm-1): 2921, 2860, 1711, 1693, 1613, 1584, 1563, 1452, 1425, 1323, 1274, 
1258, 1167, 1113, 1070, 1025, 1016, 913, 847, 730, 714, 685. 




N,N-Diallyl-5-phenyl-1,3,4-oxadiazol-2-amine was prepared according to TP6 using 
2-phenyl-1,3,4-oxadiazole 28a (73 mg, 0.50 mmol) and N,N-diallyl-O-benzoylhydroxylamine 
(76 mg, 0.35 mmol). Purification via column chromatography (silica gel, ihexane / EtOAc = 
3:1) yielded the title compound 31e (78 mg, 0.32 mmol, 92%) as a colorless oil. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 7.89 (dt, J = 5.9, 3.6 Hz, 2 H), 7.48 – 7.38 (m, 3 H), 
5.87 (ddt, J = 17.2, 10.1, 6.0 Hz, 2 H), 5.33 – 5.20 (m, 4 H), 4.09 (dt, J = 6.0, 1.5 Hz, 4 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 164.0, 159.1, 132.2, 130.4, 128.8, 125.7, 124.7, 
118.5, 50.6. 
MS (70 eV, EI) m/z (%): 241 (6) [M]+, 200 (16), 174 (29), 105 (82), 77 (100). 
IR (ATR) ~ (cm-1): 2920, 2359, 1712, 1643, 1613, 1604, 1583, 1556, 1491, 1449, 1418, 
1355, 1281, 1255, 1221, 1179, 1113, 1057, 1024, 1004, 991, 964, 925, 888, 769, 728, 689, 
683, 668. 





2-(Azepan-1-yl)-5-(4-methoxyphenyl)-1,3,4-oxadiazole was prepared according to TP6 using 
2-(4-methoxyphenyl)-1,3,4-oxadiazole 28f (88 mg, 0.50 mmol) and azepan-1-yl benzoate 
(77 mg, 0.35 mmol). Purification via column chromatography (silica gel, ihexane / EtOAc = 
3:1) yielded the title compound 31f (75 mg, 0.27 mmol, 78%) as a colorless oil. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 7.84 (d, J = 8.3 Hz, 2 H), 6.95 (d, J = 8.2 Hz, 2 H), 
3.85 (s, 3 H), 3.74 – 3.55 (m, 3 H), 1.80 (d, J = 25.9 Hz, 5 H), 1.62 (p, J = 2.6 Hz, 4 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 161.1, 127.3, 117.6, 114.2, 55.4, 48.4, 28.2, 27.6. 
MS (70 eV, EI) m/z (%): 273 (20) [M]+, 175 (100), 133 (19), 98 (6). 
IR (ATR) ~ (cm-1): 2928, 2856, 1710, 1624, 1607, 1583, 1562, 1502, 1463, 1443, 1425, 
1378, 1360, 1301, 1280, 1252, 1219, 1172, 1113, 1103, 1059, 1025, 996, 884, 836, 812, 
798, 735, 721, 683. 




2-Phenyl-5-(4-(pyrimidin-2-yl)piperazin-1-yl)-1,3,4-oxadiazole was prepared according to TP6 
using 2-phenyl-1,3,4-oxadiazole 28a (73 mg, 0.50 mmol) and 4-(pyrimidin-2-yl)piperazin-1-yl 
benzoate (100 mg, 0.35 mmol). Purification via column chromatography (silica gel, ihexane / 
EtOAc = 3:1) yielded the title compound 31g (101 mg, 0.33 mmol, 94%) as a colorless oil. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 8.30 (d, J = 4.7 Hz, 2 H), 7.94 – 7.85 (m, 2 H), 7.46 – 
7.36 (m, 3 H), 6.52 (t, J = 4.7 Hz, 1 H), 4.02 – 3.89 (m, 4 H), 3.67 – 3.55 (m, 4 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 164.1, 161.5, 159.5, 157.8, 130.6, 128.9, 125.8, 
124.4, 110.6, 46.0, 42.8. 
MS (70 eV, EI) m/z (%): 308 (21) [M]+, 146 (39), 134 (100), 122 (75). 
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IR (ATR) ~ (cm-1): 2359, 2342, 2338, 1738, 1733, 1708, 1605, 1580, 1552, 1464, 1456, 
1446, 1436, 1419, 1354, 1247, 1219, 949, 725, 694, 684, 668. 
HRMS (EI) calculated for C16H16N6O+: 308.1386, found 308.1379 [M]+. 
 
Ethyl 1-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl)piperidine-3-carboxylate (31h) 
 
Ethyl 1-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl)piperidine-3-carboxylate was prepared 
according to TP6 using 2-(4-chlorophenyl)-1,3,4-oxadiazole 28c (90 mg, 0.50 mmol) and 
ethyl 1-(benzoyloxy)-piperidine-3-carboxylate (97 mg, 0.35 mmol). Purification via column 
chromatography (silica gel, ihexane / EtOAc = 3:1) yielded the title compound 31h (110 mg, 
0.33 mmol, 94%) as a colorless oil. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 7.83 (d, J = 8.6 Hz, 2 H), 7.45 – 7.36 (m, 2 H), 4.20 – 
4.08 (m, 3 H), 3.91 (dt, J = 12.8, 4.0 Hz, 1 H), 3.36 (dd, J = 13.1, 10.0 Hz, 1 H), 3.18 (ddd, 
J = 13.5, 10.5, 3.3 Hz, 1 H), 2.64 (ddd, J = 10.1, 6.1, 4.0 Hz, 1 H), 2.18 – 2.07 (m, 1 H), 1.90 
– 1.78 (m, 1 H), 1.78 – 1.59 (m, 2 H), 1.25 (t, J = 7.1 Hz, 3 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 172.8, 164.1, 158.5, 136.6, 129.3, 127.1, 123.1, 61.0, 
48.0, 46.6, 40.7, 26.8, 23.6, 14.3. 
MS (70 eV, EI) m/z (%): 335 (9) [M]+, 262 (100), 137 (22). 
IR (ATR) ~ (cm-1): 2937, 2359, 2334, 1726, 1615, 1600, 1576, 1552, 1485, 1465, 1450, 
1396, 1382, 1301, 1265, 1183, 1135, 1092, 1058, 1028, 1013, 928, 908, 857, 833, 727, 681, 
668. 






8-(5-(4-Methoxyphenyl)-1,3,4-oxadiazol-2-yl)-1,4-dioxa-8-azaspiro[4.5]decane was prepared 
according to TP6 using 2-(4-methoxyphenyl)-1,3,4-oxadiazole 28f (88 mg, 0.50 mmol) and 
1,4-dioxa-8-azaspiro[4.5]decan-8-yl benzoate (92 mg, 0.35 mmol). Purification via column 
chromatography (silica gel, ihexane / EtOAc = 3:1) yielded the title compound 31i (94 mg, 
0.30 mmol, 85%) as a colorless oil. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 7.83 (s, 2 H), 7.00 – 6.82 (m, 2 H), 3.96 (s, 4 H), 3.80 
(s, 3 H), 3.72 (s, 4 H), 1.80 (s, 4 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 161.4, 127.5, 114.3, 106.3, 64.5, 55.4, 44.6, 34.1. 
MS (70 eV, EI) m/z (%): 317 (100) [M]+, 203 (15), 135 (66), 57 (27). 
IR (ATR) ~ (cm-1): 2963, 2877, 1708, 1625, 1621, 1608, 1582, 1562, 1503, 1464, 1443, 
1425, 1403, 1365, 1306, 1256, 1174, 1148, 1114, 1080, 1025, 945, 925, 837, 719. 






pared according to TP6 using N,N-dimethyl-4-(1,3,4-oxadiazol-2-yl)aniline 28g (95 mg, 
0.50 mmol) and 1,4-dioxa-8-azaspiro[4.5]decan-8-yl benzoate (92 mg, 0.35 mmol). 
Purification via column chromatography (silica gel, ihexane / EtOAc = 3:1) yielded the title 
compound 31j (91 mg, 0.28 mmol, 79%) as a colorless oil. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 7.80 – 7.62 (m, 2 H), 6.73 – 6.58 (m, 2 H), 3.96 (s, 
4 H), 3.73 – 3.57 (m, 4 H), 2.98 (s, 6 H), 1.93 – 1.72 (m, 4 H). 
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13C-NMR (CDCl3, 101 MHz, ppm): δ = 163.4, 160.1, 151.6, 127.1, 111.9, 111.6, 106.5, 64.5, 
44.8, 40.1, 34.1. 
MS (70 eV, EI) m/z (%): 330 (100) [M]+, 216 (11), 96 (22), 57 (6). 
IR (ATR) ~ (cm-1): 2958, 2929, 2884, 1603, 1571, 1555, 1509, 1466, 1445, 1432, 1363, 
1282, 1262, 1230, 1191, 1170, 1147, 1111, 1079, 1034, 1022, 944, 924, 886, 820, 737. 




N-(1-(5-Phenyl-1,3,4-oxadiazol-2-yl)piperidin-3-yl)cyclopropanecarboxamide was prepared 
according to TP6 using 2-phenyl-1,3,4-oxadiazole 28a (73 mg, 0.50 mmol) and 
3-(cyclopropanecarboxamido)piperidin-1-yl benzoate (101 mg, 0.35 mmol). Purification via 
column chromatography (silica gel, ihexane / EtOAc = 3:1) yielded the title compound 31k 
(86 mg, 0.28 mmol, 79%) as a colorless oil. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 7.94 – 7.80 (m, 2 H), 7.42 (d, J = 6.5 Hz, 3 H), 6.52 (d, 
J = 7.4 Hz, 1 H), 4.19 – 4.08 (m, 1 H), 3.86 – 3.73 (m, 1 H), 3.62 – 3.43 (m, 3 H), 1.96 – 1.81 
(m, 2 H), 1.73 (dd, J = 10.6, 6.7 Hz, 2 H), 1.41 (tt, J = 8.1, 4.5 Hz, 1 H), 0.98 – 0.59 (m, 4 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 173.5, 171.3, 130.9, 129.0, 126.0, 124.2, 50.9, 46.7, 
44.8, 29.1, 21.8, 14.7, 7.4, 7.4. 
MS (70 eV, EI) m/z (%): 312 (1) [M]+, 227 (100), 145 (45), 77 (43). 
IR (ATR) ~ (cm-1): 2929, 2856, 2356, 2334, 1642, 1626, 1585, 1557, 1450, 1270, 1247, 
1031, 930, 772, 729, 690. 






5-Iodo-1-propyl-1H-1,2,4-triazole was prepared according to TP7 using iodine (152 mg, 
0.60 mmol). Purification via column chromatography (silica gel, ihexane / EtOAc = 4:1 + 5% 
triethylamine) yielded the title compound 35a (96 mg, 0.41 mmol, 81%) as an orange oil. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 7.94 (s, 1 H), 4.19 – 4.11 (m, 5 H), 1.90 (h, J = 7.4 Hz, 
2 H), 0.95 (t, J = 7.4 Hz, 3 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 154.5, 99.7, 52.5, 23.3, 11.1. 
MS (70 eV, EI) m/z (%): [M]+ 237 (1) [M]+, 209 (25), 208 (12), 196 (27), 195 (100), 168 (16), 
110 (68), 55 (18). 
IR (ATR) ~ (cm-1): 3448, 3114, 2966, 2935, 2877, 2626, 2362, 1740, 1636, 1470, 1416, 
1385, 1346, 1315, 1266, 1206, 1168, 1116, 1088, 1022, 966, 899, 875, 801, 747, 683. 




5-Allyl-1-propyl-1H-1,2,4-triazole was prepared according to TP7. After the metalation a 
solution of CuCN·2LiCl (0.04 mL, 0.04 mmol, 20%, 1.0 M in THF) and allyl bromide (0.07 mL, 
0.60 mmol) were added. Purification via column chromatography (silica gel, ihexane / EtOAc 
= 4:1 + 5% triethylamine) yielded the title compound 35b (63 mg, 0.42 mmol, 83%) as a pale 
yellow solid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 7.83 (s, 1 H), 5.96 (ddt, J = 16.6, 10.1, 6.3 Hz, 1 H), 
5.23 – 5.10 (m, 2 H), 4.05 – 3.98 (m, 2 H), 3.56 (d, J = 6.3 Hz, 2 H), 1.87 (h, J = 7.4 Hz, 2 H), 
0.92 (t, J = 7.4 Hz, 3 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 153.0, 150.4, 131.9, 118.3, 50.0, 30.6, 23.3, 11.2. 
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MS (70 eV, EI) m/z (%): 151 (17) [M]+, 150 (100), 136 (14), 123 (40), 122 (79), 110 (34), 108 
(80), 84 (26), 83 (16), 81 (11), 68 (11). 
IR (ATR) ~ (cm-1): 3426, 3084, 2968, 2936, 2878, 2361, 1740, 1642, 1511, 1483, 1427, 
1401, 1348, 1275, 1185, 1152, 1090, 1047, 994, 920, 877, 811, 748, 688, 678. 




5-(Cyclohex-2-en-1-yl)-1-propyl-1H-1,2,4-triazole was prepared according to TP7. After the 
metalation a solution of CuCN·2LiCl (0.04 mL, 0.04 mmol, 20%, 1.0 M in THF) and 
3-bromocyclohexene (0.05 mL, 0.60 mmol) were added. Purification via column 
chromatography (silica gel, ihexane / EtOAc = 4:1 + 5% triethylamine) yielded the title 
compound 35c (84 mg, 0.44 mmol, 88%) as a pale yellow solid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 7.81 (s, 1 H), 6.01 – 5.91 (m, 1 H), 5.64 (dd, J = 10.0, 
2.2 Hz, 1 H), 4.12 – 3.99 (m, 2 H), 3.70 – 3.62 (m, 1 H), 2.25 – 1.97 (m, 3 H), 1.96 – 1.76 (m, 
4 H), 1.72 – 1.59 (m, 1 H), 0.95 (t, J = 7.4 Hz, 3 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 158.0, 150.3, 130.2, 125.4, 49.9, 33.3, 28.5, 24.6, 
23.6, 21.1, 11.3. 
MS (70 eV, EI) m/z (%): 192 (4) [M]+, 191 (7), 190 (17), 176 (32), 163 (25), 162 (100), 150 
(15), 148 (41), 134 (28), 120 (61), 108 (13), 96 (13). 
IR (ATR) ~ (cm-1): 3433, 3027, 2935, 2877, 2361, 1653, 1506, 1470, 1398, 1348, 1273, 
1217, 1188, 1133, 1052, 1040, 992, 932, 898, 882, 842, 807, 772, 744, 720, 671. 






5-(Cyclohex-2-en-1-yl)-1-benzyl-1H-1,2,4-triazole was prepared according to TP7. After the 
metalation a solution of CuCN·2LiCl (0.04 mL, 0.04 mmol, 20%, 1.0 M in THF) and 
3-bromocyclohexene (0.05 mL, 0.60 mmol) were added. Purification via column 
chromatography (silica gel, ihexane / EtOAc = 4:1 + 5% triethylamine) yielded the title 
compound 35d (96 mg, 0.40 mmol, 80%) as a pale yellow solid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 7.88 (s, 1 H), 7.43 – 7.29 (m, 3 H), 7.20 – 7.15 (m, 
2 H), 5.95 (ddt, J = 10.0, 4.2, 2.8 Hz, 1 H), 5.61 – 5.55 (m, 1 H), 5.37 (s, 2 H), 3.67 (ddp, J = 
8.5, 5.7, 2.8 Hz, 1 H), 2.22 – 2.00 (m, 2 H), 1.95 – 1.80 (m, 2 H), 1.80 – 1.70 (m, 1 H), 1.67 – 
1.54 (m, 1 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 158.5, 150.7, 135.7, 130.0, 128.9, 128.2, 127.1, 
125.2, 52.0, 33.4, 28.2, 24.5, 20.9. 
MS (70 eV, EI) m/z (%): 239 (19) [M]+, 238 (43), 210 (58), 207 (38), 172 (10), 148 (25), 133 
(13), 120 (25), 106 (18), 91 (100). 
IR (ATR) ~ (cm-1): 3031, 2937, 1710, 1676, 1497, 1455, 1397, 1360, 1274, 1222, 1188, 
1136, 1089, 1030, 991, 884, 803, 770, 719, 694, 670. 




Phenyl(1-propyl-1H-1,2,4-triazol-5-yl)methanol was prepared according to TP7 using 
benzaldehyde (0.06 mL, 0.60 mmol) as electrophile. Purification via column chromatography 
(silica gel, ihexane / EtOAc = 1:1 + 5% triethylamine) yielded the title compound 35e 
(103 mg, 0.48 mmol, 95%) as a colorless oil.  
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1H-NMR (CDCl3, 400 MHz, ppm): δ = 7.82 (s, 1 H), 7.40 – 7.28 (m, 5 H), 6.02 (s, 1 H), 3.94 
– 3.88 (m, 2 H), 1.62 (h, J = 7.4 Hz, 2 H), 0.78 – 0.71 (m, 3 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 156.1, 149.5, 139.5, 129.0, 128.7, 126.6, 68.6, 50.6, 
22.8, 11.0. 
MS (70 eV, EI) m/z (%): 217 (60) [M]+, 216 (12), 184 (13), 175 (17), 174 (40), 170 (100), 158 
(41), 143 (48), 140 (18), 118 (26), 116 (14), 110 (20), 105 (28), 98 (26), 77 (14). 
IR (ATR) ~ (cm-1): 3202, 2967, 2936, 2877, 1652, 1603, 1492, 1451, 1385, 1321, 1281, 
1228, 1184, 1155, 1086, 1058, 1027, 984, 900, 877, 849, 800, 749, 718, 697, 674. 




Phenyl(1-benzyl-1H-1,2,4-triazol-5-yl)methanol was prepared according to TP7 using 
benzaldehyde (0.06 mL, 0.60 mmol) as electrophile. Purification via column chromatography 
(silica gel, ihexane / EtOAc = 2:1 + 5% triethylamine) yielded the title compound 35f (121 mg, 
0.46 mmol, 91%) as a colorless solid.  
1H-NMR (CDCl3, 400 MHz, ppm): δ = δ 7.88 (s, 1 H), 7.37 – 7.28 (m, 5 H), 7.29 – 7.23 (m, 
2 H), 7.05 – 6.98 (m, 2 H), 6.00 (s, 2 H), 5.27 (d, J = 15.2 Hz, 1 H), 5.10 (d, J = 15.2 Hz, 1 H), 
2.89 (br. s, 1 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 156.2, 149.4, 139.0, 134.6, 129.1, 128.9, 128.8, 
128.5, 127.8, 126.8, 68.7, 52.9. 
MS (70 eV, EI) m/z (%): 265 (6) [M]+, 247 (37), 246 (16), 186 (19), 174 (100), 170 (15), 167 
(13), 158 (28), 131 (14), 117 (17), 105 (36), 104 (27), 96 (13), 91 (67), 77 (21). 
IR (ATR) ~ (cm-1): 3064, 2862, 2361, 1602, 1494, 1453, 1436, 1399, 1358, 1334, 1303, 
1280, 1264, 1178, 1099,1071, 1052, 1028, 989, 954, 899, 853, 779, 735, 714, 699, 690. 






Phenyl(1-propyl-1H-1,2,4-triazol-5-yl)methanone was prepared according to TP7 using 
benzoyl chloride (0.07 mg, 0.60 mmol) as electrophile. Purification via column 
chromatography (silica gel, ihexane + 5% triethylamine) yielded the title compound 35g 
(95 mg, 0.44 mmol, 88%) as a colorless oil.  
1H-NMR (CDCl3, 400 MHz, ppm): δ = 8.33 – 8.27 (m, 2 H), 8.03 (s, 1 H), 7.69 – 7.61 (m, 
1 H), 7.57 – 7.48 (m, 2 H), 4.59 – 4.53 (m, 2 H), 1.96 (h, J = 7.4 Hz, 2 H), 0.97 (t, J = 7.4 Hz, 
3 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 183.7, 150.1, 149.1, 136.1, 134.2, 131.0, 128.7, 52.9, 
23.8, 11.1. 
MS (70 eV, EI) m/z (%): 215 (16) [M]+, 214 (57), 187 (11), 186 (100), 108 (15), 105 (35), 77 
(16). 
IR (ATR) ~ (cm-1): 2968, 2878, 1659, 1598, 1579, 1495, 1449, 1431, 1375, 1266, 1212, 
1178, 1144, 1063, 1002, 977, 912, 807, 737, 680. 




(1-Benzyl-1H-1,2,4-triazol-5-yl)(phenyl)methanone was prepared according to TP7 using 
benzaldehyde (0.06 mL, 0.60 mmol) as electrophile. Purification via column chromatography 
(silica gel, ihexane / EtOAc = 2:1 + 5% triethylamine) yielded the title compound 35h 
(104 mg, 0.40 mmol, 79%) as a colorless solid.  
1H-NMR (CDCl3, 400 MHz, ppm): δ = 8.26 – 8.20 (m, 2 H), 7.99 (s, 1 H), 7.60 – 7.53 (m, 
1 H), 7.47 – 7.41 (m, 2 H), 7.34 – 7.20 (m, 5 H), 5.74 (s, 2 H). 
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13C-NMR (CDCl3, 101 MHz, ppm): δ = 183.4, 150.4, 148.9, 135.8, 135.5, 134.1, 131.0, 
128.8, 128.5, 128.3, 128.2, 54.5. 
MS (70 eV, EI) m/z (%): 264 (13), 263 (79) [M]+, 262 (29), 236 (15), 235 (36), 186 (10), 
160 (12), 158 (52), 157 (37), 133 (18), 131 (100), 116 (13), 105 (75), 104 (66), 91 (23), 
77 (44). 
IR (ATR) ~ (cm-1): 3064, 1659, 1597, 1578, 1495, 1484, 1448, 1426, 1372, 1319, 1266, 
1175, 1098, 1072, 1029, 1002, 976, 911, 807, 785, 717, 681. 




5-(4-Methoxyphenyl)-1-propyl-1H-1,2,4-triazole was prepared according to TP8 using 
4-bromoanisole (112 mg, 0.6 mmol). Purification via column chromatography (silica gel, 
ihexane / EtOAc = 4:1 + 5% triethylamine) yielded the title compound 35i (99 mg, 0.46 mmol, 
91%) as an orange oil.  
1H-NMR (CDCl3, 400 MHz, ppm): δ = 7.95 (s, 1 H), 7.59 – 7.54 (m, 2 H), 7.05 – 7.00 (m, 
2 H), 4.20 – 4.13 (m, 2 H), 3.87 (s, 3 H), 1.92 (h, J = 7.4 Hz, 2 H), 0.90 (t, J = 7.4 Hz, 3 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 161.1, 154.5, 150.5, 130.4, 120.3, 114.5, 55.6, 50.9, 
23.5, 11.2. 
MS (70 eV, EI) m/z (%): 217 (32) [M]+, 188 (63), 175 (100), 160 (25), 134 (90), 133 (13), 132 
(10). 
IR (ATR) ~ (cm-1): 3426, 2965, 2936, 2877, 2839, 2361, 2049, 1740, 1613, 1579, 1541, 
1486, 1461, 1440, 1384, 1297, 1277, 1250, 1177, 1163, 1111, 1085, 1031, 1017, 1003, 973, 
900, 880, 836, 798, 748, 713, 669. 






5-(4-Methoxyphenyl)-1-benzyl-1H-1,2,4-triazole was prepared according to TP8 using 
4-iodoanisole (140 mg, 0.6 mmol). Purification via column chromatography (silica gel, 
ihexane / EtOAc = 4:1 + 5% triethylamine) yielded the title compound 35j (103 mg, 
0.39 mmol, 78%) as an colorless solid.  
1H-NMR (CDCl3, 400 MHz, ppm): δ = 8.00 (s, 1 H), 7.52 (d, J = 8.8 Hz, 2 H), 7.41 – 7.28 (m, 
3 H), 7.16 (d, J = 6.6 Hz, 2 H), 6.96 (d, J = 8.8 Hz, 2 H), 5.42 (s, 2 H), 3.85 (s, 3 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 161.2, 155.3, 151.3, 136.1, 130.3, 129.1, 128.2, 
127.0, 120.3, 114.4, 55.5, 52.8. 
MS (70 eV, EI) m/z (%): 265 (100) [M]+, 264 (26), 132 (15), 131 (12), 119 (11), 91 (55). 
IR (ATR) ~ (cm-1): 3032, 2938, 2837, 1612, 1578, 1541, 1486, 1462, 1439, 1381, 1298, 
1276, 1252, 1176, 1124, 1112, 1077, 1037, 1020, 1005, 973, 883, 836, 779, 748, 726, 694, 
668. 




4-(1-Benzyl-1H-1,2,4-triazol-5-yl)benzonitrile was prepared according to TP8 using 
4-iodobenzonitrile (137 mg, 0.6 mmol). Purification via column chromatography (silica gel, 
ihexane / EtOAc = 4:1 + 5% triethylamine) yielded the title compound 35k (100 mg, 
0.47 mmol, 94%) as a colorless solid.  
1H-NMR (CDCl3, 400 MHz, ppm): δ = 8.00 (s, 1 H), 7.84 – 7.80 (m, 2 H), 7.79 – 7.75 (m, 
2 H), 4.23 – 4.15 (m, 2 H), 1.94 (h, J = 7.4 Hz, 2 H), 0.90 (t, J = 7.4 Hz, 3 H). 
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13C-NMR (CDCl3, 101 MHz, ppm): δ = 152.9, 151.2, 132.8, 132.5, 129.6, 118.1, 114.1, 51.3, 
23.5, 11.1. 
MS (70 eV, EI) m/z (%): 212 (11) [M]+, 211 (26), 184 (17), 183 (70), 170 (100), 143 (34), 129 
(40). 
IR (ATR) ~ (cm-1): 2968, 2879, 2231, 1614, 1485, 1462, 1406, 1385, 1283, 1283, 1241, 
1197, 1182, 1164, 1111, 1010, 974, 901, 845, 804, 782, 747, 713, 700. 




4-(1-Propyl-1H-1,2,4-triazol-5-yl)morpholine was prepared according to TP9 using 
morpholino benzoate (124 mg, 0.6 mmol). Purification via column chromatography (silica gel, 
ihexane / EtOAc = 2:1 + 5% triethylamine) yielded the title compound 35l (71 mg, 0.36 mmol, 
72%) as a pale yellow oil.  
1H-NMR (CDCl3, 400 MHz, ppm): δ = 7.67 (s, 1 H), 3.94 – 3.89 (m, 2 H), 3.86 – 3.82 (m, 
4 H), 3.17 – 3.12 (m, 4 H), 1.90 (h, J = 7.4 Hz, 2 H), 0.93 (t, J = 7.4 Hz, 3 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 158.4, 149.2, 66.6, 51.0, 49.4, 22.6, 11.3. 
MS (70 eV, EI) m/z (%): 196 (6) [M]+, 167 (28), 139 (100), 123 (19), 97 (34). 
IR (ATR) ~ (cm-1): 3434, 2966, 2855, 2362, 1636, 1523, 1492, 1451, 1412, 1371, 1331, 
1304, 1272, 1262, 1200, 1175, 1146, 1115, 1072, 1036, 975, 947, 928, 876, 846, 805, 752, 
661. 




Ethyl 1-(1-benzyl-1H-1,2,4-triazol-5-yl)piperidine-3-carboxylate (35m) 
 
Ethyl 1-(1-benzyl-1H-1,2,4-triazol-5-yl)piperidine-3-carboxylate was prepared according to 
TP9 using ethyl 1-(benzoyloxy)piperidine-3-carboxylate (166 mg, 0.6 mmol). Purification via 
column chromatography (silica gel, ihexane / EtOAc = 2:1 + 5% triethylamine) yielded the 
title compound 35m (94 mg, 0.35 mmol, 70%) as a colorless solid.  
1H-NMR (CDCl3, 400 MHz, ppm): δ = 7.63 (s, 1 H), 7.30 – 7.21 (m, 3 H), 7.19 – 7.14 (m, 
2 H), 5.15 (d, J = 2.3 Hz, 2 H), 4.14 – 3.90 (m, 2 H), 3.30 (ddt, J = 12.2, 3.8, 1.3 Hz, 1 H), 
3.15 – 3.03 (m, 2 H), 2.87 (ddd, J = 12.2, 9.4, 3.0 Hz, 1 H), 2.66 – 2.53 (m, 1 H), 1.97 – 1.75 
(m, 1 H), 1.76 – 1.67 (m, 2 H), 1.15 (t, J = 7.1 Hz, 4 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 173.1, 159.1, 149.6, 135.8, 128.8, 127.9, 127.3, 60.7, 
52.7, 51.3, 51.1, 41.0, 26.2, 23.9, 14.2. 
MS (70 eV, EI) m/z (%): 314 (11) [M]+, 313 (55), 269 (15), 241 (86), 237 (26), 207 (29), 177 
(19), 156 (16), 149 (17), 91 (100).  
IR (ATR) ~ (cm-1): 2940, 2855, 1985, 1726, 1636, 1526, 1488, 1454, 1381, 1309, 1273, 
1181, 1128, 1096, 1030, 963, 939, 859, 727, 696, 658. 






1,2,4-triazol-5-amine was prepared according to TP9 using O-benzoyl-N-((1S,4S)-4-(3,4-
dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl)-N-methylhydroxylamine (256 mg, 
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0.6 mmol). Purification via column chromatography (silica gel, ihexane / EtOAc = 2:1 + 5% 
triethylamine) yielded the title compound 35n (220 mg, 0.48 mmol, 95%) as a colorless solid.  
1H-NMR (CDCl3, 400 MHz, ppm): δ = 7.63 (s, 1 H), 7.35 – 7.15 (m, 5 H), 7.15 – 7.04 (m, 
4 H), 6.99 (d, J = 2.1 Hz, 1 H), 6.84 (dd, J = 7.0, 2.0 Hz, 1 H), 6.71 (dd, J = 8.3, 2.1 Hz, 1 H), 
5.33 – 5.15 (m, 2 H), 4.72 (dd, J = 10.4, 5.8 Hz, 1 H), 4.03 (dd, J = 5.8, 3.1 Hz, 1 H), 2.64 (s, 
3 H), 2.08 – 1.53 (m, 4 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 159.3, 149.3, 147.1, 138.3, 136.3, 132.3, 130.8, 
130.7, 130.1, 130.1, 128.9, 128.0, 128.0, 127.6, 127.5, 127.4, 126.6, 60.5, 52.2, 43.1, 33.6, 
29.9, 20.4. 
MS (70 eV, EI) m/z (%): 464 (27) [M]+, 462 (42), 447 (22), 277 (36), 275 (58), 188 (56), 187 
(33), 160 (61), 158 (100), 129 (60), 91 (94).  
IR (ATR) ~ (cm-1): 2938, 1540, 1488, 1466, 1453, 1417, 1395, 1356, 1317, 1279, 1204, 
1131, 1080, 1029, 986, 964, 920, 878, 849, 817, 791, 768, 727, 704, 694, 678, 665. 




3,5-Di(cyclohex-2-en-1-yl)-1-propyl-1H-1,2,4-triazole was prepared according to TP10. After 
the metalation a solution of CuCN·2LiCl (0.04 mL, 0.04 mmol, 20%, 1.0 M in THF) and 
3-bromocyclohexene (0.25 mL, 2.2 mmol)) were added. Purification via column 
chromatography (silica gel, ihexane / EtOAc = 9:1 + 5% triethylamine) yielded the title 
compound 37a (99 mg, 0.37 mmol, 73%) as an orange oil. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 5.96 – 5.80 (m, 3 H), 5.67 – 5.60 (m, 1 H), 4.05 – 3.89 
(m, 2 H), 3.69 – 3.49 (m, 2 H), 2.22 – 1.95 (m, 6 H), 1.93 – 1.71 (m, 6 H), 1.68 – 1.56 (m, 
2 H), 0.91 (t, J = 7.4 Hz, 3 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 165.9, 157.9, 129.7, 128.4, 127.8, 125.8, 49.6, 35.7, 
33.8, 29.0, 28.6, 24.9, 24.5, 23.7, 21.5, 21.2, 11.1. 
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MS (70 eV, EI) m/z (%): 271 (100) [M]+, 270 (78), 256 (45), 242 (66), 230 (11), 228 (53), 216 
(12), 214 (36), 205 (29), 200 (42), 190 (12), 188 (17), 176 (14), 163 (16), 148 (11), 81 (13), 
79 (14). 
IR (ATR) ~ (cm-1): 3026, 2933, 2875, 2836, 2362, 1652, 1497, 1447, 1435, 1361, 1326, 
1297, 1258, 1239, 1218, 1190, 1155, 1134, 1063, 1044, 991, 932, 893, 850, 809, 722, 679. 




3,5-Bis(4-methoxyphenyl)-1-propyl-1H-1,2,4-triazole was prepared according to TP10. After 
the metalation a solution of ZnCl2 (2.0 mL, 2.0 mmol, 1.0 M in THF), Pd(OAc)2 (5.6 mg, 
0.025 mmol, 5%), SPhos (20.5 mg, 0.05 mmol, 10%) and 4-iodoanisole (515 mg, 2.2 mmol) 
were added. Purification via column chromatography (silica gel, ihexane / EtOAc = 4:1 + 5% 
triethylamine) yielded the title compound 37b (84 mg, 0.26 mmol, 52%) as an orange oil. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 8.12 – 8.04 (m, 2 H), 7.63 – 7.56 (m, 2 H), 7.06 – 6.99 
(m, 2 H), 6.98 – 6.93 (m, 2 H), 4.19 – 4.11 (m, 2 H), 3.88 (s, 3 H), 3.85 (s, 3 H), 1.95 (h, J = 
7.4 Hz, 2 H), 0.92 (t, J = 7.4 Hz, 3 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 161.1, 161.0, 160.5, 155.5, 130.4, 127.9, 124.2, 
121.0, 114.4, 114.0, 55.6, 55.4, 50.9, 23.7, 11.2. 
MS (70 eV, EI) m/z (%): 323 (100) [M]+, 295 (11), 294 (67), 282 (13), 281 (77), 267 (11), 207 
(16), 161 (21), 134 (45), 133 (76). 
IR (ATR) ~ (cm-1): 2963, 2936, 2837, 2361, 1739, 1612, 1532, 1465, 1441, 1349, 1294, 
1245, 1169, 1134, 1107, 1029, 981, 902, 836, 797, 764, 736, 692. 






4-(1-Propyl-1H-1,2,4-triazol-5-yl)morpholino (35l, 86 mg, 0.44 mmol, 1.0 equiv) was 
dissolved in THF (1.5 mL) and cooled to 0 °C. TMPMgCl∙LiCl solution (33, 0.88 mmol, 
2.0 equiv) was slowly added to the vigorously stirred solution. After 30 min a solution of 
CuCN·2LiCl (0.04 mL, 0.04 mmol, 20%, 1.0 M in THF) and 3-bromocyclohexene (0.05 mL, 
0.60 mmol) were added. After stirring for 30 min the mixture was quenched with sat. aq. 
NH4Cl solution (15 mL), extracted with DCM (3×15 mL) and dried over anhydrous MgSO4. 
Purification via column chromatography (silica gel, ihexane / EtOAc = 4:1 + 5% triethylamine) 
yielded the title compound 37c (97 mg, 0.35 mmol, 80%) as a colorless oil. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 5.86 – 5.75 (m, 2 H), 3.85 – 3.79 (m, 2 H), 3.79 – 3.73 
(m, 4 H), 3.42 (ddd, J = 8.7, 5.7, 3.0 Hz, 1 H), 3.10 – 3.03 (m, 4 H), 2.11 – 1.94 (m, 3 H), 1.87 
– 1.66 (m, 4 H), 1.62 – 1.50 (m, 1 H), 0.86 (t, J = 7.4 Hz, 3 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 164.5, 158.5, 128.4, 127.6, 66.6, 50.9, 49.0, 36.0, 
28.7, 24.9, 22.7, 21.2, 11.1. 
MS (70 eV, EI) m/z (%): 276 (60) [M]+, 275 (19), 247 (37), 233 (20), 220 (13), 219 (100), 210 
(19), 205 (14), 203 (11), 189 (10), 177 (31), 167 (10). 
IR (ATR) ~ (cm-1): 2935, 2858, 1713, 1530, 1497, 1453, 1372, 1261, 1219, 1117, 1072, 
1029, 984, 964, 945, 921, 881, 849, 792, 727, 678. 




5-(4-Methoxyphenyl)-1-propyl-1H-1,2,4-triazole (35i, 95 mg, 0.44 mmol, 1.0 equiv) was 
dissolved in THF (1.5 mL) and cooled to 0 °C. TMPZnCl∙LiCl solution (36, 0.53 mmol, 
1.2 equiv) was slowly added to the vigorously stirred solution. A dry, argon flushed Schlenk-
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flask equipped with a magnetic stirring bar and a septum was charged with morpholino 
benzoate (109 mg, 0.53 mmol, 1.2 equiv), copper (II) triflate (36 mg, 0.1 mmol, 20%) and 
THF (2.0 mL). After 30 min the metalated species was slowly added to the vigorously stirred 
solution. After 2 h the mixture was quenched with sat. aq. NH4Cl solution (15 mL), extracted 
with DCM (3×15 mL) and dried over anhydrous MgSO4. Purification via column 
chromatography (silica gel, ihexane / EtOAc = 4:1 + 5% triethylamine) yielded the title 
compound 37d (115 mg, 0.38 mmol, 87%) as a colorless oil. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 7.54 – 7.47 (m, 2 H), 7.02 – 6.95 (m, 2 H), 4.01 – 3.92 
(m, 2 H), 3.85 (s, 3 H), 3.84 – 3.79 (m, 4 H), 3.48 – 3.41 (m, 4 H), 1.86 (h, J = 7.4 Hz, 2 H), 
0.87 (t, J = 7.4 Hz, 3 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 161.0, 153.8, 142.3, 138.1, 130.4, 114.4, 66.7, 55.5, 
50.5, 47.2, 23.4, 11.2. 
MS (70 eV, EI) m/z (%): 303 (14) [M]+, 302 (93), 287 (24), 271 (26), 271 (17), 246 (11), 245 
(100), 244 (29), 243 (16), 229 (10), 215 (32), 203 (31), 202 (27), 188 (12), 134 (36). 
IR (ATR) ~ (cm-1): 3442, 2964, 2838, 2361, 1614, 1579, 1547, 1527, 1482, 1452, 1411, 
1379, 1357, 1331, 1304, 1273, 1250, 1174, 1115, 1073, 1032, 1002, 926, 902, 835, 797, 
765, 733, 661. 




A dry, argon flushed Schlenk-flask equipped with a magnetic stirring bar and a septum was 
charged with 1-(2-Iodobenzyl)-1H-1,2,4-triazole (32c, 143 mg, 0.5 mmol, 1.0 equiv) and THF 
(1.5 mL). The mixture was cooled down to 0 °C and a solution of TMPZnCl∙LiCl (36, 
0.75 mmol, 1.5 equiv) was slowly added. After 30 min a solution of CuCN·2LiCl (0.10 mL, 
0.10 mmol, 20%, 1.0 M in THF) was added. The mixture was heated to 40 °C for 18 h. The 
reaction mixture was quenched with sat. aq. NH4Cl solution (15 mL), extracted with DCM 
(3×15 mL) and dried over anhydrous MgSO4. After filtration and evaporation, the crude 
product was purified by flash column chromatography (silica gel, ihexane / EtOAc = 4:1 + 5% 
triethylamine) to obtain 5H-[1,2,4]triazolo[5,1-a]isoindole 38 (0.147g, 0.47 mmol, 94%) as a 
pale yellow solid.  
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1H-NMR (CDCl3, 400 MHz, ppm): δ = 8.11 (s, 1 H), 7.98 – 7.91 (m, 1 H), 7.59 – 7.46 (m, 
3 H), 5.10 (s, 2 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 160.2, 155.8, 142.2, 129.7, 129.1, 127.1, 124.1, 
121.9, 50.4. 
MS (70 eV, EI) m/z (%): 157 (100) [M]+, 130 (16), 129 (14), 103 (25), 102 (11). 
IR (ATR) ~ (cm-1): 3088, 2954, 1722, 1539, 1506, 1447, 1403, 1317, 1274, 1248, 1215, 
1191, 1175, 1136, 1101, 1011, 969, 941, 918, 895, 883, 816, 769, 730, 699, 689, 679, 655. 




7-(Methylthio)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[1,2-b]pyrazole was synthesized 
according to TP11 on a 0.88 mmol scale using S-methyl benzenesulfonothioate (412 mg, 
2.2 mmol, 2.5 equiv) as electrophile (30 min, 25 °C). Purification via column chromatography 
(silica gel, iHex/EtOAc = 2:1) yielded the title compound 43a (206 mg, 0.73 mmol, 83%) as a 
colorless solid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 7.60 (d, J = 1.1 Hz, 1 H), 7.27 (d, J = 2.3 Hz, 1 H), 
6.83 (t, J = 2.3, 1.1 Hz, 1 H), 5.50 (s, 2 H), 3.57 (t, J = 8.1 Hz, 2 H), 2.23 (s, 2 H), 0.89 (t, J = 
8.3 Hz, 2 H), 0.06 (s, 9 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 148.7, 141.3, 119.6, 109.5, 84.9, 75.4, 66.5, 22.7, 
17.9, 1.4. 
MS (70 eV, EI) m/z (%): 283 (27) [M]+, 225 (14), 210 (19), 166 (21), 111 (9), 73 (100). 
IR (ATR) ~ (cm-1): 3156, 3111, 3055, 2951, 2917, 1588, 1539, 1466, 1442, 1416, 1317, 
1288, 1273, 1248, 1218, 1172, 1151, 1096, 1069, 1009, 971, 930, 857, 834, 766, 728, 718, 
706, 683. 
HRMS (EI) calculated for C12H21N3OSSi+: 283.1169, found 283.1164 [M]+. 





1-((2-(Trimethylsilyl)ethoxy)methyl)-1H-imidazo[1,2-b]pyrazole-7-carbonitrile was synthesized 
according to TP11 on a 5.0 mmol scale using tosyl cyanide (2.2 g, 11 mmol, 2.2 equiv) as 
electrophile (1 h, 25 °C). The white solid that was formed during the reaction was filtered off 
through a pad of Celite before the work-up. Purification via column chromatography (silica 
gel, iHex/EtOAc = 2:1 + 5% Net3) yielded the title compound 43b (1.31 g, 4.79 mmol, 96%) 
as a slightly yellow solid. 
1H-NMR (C6D6, 400 MHz, ppm): δ = 7.56 (d, J = 1.1 Hz, 1 H), 6.62 (d, J = 2.3 Hz, 1 H), 5.86 
(dd, J = 2.2, 1.2 Hz, 1 H), 4.62 (s, 2 H), 3.42 (t, J = 8.1 Hz, 2 H), 0.79 (t, J = 8.1 Hz, 2 H), 
0.08 (s, 9 H).  
13C-NMR (C6D6, 101 MHz, ppm): δ = 146.3, 141.7, 120.0, 114.3, 109.9, 76.1, 67.7, 67.3, 
17.7, 1.4. 
MS (70 eV, EI) m/z (%): 262 (24) [M]+, 219 (14), 204 (100), 189 (30), 145 (14), 73 (65). 
IR (ATR) ~ (cm-1): 3150, 3102, 3055, 2953, 2920, 2896, 2869, 2216, 1611, 1543, 1491, 
1478, 1454, 1399, 1381, 1335, 1309, 1289, 1260, 1245, 1225, 1196, 1179, 1123, 1085, 
1068, 1035, 1018, 972, 916, 875, 843, 832, 779, 742, 721, 709, 690, 663. 
HRMS (EI) calculated for C12H18N4OSi+: 262.1244, found 262.1245 [M]+. 





zed according to TP11 on a 0.20 mmol scale using TESCl (75 mg, 0.50 mmol, 2.5 equiv) as 
electrophile (2 h, 25 °C). Purification via column chromatography (silica gel, iHex/EtOAc = 
4:1) yielded the title compound 43c (53 mg, 0.15 mmol, 76%) as a colorless liquid. 
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1H-NMR (C6D6, 400 MHz, ppm): δ = 7.92 (s, 1 H), 6.99 (d, J = 2.3 Hz, 1 H), 6.03 – 6.01 (m, 
1 H), 4.74 (s, 2 H), 3.23 (t, J = 8.0 Hz, 2 H), 1.04 (t, J = 7.8 Hz, 9 H), 0.87 (q, J = 7.7 Hz, 
6 H), 0.79 (t, J = 8.1 Hz, 2 H), 0.09 (s, 9 H). 
13C-NMR (C6D6, 101 MHz, ppm): δ = 150.4, 145.8, 119.6, 108.4, 82.4, 77.0, 65.9, 17.7, 7.9, 
5.1, 1.4. 
MS (70 eV, EI) m/z (%): 351 (16) [M]+, 292 (14), 264 (52), 250 (14), 236 (12), 234 (38), 220 
(24), 208 (28), 192 (16), 178 (14), 165 (21), 164 (11), 150 (20), 73 (100).  
IR (ATR) ~ (cm-1): 3132, 2952, 2874, 1565, 1543, 1458, 1413, 1376, 1321, 1248, 1158, 
1075, 1041, 1003, 971, 916, 833, 691. 




7-Allyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[1,2-b]pyrazole was synthesized 
according to TP11 on a 1.69 mmol scale using allyl bromide (0.37 mL, 4.23 mmol, 2.5 equiv) 
and CuCN2LiCl (1.0 M in THF, 0.34 mL, 0.34 mmol, 0.20 equiv) as electrophile (30 min, 
25 °C.). Purification via column chromatography (silica gel, iHex/EtOAc = 3:7) yielded the title 
compound 43d (438 mg, 1.58 mmol, 94%) as a colorless liquid. 
1H-NMR (C6D6, 400 MHz, ppm): δ = 7.67 (s, 1 H), 6.93 (d, J = 2.3 Hz, 1 H), 6.03 – 5.93 (m, 
2 H), 5.09 – 4.95 (m, 2 H), 4.65 (s, 2 H), 3.37 – 3.31 (m, 2 H), 3.23 (t, J = 7.8 Hz, 2 H), 0.74 
(t, J = 7.8 Hz, 2 H), 0.11 (s, 9 H). 
13C-NMR (C6D6, 101 MHz, ppm): δ = 143.8, 139.9, 139.4, 119.4, 114.6, 108.5, 92.6, 76.4, 
65.8, 28.4, 17.7, 1.4. 
MS (70 eV, EI) m/z (%): 277 (38) [M]+, 219 (27), 218 (36), 204 (21), 192 (34), 191 (14), 160 
(42), 133 (22), 119 (14), 73 (100). 
IR (ATR) ~ (cm-1): 3130, 2952, 2894, 1638, 1609, 1544, 1490, 1413, 1379, 1322, 1247, 
1216, 1169, 1074, 994, 914, 832, 758, 688. 
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Ethyl 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[1,2-b]pyrazole-7-carboxylate was syn-
thesized according to TP11 on a 0.20 mmol scale using ethyl cyanoformate (0.05 mL, 
0.5 mmol, 2.5 equiv) and CuCN2LiCl (1.0 M in THF, 0.20 mL, 0.20 mmol, 1.0 equiv) as 
electrophile (2 h, 25 °C). Purification via column chromatography (silica gel, iHex/EtOAc = 
4:1) yielded the title compound 43e (31 mg, 0.10 mmol, 50%) as a colorless liquid. 
1H-NMR (CDCl3, 400 MHz, ppm): δ = 8.02 (d, J = 1.1 Hz, 1 H), 7.37 (d, J = 2.2 Hz, 1 H), 
6.95 (t, J = 2.2, 1.1 Hz, 1 H), 5.82 (s, 2 H), 4.28 (q, J = 7.1 Hz, 2 H), 3.56 (t, J = 8.2 Hz, 2 H), 
1.35 (t, J = 7.1 Hz, 3 H), 0.88 (t, J = 8.2 Hz, 2 H), 0.07 (s, 9 H). 
13C-NMR (CDCl3, 101 MHz, ppm): δ = 163.2, 146.2, 140.8, 120.2, 110.1, 91.9, 76.8, 66.4, 
59.9, 17.9, 14.7, 1.4. 
MS (70 eV, EI) m/z (%): 309 (9) [M]+, 279 (10), 251 (37), 250 (42), 238 (11), 236 (34), 223 
(13), 208 (49), 206 (14), 192 (25), 182 (13), 164 (35), 148 (29), 134 (18), 133 (100), 73 (49). 
IR (ATR) ~ (cm-1): 3132, 2953, 2898, 1687, 1597, 1548, 1488, 1394, 1375, 1344, 1292, 
1269, 1248, 1204, 1194, 1174, 1085, 1056, 971, 916, 856, 833, 768, 731, 691. 








synthesized according to TP11 on a 0.2 mmol scale using benzoyl chloride (0.035 mL, 
0.50 mmol, 2.5 equiv) as electrophile and Pd(PPh3)4 (11.6 mg, 0.01 mmol, 5%) as catalyst 
(2 h, 25 °C). Purification via column chromatography (silica gel, iHex/EtOAc = 7:3) yielded 
the title compound 43f (41 mg, 0.12 mmol, 60%) as a colorless liquid. 
1H-NMR (C6D6, 400 MHz, ppm): δ = 8.04 – 8.00 (m, 1 H), 7.94 (dd, J = 7.9, 1.6 Hz, 2 H), 
7.21 – 7.10 (m, 3 H), 6.85 (d, J = 2.0 Hz, 1 H), 6.24 (dd, J = 2.1, 1.2 Hz, 1 H), 5.83 (s, 2 H), 
3.65 (t, J = 8.0 Hz, 2 H), 0.89 (t, J = 8.0 Hz, 2 H), 0.09 (s, 9 H). 
13C-NMR (C6D6, 101 MHz, ppm): δ = 186.6, 148.0, 142.0, 140.8, 131.2, 129.1, 128.5, 120.6, 
109.8, 102.6, 77.3, 66.2, 17.9, 1.4. 
MS (70 eV, EI) m/z (%): 341 (12) [M]+, 298 (13), 283 (10), 282 (100), 269 (10), 268 (83), 255 
(25), 241 (11), 240 (54), 224 (11), 206 (14), 73 (19). 
IR (ATR) ~ (cm-1): 3128, 3066, 2952, 2892, 1614, 1599, 1568, 1481, 1418, 1365, 1324, 
1293, 1269, 1248, 1217, 1195, 1176, 1124, 1068, 1028, 1013, 982, 936, 916, 899, 857, 831, 
795, 760, 736, 694, 663. 







Ethyl 4-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[1,2-b]pyrazol-7-yl)benzoate was 
synthesized according to TP11 on a 0.2 mmol scale using ethyl 4-iodobenzoate (166 mg, 
0.60 mmol, 3.0 equiv) as electrophile and PEPPSI-iPr (2.7 mg, 0.004 mmol, 2%) as catalyst 
(4 h, 40 °C). Purification via column chromatography (silica gel, iHex/EtOAc = 2:1) yielded 
the title compound 43g (63 mg, 0.16 mmol, 82%) as a slightly yellow oil. 
1H-NMR (C6D6, 400 MHz, ppm): δ = 8.27 (d, J = 8.4 Hz, 2 H), 7.89 (d, J = 1.1 Hz, 1 H), 7.56 
(d, J = 8.4 Hz, 2 H), 6.91 (d, J = 2.3 Hz, 1 H), 6.00 (dd, J = 2.1, 1.1 Hz, 1 H), 4.65 (s, 2 H), 
4.18 (q, J = 7.1 Hz, 2 H), 3.14 (t, J = 7.9 Hz, 2 H), 1.07 (t, J = 7.1 Hz, 3 H), 0.65 (t, J = 
7.9 Hz, 2 H), 0.16 (s, 9 H). 
13C-NMR (C6D6, 101 MHz, ppm): δ = 166.3, 143.2, 138.7, 138.4, 130.7, 127.7, 127.0, 120.8, 
108.7, 99.1, 76.1, 66.2, 60.7, 17.7, 14.4, 1.5. 
MS (70 eV, EI) m/z (%): 385 (13) [M]+, 327 (43), 268 (12), 210 (12), 209 (100), 195 (13), 194 
(17), 181 (42), 154 (13), 73 (53). 
IR (ATR) ~ (cm-1): 3134, 2981, 2951, 2915, 1699, 1608, 1563, 1548, 1520, 1474, 1414, 
1368, 1347, 1309, 1270, 1249, 1220, 1181, 1149, 1121, 1099, 1066, 1042, 1024, 1013, 993, 
983, 935, 834, 772, 743, 715, 695. 








was synthesized according to TP11 on a 0.2 mmol scale using 1-iodo-4-(trifluoromethyl)-
benzene (163 mg, 0.60 mmol, 3.0 equiv) as electrophile and PEPPSI-iPr (2.7 mg, 
0.004 mmol, 2%) as catalyst (2 h, 40 °C). Purification via column chromatography (silica gel, 
iHex/EtOAc = 1:1) yielded the title compound 43h (67 mg, 0.18 mmol, 88%) as a slightly 
yellow solid. 
1H-NMR (C6D6, 400 MHz, ppm): δ = 7.85 (s, 1 H), 7.51 – 7.39 (m, 4 H), 6.89 (d, J = 2.3 Hz, 
1 H), 5.95 (s, 1 H), 4.58 (s, 2 H), 3.10 (t, J = 7.9 Hz, 2 H), 0.64 (t, J = 7.9 Hz, 2 H), 0.16 (s, 
9 H). 
13C-NMR (C6D6, 101 MHz, ppm): δ = 143.1, 138.3, 137.8, 127.4, 127.2 (q, J = 32.4 Hz), 
126.0 (q, J = 3.9 Hz), 125.6 (q, J = 271.9 Hz) 120.7, 108.7, 98.4, 76.0, 66.2, 17.6, 1.5. 
MS (70 eV, EI) m/z (%): 381 (20) [M]+, 323 (56), 264 (47), 231 (36), 230 (38), 204 (12), 196 
(11), 195 (15), 194 (22), 181 (17), 73 (100). 
IR (ATR) ~ (cm-1): 3178, 3114, 3069, 2952, 2892, 1614, 1592, 1553, 1523, 1481, 1464, 
1416, 1367, 1325, 1298, 1260, 1249, 1223, 1193, 1174, 1162, 1150, 1105, 1061, 1031, 
1012, 982, 937, 897, 859, 850, 831, 760, 745, 736, 671, 694, 686, 671, 666. 
HRMS (EI) calculated for C18H22F3N3OSi+: 381.1479, found 381.1477 [M]+. 








was synthesized according to TP11 on a 0.2 mmol scale using 4-(4-iodophenyl)morpholine 
(174 mg, 0.60 mmol, 3.0 equiv) as electrophile and PEPPSI-iPr (2.7 mg, 0.004 mmol, 2%) as 
catalyst (2 h, 40 °C). Purification via column chromatography (silica gel, iHex/EtOAc = 1:1) 
yielded the title compound 43i (54 mg, 0.14 mmol, 68%) as a slightly yellow solid. 
1H-NMR (C6D6, 400 MHz, ppm): δ = 8.02 (d, J = 1.0 Hz, 1 H), 7.53 (d, J = 8.7 Hz, 2 H), 6.97 
(d, J = 2.3 Hz, 1 H), 6.78 (d, J = 8.7 Hz, 2 H), 6.04 – 5.99 (m, 1 H), 4.78 (s, 2 H), 3.59 (t, J = 
4.8 Hz, 4 H), 3.19 (t, J = 7.9 Hz, 2 H), 2.80 (t, J = 4.7 Hz, 4 H), 0.70 (t, J = 7.9 Hz, 2 H), 0.14 
(s, 9 H). 
13C-NMR (C6D6, 101 MHz, ppm): δ = 149.9, 142.9, 138.5, 129.0, 125.5, 120.2, 116.5, 108.8, 
99.1, 75.8, 67.0, 66.1, 49.7, 17.8, 1.4. 
MS (70 eV, EI) m/z (%): 398 (17) [M]+, 340 (11), 299 (12), 281 (36), 267 (19), 265 (12), 240 
(13), 225 (60), 209 (31), 208 (14), 207 (100), 194 (15), 191 (23), 181 (15), 155 (14), 75 (28), 
73 (46), 44 (23). 
IR (ATR) ~ (cm-1): 3105, 2813, 1653, 1591, 1558, 1521, 1506, 1484, 1447, 1376, 1363, 
1340, 1312, 1259, 1250, 1242, 1232, 1220, 1183, 1118, 1069, 1048, 991, 927, 853, 844, 
828, 763, 739, 722, 702, 655. 
HRMS (EI) calculated for C21H30N4O2SI+: 398.2133, found 398.2134 [M]+. 






1-((2-(Trimethylsilyl)ethoxy)methyl)-1H-imidazo[1,2-b]pyrazole-7-carbonitrile (135 mg, 
0.50 mmol, 1.0 equiv) was dissolved in MeCN (3.5 mL) and treated with N-bromosuccinimide 
(178 mg, 1.0 mmol, 2.0 equiv). After stirring for 80 min at 25 °C the solvent was removed in 
vacuo and the residue was directly purified via column chromatography (silica gel, 
iHex/EtOAc = 4:1 + 5% Net3) to yield the title compound 44 (79 mg, 0.35 mmol, 70%) as a 
colorless solid. 
1H-NMR (C6D6, 400 MHz, ppm): δ = 7.46 (d, J = 1.2 Hz, 1 H), 5.74 (d, J = 1.2 Hz, 1 H), 4.52 
(s, 2 H), 3.38 (t, J = 8.0 Hz, 2 H), 0.79 (t, J = 8.0 Hz, 2 H), 0.07 (s, 9 H). 
13C-NMR (C6D6, 101 MHz, ppm): δ = 146.4, 141.4, 119.6, 113.8, 94.7, 76.3, 69.2, 67.5, 17.7, 
1.4. 
MS (70 eV, EI) m/z (%): 340 (0.2) [M]+, 284 (72), 282 (71), 225 (10), 223 (10), 218 (32), 176 
(35), 144 (13), 73 (100). 
IR (ATR) ~ (cm-1): 3132, 2952, 2922, 2897, 2211, 1607, 1544, 1485, 1456, 1418, 1380, 
1362, 1336, 1304, 1288, 1251, 1190, 1172, 1124, 1104, 1089, 1058, 1036, 1026, 979, 938, 
916, 903, 874, 856, 833, 789, 752, 733, 722, 697, 664. 
HRMS (EI) calculated for C12H17BrN4OSi+: 340.0350, found 340.0349 [M]+. 








thesized according to TP12 on a 0.2 mmol scale using allyl bromide (0.04 mL, 0.44 mmol, 
2.2 equiv) and CuCN2LiCl (1.0 M in THF, 0.04 mL, 0.04 mmol, 0.20 equiv) as electrophile 
(5 min, 25 °C). Purification via column chromatography (silica gel, iHex/EtOAc = 4:1 + 5% 
NEt3) yielded the title compound 45a (39 mg, 0.13 mmol, 65%) as a colorless liquid. 
1H-NMR (C6D6, 400 MHz, ppm): δ = 7.55 (d, J = 1.1 Hz, 1 H), 5.77 (d, J = 1.1 Hz, 1 H), 5.71 
(ddt, J = 16.8, 10.0, 6.7 Hz, 1 H), 5.02 – 4.93 (m, 2 H), 4.69 (s, 2 H), 3.50 (t, J = 8.0 Hz, 2 H), 
3.19 – 3.13 (m, 2 H), 0.83 (t, J = 8.1 Hz, 2 H), 0.06 (s, 9 H). 
13C-NMR (C6D6, 101 MHz, ppm): δ = 146.0, 141.6, 132.2, 122.4, 118.0, 116.4, 114.5, 76.0, 
67.9, 67.3, 27.7, 17.8, 1.4.  
MS (70 eV, EI) m/z (%): 302 (2) [M]+, 259 (13), 245 (11), 244 (100), 243 (95), 229 (11), 217 
(12), 185 (25), 73 (66). 
IR (ATR) ~ (cm-1): 3121, 2952, 2894, 2215, 1613, 1600, 1488, 1457, 1419, 1379, 1335, 
1302, 1248, 1221, 1183, 1104, 1080, 1031, 992, 970, 916, 856, 833, 748, 693, 667. 






was synthesized according to TP12 on a 0.2 mmol scale using S-methyl 
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benzenesulfonothioate (75 mg, 0.30 mmol, 1.5 equiv) as electrophile (2 h, 25 °C). 
Purification via column chromatography (silica gel, iHex/EtOAc = 4:1 + 5% NEt3) and HPLC 
yielded the title compound 45b (51 mg, 0.14 mmol, 69%) as a colorless solid. 
1H-NMR (C6D6, 400 MHz, ppm): δ = 7.46 (d, J = 1.0 Hz, 1 H), 7.37 – 7.31 (m, 2 H), 6.96 – 
6.89 (m, 2 H), 6.88 – 6.82 (m, 1 H), 6.24 (d, J = 1.1 Hz, 1 H), 4.59 (s, 2 H), 3.41 (t, J = 
8.0 Hz, 2 H), 0.79 (t, J = 8.1 Hz, 2 H), 0.09 (s, 9 H). 
13C-NMR (C6D6, 101 MHz, ppm): δ = 146.2, 142.0, 134.3, 129.7, 129.5, 127.8, 127.7, 126.0, 
113.8, 76.4, 69.4, 67.5, 17.8, 1.4. 
MS (70 eV, EI) m/z (%): 370 (8) [M]+, 313 (19), 312 (86), 285 (13), 253 (15), 121 (11), 73 
(100). 
IR (ATR) ~ (cm-1): 3128, 3058, 2949, 2893, 2862, 2221, 1603, 1583, 1538, 1474, 1454, 
1440, 1398, 1377, 1334, 1296, 1281, 1242, 1196, 1180, 1169, 1136, 1085, 1022, 997, 977, 
922, 909, 857, 835, 781, 755, 735, 715, 695, 686, 670. 
HRMS (EI) calculated for C18H22N4OSSi+: 370.1278, found 370 1276 [M]+. 






was synthesized according to TP12 on a 0.2 mmol scale using ethyl cyanoformate (30 mg, 
0.30 mmol, 1.5 equiv) as electrophile (2 h, 25 °C). Purification via column chromatography 
(silica gel, iHex/EtOAc = 2:1 + 5% NEt3) yielded the title compound 45c (35 mg, 0.11 mmol, 
53%) as a colorless solid. 
1H-NMR (C6D6, 400 MHz, ppm): δ = 7.56 (d, J = 1.3 Hz, 1 H), 6.89 (d, J = 1.2 Hz, 1 H), 4.60 
(s, 2 H), 4.12 (q, J = 7.1 Hz, 2 H), 3.39 (t, J = 8.0 Hz, 2 H), 1.05 (t, J = 7.1 Hz, 3 H), 0.80 (t, 
J = 8.0 Hz, 2 H), 0.07 (s, 9 H). 
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13C-NMR (C6D6, 101 MHz, ppm): δ = 158.0, 146.6, 142.1, 126.9, 116.6, 113.6, 76.7, 69.0, 
67.7, 61.3, 17.8, 14.3, 1.4. 
MS (70 eV, EI) m/z (%): 334 (4) [M]+, 291 (11), 277 (12), 276 (57), 204 (10), 158 (7), 74 (8), 
73 (100). 
IR (ATR) ~ (cm-1): 3158, 3112, 2953, 2895, 2219, 1704, 1603, 1581, 1471, 1451, 1398, 
1370, 1249, 1318, 1258, 1249, 1192, 1094, 1036, 948, 933, 918, 856, 833, 768, 749, 710, 
684. 
HRMS (EI) calculated for C15H22N4O3SSi+: 334.1456, found 334.1456 [M]+. 






bonitrile was synthesized according to TP12 on a 0.2 mmol scale. After the metalation a 
ZnCl2 solution (1.0 M in THF, 0.30 mL, 0.30 mmol, 1.5 equiv) was added before adding 
4-(4-iodophenyl)morpholine (46 mg, 0.16 mmol, 0.8 equiv) as electrophile and Pd(OAc)2 
(2.2 mg, 0.01 mmol, 5%) in combination with SPhos (8.2 mg, 0.02 mmol, 10%) as catalyst 
(2 h, 40 °C). Purification via column chromatography (silica gel, iHex/EtOAc = 2:1 + 5% NEt3) 
and HPLC yielded the title compound 45d (67 mg, 0.14 mmol, 89%) as a colorless solid. 
1H-NMR (C6D6, 400 MHz, ppm): δ = 8.02 (d, J = 8.8 Hz, 2 H), 7.72 – 7.58 (m, 1 H), 6.71 (d, 
J = 8.8 Hz, 2 H), 6.44 – 6.37 (m, 1 H), 4.82 (s, 2 H), 3.61 – 3.42 (m, 6 H), 2.79 – 2.66 (m, 
4 H), 0.87 (t, J = 8.0 Hz, 2 H), 0.05 (s, 9 H). 
13C-NMR (C6D6, 101 MHz, ppm): δ = 151.5, 146.1, 142.1, 126.5, 124.6, 118.5, 115.4, 114.5, 
114.3, 76.2, 67.8, 67.4, 66.7, 48.6, 17.8, 1.4. 
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MS (70 eV, EI) m/z (%): 423 (19) [M]+, 366 (23), 365 (100), 311 (6), 307 (7), 306 (14), 234 
(5), 73 (33). 
IR (ATR) ~ (cm-1): 3118, 2951, 2922, 2895, 2857, 2210, 1606, 1557, 1512, 1485, 1458, 
1449, 1428, 1379, 1336, 1316, 1306, 1263, 1248, 1229, 1221, 1192, 1120, 1099, 1072, 
1055, 1029, 1003, 975, 933, 921, 902, 858, 826, 815, 770, 753, 743, 712, 682, 665. 
HRMS (EI) calculated for C22H29N5O2Si:423.2091, found 423.2090 [M]. 






pyrazole-7-carbonitrile was synthesized according to TP12 on a 0.2 mmol scale. After the 
metalation a ZnCl2 solution (1.0 M in THF, 0.30 mL, 0.30 mmol, 1.5 equiv) was added before 
adding 6-iodo-2,3-dihydrobenzo[b][1,4]dioxine (42 mg, 0.16 mmol, 0.8 equiv) as electrophile 
and Pd(OAc)2 (2.2 mg, 0.01 mmol, 5%) in combination with SPhos (8.2 mg, 0.02 mmol, 10%) 
as catalyst (2 h, 40 °C). Purification via column chromatography (silica gel, iHex/EtOAc = 2:1 
+ 5% NEt3) yielded the title compound 45e (42 mg, 0.11 mmol, 66%) as a colorless solid. 
1H-NMR (C6D6, 400 MHz, ppm): δ = 7.91 (d, J = 2.1 Hz, 1 H), 7.57 (d, J = 1.2 Hz, 1 H), 7.53 
(dd, J = 8.5, 2.2 Hz, 1 H), 6.99 (d, J = 8.5 Hz, 1 H), 6.22 (d, J = 1.3 Hz, 1 H), 4.73 (s, 2 H), 
3.55 – 3.47 (m, 6 H), 0.86 (t, J = 8.0 Hz, 2 H), 0.06 (s, 9 H). 
13C-NMR (C6D6, 101 MHz, ppm): δ = 146.0, 144.4, 142.0, 124.0, 121.1, 119.0, 118.1, 115.0, 
114.8, 114.4, 76.1, 67.8, 67.3, 64.3, 64.2, 17.8, 1.4. 
MS (70 eV, EI) m/z (%): 396 (10) [M]+, 340 (5), 339 (20), 338 (100), 284 (14), 279 (15), 265 
(5), 73 (56). 
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IR (ATR) ~ (cm-1): 2950, 2358, 2340, 2217, 1613, 1593, 1579, 1558, 1539, 1506, 1490, 
1468, 1456, 1436, 1424, 1395, 1381, 1333, 1324, 1287, 1262, 1248, 1241, 1223, 1191, 
1179, 1134, 1109, 1081, 1068, 1054, 1044, 1032, 945, 923, 890, 879, 866, 831, 772, 762, 
750, 726, 701, 676, 668, 660. 
HRMS (EI) calculated for C20H24N4O3Si+: 396.1612, found 396.1608 [M]+. 






was synthesized according to TP12 on a 0.2 mmol scale. After the metalation a ZnCl2 
solution (1.0 M in THF, 0.30 mL, 0.30 mmol, 1.5 equiv) was added before adding ethyl 4-iodo 
benzoate (44 mg, 0.16 mmol, 0.8 equiv) as electrophile and PEPPSI-iPr (2.7 mg, 
0.004 mmol, 2%) as catalyst (2 h, 40 °C). Purification via column chromatography (silica gel, 
iHex/EtOAc = 4:1 + 5% NEt3) yielded the title compound 45f (55 mg, 0.13 mmol, 84%) as a 
colorless solid. 
1H-NMR (C6D6, 400 MHz, ppm): δ = 8.23 (d, J = 8.6 Hz, 2 H), 7.97 (d, J = 8.6 Hz, 2 H), 7.54 
(d, J = 1.1 Hz, 1 H), 6.25 (d, J = 1.1 Hz, 1 H), 4.73 (s, 2 H), 4.15 (q, J = 7.1 Hz, 2 H), 3.54 (t, 
J = 8.1 Hz, 2 H), 1.04 (t, J = 7.1 Hz, 3 H), 0.89 (t, J = 8.1 Hz, 2 H), 0.04 (s, 9 H). 
13C-NMR (C6D6, 101 MHz, ppm): δ = 165.8, 146.2, 142.2, 131.5, 130.43, 130.39, 124.9, 
123.2, 117.3, 114.1, 76.3, 68.2, 67.6, 61.1, 17.9, 14.3, 1.4. 
MS (70 eV, EI) m/z (%): 367 (8) [MC3H8]+, 353 (20), 352 (100), 298 (13), 293 (12), 281 
(11), 234 (20), 225 (14), 207 (29), 75 (11), 73 (63). 
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IR (ATR) ~ (cm-1): 3124, 2958, 2219, 1700, 1606, 1590, 1558, 1488, 1456, 1368, 1338, 
1326, 1289, 1275, 1248, 1195, 1177, 1109, 1089, 1066, 1049, 1035, 1019, 941, 919, 862, 
837, 790, 768, 741, 725, 707, 697, 660. 
HRMS (EI) calculated for C18H19N4O3Si+: 367.1221, found 367.1221 [MC3H8]+.  






le was synthesized according to TP12 on a 0.2 mmol scale. After the metalation a ZnCl2 
solution (1.0 M in THF, 0.30 mL, 0.30 mmol, 1.5 equiv) was added before adding 
2-iodotiophene (34 mg, 0.16 mmol, 0.8 equiv) as electrophile and PEPPSI-iPr (2.7 mg, 
0.004 mmol, 2%) as catalyst (2 h, 60 °C). Purification via column chromatography (silica gel, 
iHex/EtOAc = 4:1 + 5% NEt3) yielded the title compound 45g (41 mg, 0.12 mmol, 74%) as a 
colorless oil. 
1H-NMR (C6D6, 400 MHz, ppm): δ = 7.93 (dd, J = 3.5, 1.3 Hz, 1 H), 7.56 (d, J = 1.3 Hz, 1 H), 
6.77 – 6.70 (m, 2 H), 6.21 (d, J = 1.2 Hz, 1 H), 4.63 (s, 2 H), 3.47 (t, J = 8.0 Hz, 2 H), 0.84 (t, 
J = 8.0 Hz, 2 H), 0.06 (s, 9 H). 
13C-NMR (C6D6, 101 MHz, ppm): δ = 146.3, 141.5, 126.2, 124.8, 119.8, 115.0, 114.1, 76.1, 
68.3, 67.4, 17.8, 1.4. 
MS (70 eV, EI) m/z (%): 344 (1) [M]+, 287 (12), 286 (100), 259 (12), 232 (28), 227 (22), 213 
(10), 207 (24), 159 (11), 73 (29). 
IR (ATR) ~ (cm-1): 3107, 2951, 2897, 2215, 1605, 1510, 1484, 1418, 1379, 1335, 1307, 
1247, 1220, 1185, 1081, 1046, 1014, 939, 915, 856, 833, 738, 722, 692, 661. 







was synthesized according to TP12 on a 0.2 mmol scale. After the metalation a ZnCl2 
solution (1.0 M in THF, 0.30 mL, 0.30 mmol, 1.5 equiv) was added before adding 
3-iodopyridine (33 mg, 0.16 mmol, 0.8 equiv) as electrophile and PEPPSI-iPr (2.7 mg, 
0.004 mmol, 2%) as catalyst (2 h, 40 °C). Purification via column chromatography (silica gel, 
iHex/EtOAc = 1:1 + 5% NEt3) yielded the title compound 45h (45 mg, 0.13 mmol, 83%) as a 
colorless solid. 
1H-NMR (C6D6, 400 MHz, ppm): δ = 9.03 (d, J = 1.8 Hz, 1 H), 8.41 (dd, J = 4.8, 1.5 Hz, 1 H), 
8.35 (dt, J = 8.0, 1.9 Hz, 1 H), 7.55 (d, J = 1.0 Hz, 1 H), 6.78 (dd, J = 7.8, 5.0 Hz, 1 H), 6.27 
(d, J = 1.0 Hz, 1 H), 4.74 (s, 2 H), 3.53 (t, J = 8.1 Hz, 2 H), 0.88 (t, J = 8.1 Hz, 2 H), 0.04 (s, 
9 H). 
13C-NMR (C6D6, 101 MHz, ppm): δ = 149.3, 146.5, 146.3, 142.0, 131.9, 123.8, 123.5, 121.1, 
116.5, 114.1, 76.3, 68.3, 67.6, 17.9, 1.4. 
MS (70 eV, EI) m/z (%): 339 ( 0.3) [M]+, 296 (9), 282 (14), 281 (100), 254 (10), 227 (10), 222 
(15), 208 (9), 73 (46). 
IR (ATR) ~ (cm-1): 3048, 2951, 2925, 1619, 1568, 1558, 1490, 1456, 1413, 1394, 1380, 
1340, 1262, 1249, 1210, 1178, 1130, 1108, 1088, 1072, 1025, 938, 928, 905, 862, 832, 810, 
768, 759, 748, 719, 708, 687. 
HRMS (EI) calculated for C17H21N5OSi+: 339.1510, found 339.1511 [M]+. 








carbonitrile was synthesized according to TP12 on a 0.2 mmol scale. After the metalation a 
ZnCl2 solution (1.0 M in THF, 0.30 mL, 0.30 mmol, 1.5 equiv) was added before adding 
3-bromo-4-fluorobenzonitrile (32 mg, 0.16 mmol, 0.8 equiv) as electrophile and PEPPSI-iPr 
(2.7 mg, 0.004 mmol, 2%) as catalyst (17 h, 60 °C). Purification via column chromatography 
(silica gel, iHex/EtOAc = 4:1 + 5% NEt3) yielded the title compound 45i (50 mg, 0.13 mmol, 
82%) as a colorless solid. 
1H-NMR (C6D6, 400 MHz, ppm): δ = 9.15 (dd, J = 7.1, 2.1 Hz, 1 H), 7.53 (d, J = 1.3 Hz, 1 H), 
6.89 (dd, J = 3.2, 1.3 Hz, 1 H), 6.71 (ddd, J = 8.6, 4.8, 2.1 Hz, 1 H), 6.38 (dd, J = 11.2, 
8.6 Hz, 1 H), 4.72 (s, 2 H), 3.52 (t, J = 8.1 Hz, 2 H), 0.88 (t, J = 8.1 Hz, 2 H), 0.04 (s, 9 H). 
13C-NMR (C6D6, 101 MHz, ppm): δ = 160.1 (d, J = 258.1 Hz), 146.1, 141.4, 132.7, 131.3, 
121.2 (d, J = 17.3 Hz), 117.9, 117.6 (d, J = 13.2 Hz), 116.5 (d, J = 23.3 Hz), 116.0 (d, J = 
2.9 Hz), 113.7, 109.8 (d, J = 3.5 Hz), 76.5, 68.6, 67.7, 17.9, 1.4. 
MS (70 eV, EI) m/z (%): 381 (3) [M]+, 338 (10), 325 (5), 324 (17), 323 (86), 264 (9), 250 (5), 
73 (100). 
IR (ATR) ~ (cm-1): 3132, 3067, 2952, 2228, 2215, 1604, 1576, 1505, 1489, 1456, 1394, 
1340, 1323, 1297, 1245, 1229, 1187, 1167, 1124, 1109, 1080, 1052, 1038, 1027, 935, 911, 
894, 861, 824, 754, 728, 714, 697, 669. 
HRMS (EI) calculated for C19H20FN5OSi: 381.1421, found 381.13422 [M]. 








thyl)-1H-imidazo[1,2-b]pyrazole-7-carbonitrile was synthesized according to TP12 on a 
0.2 mmol scale. After the metalation a ZnCl2 solution (1.0 M in THF, 0.30 mL, 0.30 mmol, 
1.5 equiv) was added before adding 1-(4-iodophenyl)-3-morpholino-5,6-dihydropyridin-2(1H)-
one (62 mg, 0.16 mmol, 0.8 equiv) as electrophile and PEPPSI-iPent (4.8 mg, 0.006 mmol, 
3%) as catalyst (2 h, 60 °C). Purification via column chromatography (silica gel, iHex/EtOAc 
= 4:6 + 5% NEt3) yielded the title compound 45j (47 mg, 0.09 mmol, 57%) as a colorless 
solid. 
1H-NMR (CD2Cl2, 400 MHz, ppm): δ = 8.06 (d, J = 8.6 Hz, 2 H), 7.98 (s, 1 H), 7.44 (d, J = 
8.6 Hz, 2 H), 7.29 (s, 1 H), 5.68 (t, J = 4.7 Hz, 1 H), 5.48 (s, 2 H), 3.83 – 3.73 (m, 6 H), 3.68 
(t, J = 8.3 Hz, 2 H), 2.87 (t, J = 4.4 Hz, 4 H), 2.50 (q, J = 6.5 Hz, 2 H), 0.98 (t, J = 8.3 Hz, 
2 H), 0.01 (s, 9 H). 
13C-NMR (CD2Cl2, 101 MHz, ppm): δ = 161.8, 146.7, 144.2, 143.6, 142.3, 126.0, 125.8, 
124.9, 124.2, 116.6, 115.3, 114.6, 77.3, 67.9, 67.2, 51.0, 49.2, 23.9, 18.2, 1.3, 1.3. 
MS (70 eV, EI) m/z (%): 518 (15) [M]+, 461 (25), 460 (81), 443 (16), 442 (41), 402 (10), 401 
(25), 73 (100), 44 (20). 
IR (ATR) ~ (cm-1): 3117, 2952, 2928, 2846, 2823, 2208, 1652, 1605, 1512, 1486, 1472, 
1452, 1418, 1378, 1349, 1338, 1327, 1310, 1261, 1250, 1217, 1208, 1192, 1111, 1048, 
1025, 975, 948, 930, 921, 902, 857, 831, 795, 780, 750, 712, 682. 
HRMS (EI) calculated for C27H34N6O3Si+: 518.2456, found 518.2457 [M]+. 








xylate was synthesized according to TP13 on a 0.2 mmol scale using allyl bromide (0.03 mL, 
0.33 mmol, 1.7 equiv) and CuCN2LiCl (1 M in THF, 0.04 mL, 0.04 mmol, 0.20 equiv) as 
electrophile (20 min, 25 °C). Purification via column chromatography (silica gel, iHex/EtOAc = 
9:1 + 5% NEt3) yielded the title compound 47a (54 mg, 0.14 mmol, 72%) as a colorless solid. 
1H-NMR (C6D6, 400 MHz, ppm): δ = 7.56 (s, 1 H), 4.95 – 4.88 (m, 2 H), 4.84 (s, 2 H), 4.15 
(q, J = 7.1 Hz, 2 H), 3.63 (d, J = 6.2 Hz, 2 H), 3.55 (t, J = 8.2 Hz, 2 H), 1.07 (t, J = 7.1 Hz, 
3 H), 0.86 (t, J = 8.2 Hz, 2 H), 0.05 (s, 9 H). 
13C-NMR (C6D6, 101 MHz, ppm): δ = 159.1, 145.7, 141.5, 139.7, 132.8, 117.7, 114.0, 113.5, 
73.8, 68.5, 67.7, 61.2, 28.3, 17.9, 14.3, 1.4. 
MS (70 eV, EI) m/z (%): 374 (1) [M]+, 317 (11), 316 (70), 281 (21), 270 (37), 254 (11), 253 
(10), 243 (10), 209 (14), 208 (13), 207 (100), 198 (21), 197 (15), 191 (18), 170 (20), 169 (11), 
143 (22), 75 (14), 73 (70), 44 (15). 
IR (ATR) ~ (cm-1): 2924, 2218, 1716, 1642, 1601, 1565, 1479, 1467, 1446, 1407, 1375, 
1351, 1317, 1275, 1265, 1248, 1183, 1139, 1108, 1088, 1066, 1046, 1019, 991, 940, 922, 
883, 859, 835, 807, 769, 701, 672. 
HRMS (EI) calculated for C18H26N4O3Si+: 374.1769, found 374.1769 [M]+. 








carboxylate was synthesized according to TP13 on a 0.2 mmol scale using benzoyl chloride 
(42 mg, 0.30 mmol, 1.5 equiv) and CuCN2LiCl (1 M in THF, 0.10 mL, 0.10 mmol, 0.50 equiv) 
as electrophile (1 h, 25 °C). Purification via column chromatography (silica gel, iHex/EtOAc = 
9:1 + 5% NEt3) yielded the title compound 47b (55 mg, 0.13 mmol, 63%) as a colorless solid. 
1H-NMR (C6D6, 400 MHz, ppm): δ = 7.64 (d, J = 7.2 Hz, 2 H), 7.60 (s, 1 H), 7.05 (t, J = 
7.4 Hz, 1 H), 6.95 (t, J = 7.6 Hz, 2 H), 5.06 (s, 2 H), 3.74 (q, J = 7.1 Hz, 2 H), 3.34 (t, J = 
8.2 Hz, 2 H), 0.59 (dt, J = 11.5, 7.7 Hz, 5 H), 0.18 (s, 9 H). 
13C-NMR (C6D6, 101 MHz, ppm): δ = 185.4, 157.1, 147.6, 142.2, 137.3, 134.3, 133.7, 129.7, 
128.9, 115.9, 113.3, 74.8, 69.3, 67.6, 61.5, 17.6, 13.5, 1.5. 
MS (70 eV, EI) m/z (%): 438 (2) [M]+, 395 (11), 381 (18), 380 (65), 366 (21), 365 (75), 293 
(14), 262 (23), 105 (22), 91 (15), 77 (13), 73 (100). 
IR (ATR) ~ (cm-1): 2945, 2220, 1731, 1666, 1614, 1597, 1562, 1556, 1482, 1461, 1448, 
1375, 1349, 1320, 1278, 1242, 1234, 1191, 1174, 1146, 1113, 1094, 1024, 962, 941, 920, 
861, 838, 760, 709, 688, 676. 
HRMS (EI) calculated for C22H26N4O4Si+: 438.1718, found 438.1718 [M]+. 








zole-3-carboxylate was synthesized according to TP13 on a 0.2 mmol scale using 
4-nitrobenzoyl chloride (56 mg, 0.30 mmol, 1.5 equiv) and CuCN2LiCl (1 M in THF, 0.10 mL, 
0.10 mmol, 0.50 equiv) as electrophile (2 h, 25 °C). Purification via column chromatography 
(silica gel, iHex/EtOAc = 4:1 + 5% NEt3) yielded the title compound 47c (59 mg, 0.12 mmol, 
61%) as a yellow solid. 
1H-NMR (C6D6, 400 MHz, ppm): δ = 7.71 (d, J = 8.8 Hz, 2 H), 7.55 (s, 1 H), 7.39 (d, J = 
8.8 Hz, 2 H), 5.05 (s, 2 H), 3.77 (q, J = 7.1 Hz, 2 H), 3.36 (t, J = 8.2 Hz, 2 H), 0.75 – 0.57 (m, 
5 H), 0.17 (s, 9 H). 
13C-NMR (C6D6, 101 MHz, ppm): δ = 184.3, 157.2, 150.9, 147.9, 142.4, 141.0, 132.6, 130.2, 
123.9, 116.6, 113.0, 74.6, 69.3, 67.8, 62.0, 17.6, 13.7, 1.6. 
MS (70 eV, EI) m/z (%): 483 (0.3) [M]+, 426 (12), 425 (43), 410 (20), 307 (8), 103 (7), 74 (7), 
73 (100). 
IR (ATR) ~ (cm-1): 3108, 2951, 2226, 1727, 1690, 1664, 1605, 1562, 1551, 1524, 1475, 
1409, 1369, 1344, 1312, 1276, 1245, 1231, 1179, 1137, 1110, 1020, 967, 942, 911, 853, 
835, 803, 789, 760, 753, 735, 702, 665. 
HRMS (EI) calculated for C22H25N5O6Si+: 483.1569, found 483.1561 [M]+. 








[1,2-b]pyrazole-3-carboxylate was synthesized according to TP13 on a 0.2 mmol scale using 
cyclopropanecarbonyl chloride (31 mg, 0.30 mmol, 1.5 equiv) and CuCN2LiCl (1 M in THF, 
0.10 mL, 0.10 mmol, 0.50 equiv) as electrophile (1 h, 25 °C). Purification via column 
chromatography (silica gel, iHex/EtOAc = 4:1 + 5% NEt3) yielded the title compound 47d (65 
mg, 0.16 mmol, 81%) as a colorless solid. 
1H-NMR (C6D6, 400 MHz, ppm): δ = 7.55 (s, 1 H), 5.13 (s, 2 H), 4.09 (q, J = 7.1 Hz, 2 H), 
3.49 (t, J = 8.1 Hz, 2 H), 2.20 (tt, J = 7.9, 4.5 Hz, 1 H), 1.33 – 1.26 (m, 2 H), 1.02 (t, J = 
7.1 Hz, 3 H), 0.83 (t, J = 8.1 Hz, 2 H), 0.72 (dd, J = 7.6, 3.6 Hz, 2 H), 0.08 (s, 9 H). 
13C-NMR (C6D6, 101 MHz, ppm): δ = 194.4, 158.0, 147.7, 142.0, 135.4, 116.2, 113.3, 74.8, 
69.1, 67.7, 62.0, 24.1, 17.9, 14.4, 14.1, 1.4. 
MS (70 eV, EI) m/z (%): 402 (1) [M], 345 (10), 344 (35), 330 (11), 329 (45), 283 (18), 73 
(100). 
IR (ATR) ~ (cm-1): 2952, 2226, 1724, 1686, 1674, 1612, 1556, 1481, 1441, 1405, 1377, 
1359, 1346, 1315, 1305, 1276, 1263, 1247, 1196, 1184, 1166, 1111, 1086, 1057, 1039, 
1017, 1002, 945, 921, 897, 860, 834, 792, 772, 759, 723, 697, 682, 666. 
HRMS (EI) calculated for C19H26N4O4Si: 402.1723, found 402.1724 [M]. 








razole-3-carboxylate was synthesized according to TP13 on a 0.2 mmol scale using 
6-chloronicotinoyl chloride (53 mg, 0.30 mmol, 1.5 equiv) and CuCN2LiCl (1 M in THF, 
0.10 mL, 0.10 mmol, 0.50 equiv) as electrophile (2 h, 25 °C). Purification via column 
chromatography (silica gel, iHex/EtOAc = 9:1 + 5% NEt3) yielded the title compound 47e 
(67 mg, 0.14 mmol, 71%) as a colorless solid. 
1H-NMR (C6D6, 400 MHz, ppm): δ = 7.59 (s, 1 H), 7.55 (dd, J = 3.0, 1.2 Hz, 2 H), 7.21 (dd, 
J = 5.0, 1.2 Hz, 1 H), 6.83 (dd, J = 5.0, 3.0 Hz, 1 H), 4.68 (s, 2 H), 4.07 (q, J = 7.1 Hz, 2 H), 
3.68 – 3.60 (m, 2 H), 0.98 (t, J = 7.1 Hz, 3 H), 0.88 – 0.82 (m, 2 H), 0.03 (s, 9 H). 
13C-NMR (C6D6, 101 MHz, ppm): δ = 158.3, 146.1, 141.7, 135.5, 130.2, 130.1, 125.9, 125.4, 
114.0, 113.4, 74.2, 68.8, 68.1, 61.1, 18.2, 14.2, 1.4. 
MS (70 eV, EI) m/z (%): 473 (2) [M]+, 417 (18), 416 (12), 415 (45), 400 (22), 297 (10), 73 
(100). 
IR (ATR) ~ (cm-1): 2952, 2220, 1731, 1676, 1607, 1583, 1563, 1478, 1412, 1363, 1311, 
1291, 1275, 1245, 1186, 1134, 1093, 1068, 1021, 980, 963, 935, 923, 860, 836, 820, 783, 
765, 741, 707, 692. 
HRMS (EI) calculated for C21H24ClN5O4Si+: 473.1281, found 473.1281 [M]+. 








[1,2-b]pyrazole-3-carboxylate was synthesized according to TP13 on a 0.2 mmol scale using 
ethyl 4-iodo benzoate (44 mg, 0.16 mmol, 0.8 equiv) as electrophile and Pd(PPh3)4 (6.9 mg, 
0.006 mmol, 3%) as catalyst (90 min, 40 °C). Purification via column chromatography (silica 
gel, iHex/EtOAc = 7:1 + 5% NEt3) yielded the title compound 47f (51 mg, 0.11 mmol, 66%) 
as a slightly yellow solid. 
1H-NMR (C6D6, 400 MHz, ppm): δ = 8.17 (d, J = 8.5 Hz, 2 H), 7.64 (s, 1 H), 7.37 (d, J = 
8.5 Hz, 2 H), 4.66 (s, 2 H), 4.12 (q, J = 7.1 Hz, 2 H), 4.01 (q, J = 7.1 Hz, 2 H), 3.63 – 3.49 (m, 
3 H), 1.03 (t, J = 7.1 Hz, 3 H), 0.91 (t, J = 7.1 Hz, 3 H), 0.88 – 0.80 (m, 2 H), 0.05 (s, 9 H). 
13C-NMR (C6D6, 101 MHz, ppm): δ = 165.5, 158.0, 146.3, 141.9, 139.2, 132.7, 131.7, 130.6, 
129.5, 113.9, 113.7, 74.2, 69.0, 68.0, 61.3, 61.2, 18.2, 14.2, 14.1, 1.4. 
MS (70 eV, EI) m/z (%): 424 (3) [MC4H10]+, 281 (22), 225 (60), 209 (30), 208 (13), 207 
(100), 191 (25), 73 (11). 
IR (ATR) ~ (cm-1): 3097, 2952, 2223, 1709, 1602, 1574, 1503, 1479, 1443, 1392, 1376, 
1314, 1274, 1250, 1195, 1171, 1088, 1019, 938, 914, 883, 857, 835, 763, 743, 717, 695, 
666. 
HRMS (EI) calculated for C24H30N4O5Si+: 482.1980, found 482.1975 [M]+. 








[1,2-b]pyrazole-3-carboxylate was synthesized according to TP13 on a 0.2 mmol scale using 
1-iodo-4-(trifluoromethyl)benzene (44 mg, 0.16 mmol, 0.8 equiv) as electrophile and 
Pd(PPh3)4 (6.9 mg, 0.006 mmol, 3%) as catalyst (90 min, 40 °C). Purification via column 
chromatography (silica gel, iHex/EtOAc = 7:1 + 5% NEt3) yielded the title compound 47g (53 
mg, 0.11 mmol, 69%) as a slightly yellow solid. 
1H-NMR (C6D6, 400 MHz, ppm): δ = 7.61 (s, 1 H), 7.37 (d, J = 8.2 Hz, 2 H), 7.28 (d, J = 
8.2 Hz, 2 H), 4.58 (s, 2 H), 4.00 (q, J = 7.1 Hz, 2 H), 3.62 – 3.54 (m, 2 H), 0.91 (t, J = 7.1 Hz, 
3 H), 0.88 – 0.82 (m, 2 H), 0.04 (s, 9 H). 
13C-NMR (C6D6, 101 MHz, ppm): δ = 158.0, 146.4, 141.9, 138.5, 132.2 (q, J = 32.7 Hz), 
132.2, 130.0, 125.8 (q, J = 272.7 Hz), 125.2 (q, J = 3.6 Hz), 113.8, 113.8, 74.2, 69.0, 68.2, 
61.3, 18.2, 14.0, 1.5. 
MS (70 eV, EI) m/z (%): 478 (0.2) [M]+, 435 (21), 421 (22), 420 (96), 349 (12), 348 (72), 328 
(18), 320 (12), 315 (14), 302 (26), 287 (12), 275 811), 256 (33), 172 (10), 73 (100). 
IR (ATR) ~ (cm-1): 2954, 2221, 1720, 1606, 1572, 1513, 1478, 1443, 1409, 1378, 1354, 
1321, 1274, 1249, 1167, 1127, 1101, 1068, 1018, 942, 915, 834, 765, 722, 692, 671. 
HRMS (EI) calculated for C22H25F3N4O3Si+: 478.1643, found 478.1643 [M]+. 








pyrazole-3-carboxylate was synthesized according to TP13 on a 0.2 mmol scale using 
1-iodo-4-methoxybenzene (37 mg, 0.16 mmol, 0.8 equiv) as electrophile and Pd(PPh3)4 
(6.9 mg, 0.006 mmol, 3%) as catalyst (80 min, 40 °C). Purification via column 
chromatography (silica gel, iHex/EtOAc = 4:1 + 5% NEt3) and HPLC yielded the title 
compound 47h (37 mg, 0.08 mmol, 53%) as a colorless solid. 
1H-NMR (C6D6, 400 MHz, ppm): δ = 7.65 (s, 1 H), 7.37 (d, J = 8.8 Hz, 2 H), 6.78 (d, J = 
8.8 Hz, 2 H), 4.73 (s, 2 H), 4.07 (q, J = 7.1 Hz, 2 H), 3.63 (t, J = 8.3 Hz, 2 H), 3.25 (s, 3 H), 
0.98 (t, J = 7.1 Hz, 3 H), 0.87 (t, J = 8.3 Hz, 2 H), 0.03 (s, 9 H). 
13C-NMR (C6D6, 101 MHz, ppm): δ = 161.6, 158.4, 146.0, 141.7, 140.7, 133.2, 118.3, 114.1, 
113.9, 113.2, 74.1, 69.0, 67.9, 61.0, 54.9, 18.2, 14.2, 1.4. 
MS (70 eV, EI) m/z (%): 440 (2) [M]+, 397 (15), 383 (22), 382 (100), 311 (10), 310 (60), 282 
(31), 277 (11), 264 (31), 256 (13), 236 (11), 209 (10), 183 (20), 73 (34). 
IR (ATR) ~ (cm-1): 2980, 2930, 2220, 1720, 1604, 1582, 1568, 1510, 1477, 1462, 1438, 
1412, 1376, 1344, 1314, 1296, 1265, 1256, 1248, 1180, 1171, 1119, 1088, 1056, 1036, 
1024, 1014, 1008, 944, 933, 916, 874, 858, 838, 790, 768, 758, 728, 701, 686, 676. 
HRMS (EI) calculated for C22H28N4O4Si+: 440.1874, found 440.1876 [M]+. 








[1,2-b]pyrazole-3-carboxylate was synthesized according to TP13 on a 0.3 mmol scale using 
5-iodo-1,2,3-trimethoxybenzene (71 mg, 0.24 mmol, 0.8 equiv) as electrophile and Pd(PPh3)4 
(17 mg, 0.015 mmol, 5%) as catalyst (4 h, 40 °C). Purification via column chromatography 
(silica gel, iHex/EtOAc = 6:1 + 5% NEt3) yielded the title compound 47i (60 mg, 0.12 mmol, 
50%) as a slightly yellow solid. 
1H-NMR (C6D6, 400 MHz, ppm): δ = 7.68 (s, 1 H), 6.74 (s, 2 H), 4.82 (s, 2 H), 4.09 (q, J = 
7.1 Hz, 2 H), 3.83 (s, 3 H), 3.65 (t, J = 8.4 Hz, 2 H), 3.54 (s, 6 H), 0.98 (t, J = 7.1 Hz, 3 H), 
0.88 (t, J = 8.4 Hz, 2 H), 0.03 (s, 9 H). 
13C-NMR (C6D6, 101 MHz, ppm): δ = 158.4, 153.7, 146.2, 141.6, 141.1, 140.7, 121.0, 114.1, 
113.2, 109.6, 74.4, 69.0, 68.0, 61.0, 60.6, 56.1, 18.4, 14.2, 1.4. 
MS (70 eV, EI) m/z (%): 500 (5) [M]+, 443 (27), 442 (100), 418 (10), 427 (42), 381 (10), 370 
(20), 355 (13), 342 (13), 324 (15), 243 (10), 73 (32). 
IR (ATR) ~ (cm-1): 3094, 2946, 2836, 2214, 1719, 1612, 1591, 1560, 1509, 1493, 1467, 
1456, 1421, 1395, 1382, 1366, 1358, 1353, 1317, 1281, 1249, 1228, 1181, 1165, 1128, 
1098, 1067, 1033, 990, 945, 931, 859, 834, 791, 772, 758, 748, 724, 711, 691. 
HRMS (EI) calculated for C24H32N4O6Si+: 500.2086, found 500.2087 [M]+. 








zole-3-carboxylate was synthesized according to TP13 on a 0.30 mmol scale using 
3-iodothiophene (34 mg, 0.16 mmol, 0.8 equiv) as electrophile and Pd(PPh3)4 (17 mg, 
0.015 mmol, 5%) as catalyst (4 h, 40 °C). Purification via column chromatography (silica gel, 
iHex/EtOAc = 7:1 + 5% NEt3) yielded the title compound 47j (54 mg, 0.13 mmol, 54%) as a 
colorless solid. 
1H-NMR (C6D6, 400 MHz, ppm): δ = 7.59 (s, 1 H), 7.55 (dd, J = 3.0, 1.2 Hz, 1 H), 7.21 (dd, 
J = 5.0, 1.2 Hz, 1 H), 6.83 (dd, J = 5.0, 3.0 Hz, 1 H), 4.68 (s, 2 H), 4.07 (q, J = 7.1 Hz, 2 H), 
3.67 – 3.61 (m, 2 H), 0.98 (t, J = 7.1 Hz, 3 H), 0.88 – 0.82 (m, 2 H), 0.03 (s, 9 H). 
13C-NMR (C6D6, 101 MHz, ppm): δ = 158.3, 146.1, 141.7, 135.5, 130.2, 130.1, 125.9, 125.4, 
114.0, 113.4, 74.2, 68.8, 68.1, 61.1, 18.2, 14.2, 1.4. 
MS (70 eV, EI) m/z (%): 416 (1) [M]+, 373 (12), 359 (19), 358 (100), 286 (68), 258 (38), 253 
(17), 240 (43), 232 (13), 225 (10), 212 (12), 207 (10), 159 (16), 73 (74). 
IR (ATR) ~ (cm-1): 3097, 2945, 2218, 1713, 1606, 1582, 1519, 1501, 1476, 1443, 1416, 
1373, 1337, 1310, 1267, 1243, 1220, 1189, 1166, 1088, 1060, 1018, 942, 912, 837, 810, 
764, 721, 711, 689, 660. 
HRMS (EI) calculated for C19H24N4O3SSi+: 416.1333, found 416.1334 [M]+. 










sized according to TP14 on a 0.087 mmol scale. The reaction was completed within 40 min 
and yielded the title compound 48a (32 mg, 0.033 mmol, 76%) as a yellow solid. 
1H-NMR (acetone-d6, 400 MHz, ppm): δ = 8.08 (d, J = 8.4 Hz, 4 H), 7.64 (d, J = 8.4 Hz, 
4 H), 5.19 (s, 4 H), 4.38 (q, J = 7.1 Hz, 4 H), 4.11 (q, J = 7.1 Hz, 4 H), 3.49 (t, J = 8.2 Hz, 
4 H), 1.39 (t, J = 7.1 Hz, 6 H), 1.05 (t, J = 7.1 Hz, 6 H), 0.85 (t, J = 8.2 Hz, 4 H), 0.03 (s, 
18 H). 
13C-NMR (acetone-d6, 101 MHz, ppm): δ = 166.4, 165.0, 153.1, 136.2, 135.1, 132.1, 131.2, 
129.4, 128.2, 125.2, 73.0, 65.7, 61.6, 61.0, 24.6, 18.4, 14.6, 14.2, 1.3. 
IR (ATR) ~ (cm-1): 2953, 2186, 2143, 1714, 1694, 1612, 1575, 1519, 1466, 1403, 1378, 
1366, 1270, 1248, 1180, 1101, 1079, 1025, 963, 939, 916, 859, 834, 774, 759, 724, 706, 
667. 
HRMS (ESI) calculated for C48H59N8O10Si2: 963.3898, found 963.38977 [MH]. 










sized according to TP14 on a 0.096 mmol scale. The reaction was completed within 30 min 
and yielded the title compound 48b (30 mg, 0.032 mmol, 67%) as a slightly orange solid. 
1H-NMR (acetone-d6, 400 MHz, ppm): δ = 7.89 (q, J = 8.4 Hz, 8 H), 5.30 (s, 4 H), 4.14 (q, 
J = 7.1 Hz, 4 H), 3.57 – 3.44 (m, 4 H), 1.07 (t, J = 7.1 Hz, 6 H), 0.93 – 0.80 (m, 4 H), −0.03 
(s, 18 H). 
13C-NMR (acetone-d6, 101 MHz, ppm): δ = 159.7, 152.0, 136.5, 133.0, 132.0 (q, 
J = 32.4 Hz) 131.7, 126.0 (q, J = 3.8 Hz), 125.1 (q, J = 271.7 Hz), 120.6, 119.7, 73.6, 66.5, 
61.9, 28.2, 18.3, 14.1, 1.3. 
IR (ATR) ~ (cm-1): 3050, 2954, 2897, 2746, 2213, 2171, 2149, 1725, 1614, 1599, 1518, 
1465, 1431, 1408, 1371, 1323, 1298, 1262, 1250, 1228, 1214, 1203, 1184, 1163, 1126, 
1108, 1082, 1067, 1026, 1013, 947, 924, 854, 835, 774, 758, 743, 711, 697, 674. 
HRMS (ESI) calculated for C44H49F6N8O6Si2: 955.3223, found 955.3220 [MH]. 










sized according to TP14 on a 0.148 mmol scale. The reaction was completed within 40 min 
and yielded the title compound 48c (71 mg, 0.071 mmol, 96%) as a slightly yellow solid. 
1H-NMR (acetone-d6, 400 MHz, ppm): δ = 6.80 (s, 4 H), 5.20 (s, 4 H), 4.13 (q, J = 7.1 Hz, 
4 H), 3.85 (s, 12 H), 3.78 (s, 6 H), 3.59 – 3.47 (m, 4 H), 1.09 (t, J = 7.1 Hz, 6 H), 0.92 – 0.84 
(m, 4 H), 0.02 (s, 18 H). 
13C-NMR (acetone-d6, 101 MHz, ppm): δ = 165.4, 153.7, 152.2, 139.5, 137.7, 127.3, 125.4, 
125.3, 109.5, 72.9, 65.6, 60.8, 60.6, 56.5, 24.4, 18.6, 14.3, 1.3. 
IR (ATR) ~ (cm-1): 2951, 2184, 2140, 1687, 1605, 1584, 1520, 1500, 1464, 1411, 1379, 
1364, 1341, 1319, 1245, 1189, 1124, 1077, 1028, 1003, 938, 834, 788, 769, 726, 693. 
HRMS (ESI) calculated for C48H63N8O12Si2: 999.4109, found 999.41095 [MH]. 








1H,1'H,5H,5'H-[6,6'-biimidazo[1,2-b]pyrazolylidene]-3,3'-dicarboxylate was synthesized 
according to TP14 on a 0.115 mmol scale. The reaction was completed within 150 min at 
25 °C and yielded the title compound 48d (41 mg, 0.049 mmol, 86%) as a yellow solid. 
1H-NMR (acetone-d6, 400 MHz, ppm): δ = 7.67 (dd, J = 3.0, 1.1 Hz, 2 H), 7.54 (dd, J = 5.0, 
3.0 Hz, 2 H), 7.28 (dd, J = 5.0, 1.1 Hz, 2 H), 5.21 (s, 4 H), 4.14 (q, J = 7.1 Hz, 4 H), 3.54 (t, 
J = 8.1 Hz, 4 H), 1.12 (t, J = 7.1 Hz, 6 H), 0.89 (t, J = 8.1 Hz, 4 H), 0.01 (s, 18 H). 
13C-NMR (acetone-d6, 101 MHz, ppm): δ = 165.3, 152.4, 132.6, 132.6, 131.1, 129.9, 127.9, 
127.7, 125.4, 72.8, 65.7, 60.9, 24.5, 18.4, 14.2, 1.3. 
IR (ATR) ~ (cm-1): 2953, 2184, 2142, 1683, 1629, 1521, 1396, 1377, 1341, 1262, 1248, 
1189, 1077, 1027, 964, 939, 916, 857, 833, 809, 785, 756, 722, 692, 668. 
HRMS (ESI) calculated for C38H48N8NaO6S2Si2+: 855.2569, found 855.25681 [M+Na]+. 








1H,1'H,5H,5'H-[6,6'-biimidazo[1,2-b]pyrazolylidene]-3,3'-dicarboxylate was synthesized 
according to TP14 on a 0.185 mmol scale. The reaction was completed within 40 min and 
yielded the title compound 48e (68 mg, 0.078 mmol, 84%) as a yellow solid. 
1H-NMR (acetone-d6, 400 MHz, ppm): δ = 7.80 (d, J = 7.0 Hz, 4 H), 7.62 (t, J = 7.4 Hz, 2 H), 
7.50 (t, J = 7.6 Hz, 4 H), 5.64 (s, 4 H), 3.75 (q, J = 7.1 Hz, 4 H), 3.54 – 3.43 (m, 4 H), 0.77 – 
0.67 (m, 10 H), 0.10 (s, 18 H). 
13C-NMR (acetone-d6, 101 MHz, ppm): δ = 186.1, 163.4, 154.7, 139.8, 135.6, 132.6, 129.8, 
129.0, 128.3, 123.6, 72.5, 65.2, 60.3, 25.0, 17.4, 12.7, 2.2. 
IR (ATR) ~ (cm-1): 2950, 2359, 2194, 2150, 1703, 1638, 1599, 1581, 1543, 1518, 1494, 
1473, 1449, 1423, 1402, 1363, 1354, 1340, 1307, 1277, 1262, 1249, 1218, 1205, 1179, 
1143, 1082, 1063, 1033, 998, 956, 936, 919, 861, 848, 835, 812, 790, 761, 733, 724, 695, 
683. 
HRMS (ESI) calculated for C44H51N8O8Si2: 875.3374, found 875.33763 [MH]. 


















1 Single Crystal X-Ray Diffraction Studies 
Phenyl(3-(1-phenylallyl)bicyclo[1.1.1]pentan-1-yl)methanone (4b) 
Table 3. Details for X-ray data collection and structure refinement for compound 4b. 
 4b 
Empirical formula C21H20O 
Formula mass 288.37 
T[K] 143(2) 
Crystal size [mm] 0.40 × 0.10 × 0.10 
Crystal description colorless rod 
Crystal system monoclinic 
Space group P21/n 
a [Ǻ] 10.7427(6) 
b [Ǻ] 10.4700(4) 
c [Ǻ] 14.4147(7) 
α [°] 90.0 
β [°] 93.099(5) 
γ [°] 90.0 
V [Ǻ3] 1618.94(14) 
Z 4 
ρcalcd. [g cm-3] 1.183 
μ [mm-1] 0.071 
F(000) 616 
Θ range [°] 4.27 – 25.24 
Index ranges -13 ≤ h ≤ 12 
 -12 ≤ k ≤ 10 
 -16 ≤ l ≤ 17 
Reflns. collected 11265 
Reflns. obsd. 2144 
Reflns. unique 3050 
(Rint = 0.0438) 
R1, wR2 (2σ data) 0.0725, 0.1831 
R1, wR2 (all data) 0.1006, 0.2079 
GOOF on F2 1.030 




Figure 10. Molecular structure of compound 4b in the crystal. DIAMOND119 representation; 




Table 4. Details for X-ray data collection and structure refinement for compound 4m. 
 4m 
Empirical formula C22H28O 
Formula mass 308.44 
T[K] 143(2) 
Crystal size [mm] 0.40 × 0.15 × 0.02 
Crystal description colorless platelet 
Crystal system monoclinic 
Space group P21 
a [Ǻ] 8.0515(6) 
b [Ǻ] 6.4231(5) 
c [Ǻ] 17.0787(16) 
α [°] 90.0 
β [°] 92.434(8) 
γ [°] 90.0 
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V [Ǻ3] 882.44(13) 
Z 2 
ρcalcd. [g cm-3] 1.161 
μ [mm-1] 0.069 
F(000) 336 
Θ range [°] 4.20 – 25.24 
Index ranges -8 ≤ h ≤ 10 
 -7 ≤ k ≤ 8 
 -21 ≤ l ≤ 21 
Reflns. collected 5879 
Reflns. obsd. 2613 
Reflns. unique 3357 
(Rint = 0.0380) 
R1, wR2 (2σ data) 0.0530, 0.0876 
R1, wR2 (all data) 0.0788, 0.0995 
GOOF on F2 1.054 
Peak/hole [e Ǻ-3] 0.215 / -0.178 
 
 
Figure 11. Molecular structure of compound 4m in the crystal. DIAMOND119 representation; 





Table 5. Details for X-ray data collection and structure refinement for compound 9c. 
 9c 
Empirical formula C18H22O2 
Formula mass 270.35 
T[K] 143(2) 
Crystal size [mm] 0.40 × 0.35 × 0.25 
Crystal description colorless block 
Crystal system monoclinic 
Space group P21/c 
a [Ǻ] 12.8464(4) 
b [Ǻ] 7.7678(3) 
c [Ǻ] 15.0626(4) 
α [°] 90.0 
β [°] 99.686(3) 
γ [°] 90.0 
V [Ǻ3] 1481.64(8) 
Z 4 
ρcalcd. [g cm-3] 1.212 
μ [mm-1] 0.077 
F(000) 584 
Θ range [°] 3.41 – 25.24 
Index ranges -16 ≤ h ≤ 16 
 -9 ≤ k ≤ 9 
 -18 ≤ l ≤ 18 
Reflns. collected 20402 
Reflns. obsd. 2429 
Reflns. unique 2863 
(Rint = 0.0292) 
R1, wR2 (2σ data) 0.0767, 0.2031 
R1, wR2 (all data) 0.0863, 0.2142 
GOOF on F2 1.027 




Figure 12. Molecular structure of compound 9c in the crystal. DIAMOND119 representation; 
thermal ellipsoids are drawn at 50 % probability level. 
 
Ethyl 4-(bicyclo[1.1.1]pentan-1-yl)-1-methylpiperidine-4-carboxylate (20) 
Table 6. Details for X-ray data collection and structure refinement for compound 20. 
 20 
Empirical formula C14H23NO2 
Formula mass 237.33 
T[K] 123(2) 
Crystal size [mm] 0.40 × 0.40 × 0.35 
Crystal description colorless block 
Crystal system monoclinic 
Space group P21/c 
a [Ǻ] 15.4834(7) 
b [Ǻ] 5.9795(3) 
c [Ǻ] 14.7917(7) 
α [°] 90.0 
β [°] 97.994(4) 
γ [°] 90.0 
V [Ǻ3] 1356.15(11) 
Z 4 
ρcalcd. [g cm-3] 1.162 
μ [mm-1] 0.077 
F(000) 520 
Θ range [°] 2.66 – 25.24 
Index ranges -22 ≤ h ≤ 22 
181 
 
 -8 ≤ k ≤ 8 
 -21 ≤ l ≤ 21 
Reflns. collected 26420 
Reflns. obsd. 3121 
Reflns. unique 4124 
(Rint = 0.0472) 
R1, wR2 (2σ data) 0.0452, 0.1104 
R1, wR2 (all data) 0.0658, 0.1242 
GOOF on F2 1.026 
Peak/hole [e Ǻ-3] 0.377 / -0.198 
 
 
Figure 13. Molecular structure of compound 20 in the crystal. DIAMOND119 representation; 




2 Details of the Computational Calculations 
Geometry optimizations have been performed using the B3LYP hybrid functional120 
complemented by the D3 dispersion correction.121 The def2SVP all electron basis set122 has 
been used for all elements. Thermal corrections to enthalpies at 298.15 K have been 
calculated at the same level using the rigid rotor/harmonic oscillator model. The abbreviation 
"qh" has been added where entropies and free energies at 298.15 K (S298 and G298) have 
been calculated using the quasi-harmonic approximation with a cutoff value of 100 cm-1. 
Single point energies have subsequently been calculated with the double-hybrid B2PLYP-D3 
functional121,123 in combination with the def2-TZVPP basis set,122 and combined with thermal 
corrections obtained at B3LYP-D3/def2SVP level in order to calculate enthalpies at 298.15 K. 
Solvent effects in tetrahydrofuran (THF) have been evaluated through single point 
calculations with the SMD continuum solvation model124 at the B3LYP-D3/def2SVP level 
using gas phase geometries. Free energies in solution have been corrected to a reference 
state of 1 mol/l at 298.15 K through addition of RTln(24.46) = +7.925 kJ/mol (= 0.0030185 
Hartree) to the gas phase (1 atm) free energies. All calculations have been performed with 
Gaussian 09.125 The value for R = 8.31451 J K-1 mol-1. Natural Bond Orbital (NBO) analysis 
was performed using NBO 6.0.126 
                                               
120 a) A. D. Becke J. Chem. Phys.1993, 98, 5648-5652. b) C. Lee, W. Yang, R. G. Parr, 
Phys. Rev. B 1988, 37, 785-789. 
121 a) S. Grimme, J. Antony, S. Ehrlich, H. Krieg, J. Chem. Phys. 2010, 132, 154104; b) S. 
Grimme, S. Ehrlich, L. Goerigk, J. Comput. Chem. 2011, 32, 1456-1465. 
122 F. Weigend, R. Ahlrichs, Phys. Chem. Chem. Phys. 2005, 7, 3297-3305. 
123 S. Grimme, J. Chem. Phys. 2006, 124, 34108. 
124 A. V. Marenich, C. J. Cramer, D. G. Truhlar, J. Phys. Chem. B 2009, 113, 6378-6396. 
125 Gaussian 09, Revision B.01, M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, 
M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G. A. Petersson, H. 
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Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, 
M. Cossi, N. Rega, J. M. Millam, M. Klene, J. E. Knox, J. B. Cross, V. Bakken, C. Adamo, J. 
Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. 
W. Ochterski, R. L. Martin, K. Morokuma, V. G. Zakrzewski, G. A. Voth, P. Salvador, J. J. 
Dannenberg, S. Dapprich, A. D. Daniels, O. Farkas, J. B. Foresman, J. V. Ortiz, J. 
Cioslowski, D. J. Fox, Gaussian, Inc., Wallingford CT, 2010. 
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Scheme 45. Reaction mechanism for the addition of propellane (1) to the prenylzinc reagent 




Figure 14. Calculated geometries of selected intermediates shown in Figure 12 (B3LYP-
D3/def2SVP). 
 












1+21 0.0 0.0 
1+52 +27.9 +28.4 
22a -47.3 -3.1 
22b -68.8 -25.5 
23 -0.1 +52.0 
49 -35.0 +19.6 
24 -96.6 -42.7 
53 -20.9 +25.1 
54 +44.6 +95.6 
















Eq. 52 > 21 -27.9 -28.4 
50 + 51 > 2 x 21 -6.9 -4.4 
Step 1: 
1 + 21 > 22a 
-47.3 -3.1 
Step 2: 
22a > 23 
+47.2 +55.1 
Step 3: 
23 > 49 
-34.9 -32.4 
Step 4: 
49 > 24 
-61.6 -62.3 
Step 5: 
24 + 2d > 
21 + 3d 
-2.5 -2.5 
sum of steps 
(1 + 2d > 3d) 
-99.1 -45.2 
Step 1’: 
1 + 52 > 53 
-48.8 -3.3 
Step 2’: 
53 > 54 
+65.5 +70.5 
Step 3’ + 4’: 

































1        
kn13_005 -193.87237324 -193.774506 -193.803999 0.00 -193.803999 -193.9042284 0.00 
kn13_002 -193.87235922 -193.774498 -193.805682 0.00 -193.805682 -193.9042207 0.00 
        
21        
ks01_085 −12411.5110482 −12411.352496 −12411.432143 0.00 −12411.427599 −12411.0653400 0.00 
ks01_084 −12411.5104746 −12411.351721 −12411.431056 0.00 −12411.426373 −12411.0641721 0.00 
ks01_086 −12411.5094574 −12411.351089 −12411.432633 0.00 −12411.426892 −12411.0649448 0.00 
ks01_006 −12411.5090628 −12411.350600 −12411.432506 0.00 −12411.426177 −12411.0654693 0.00 
ks01_002 −12411.5089516 −12411.350515 −12411.432601 0.00 −12411.426285 −12411.0649217 0.00 
ks01_005 −12411.5086638 −12411.350324 −12411.431980 0.00 −12411.426091  0.00 
        




−12605.4152459 −12605.156649 −12605.251456 0.00 −12605.243086 −12604.998245 0.00 
ks01_023 −12605.4151470 −12605.156301 −12605.249776 0.00 −12605.242495 −12604.9975198 0.00 




−12605.4140028 −12605.155483 −12605.249663 0.00 −12605.242096 −12604.996697 0.00 




−12605.4137559 −12605.155175 −12605.249919 0.00 −12605.241970  0.00 








−12605.4133826 −12605.154734 −12605.249638 0.00 −12605.241274  0.00 
ks01_019 −12605.4132439 −12605.154567 −12605.248122 0.00 −12605.240648  0.00 
ks01_013 −12605.4131086 −12605.154491 −12605.248727 0.00 −12605.240952  0.00 




−12605.4126888 −12605.154128 −12605.249455 0.00 −12605.240981  0.00 
ks01_022 −12605.4119964 −12605.153462 −12605.248601 0.00 −12605.240038  0.00 
        
22b        
ks01_026 −12605.4188114 −12605.160220 −12605.253088 0.00 −12605.246978 −12605.0022938 0.00 
ks01_040 −12605.4186432 −12605.160117 −12605.253158 0.00 −12605.246883 −12605.0025190 0.00 
ks01_042 −12605.4098360 −12605.151405 −12605.245772 0.00 −12605.238174  0.00 
ks01_041 −12605.4098354 −12605.151404 −12605.245781 0.00 −12605.238174  0.00 
187 
 
        
23        
ks01_050 −12605.3825283 −12605.124945 −12605.216249 0.00 −12605.208368 −12604.9667026 0.00 
        
49        
ks01_051 −12605.4032362 −12605.142944 −12605.231908 0.00 −12605.225409 −12604.9869363 0.00 
        
24        
ks01_014 −12605.4371295 −12605.177082 −12605.268961 0.00 −12605.259814 −12605.0211343 0.00 
ks01_011 −12605.4371134 −12605.177034 −12605.268950 0.00 −12605.259735 −12605.0211232 0.00 
ks01_012 −12605.4370486 −12605.177082 −12605.269143 0.00 −12605.259890  0.00 




−12605.4367909 −12605.176699 −12605.267519 0.00 −12605.259407  0.00 
ks01_015 −12605.4336522 −12605.173626 −12605.265466 0.00 −12605.256550  0.00 
        
2d        
kn13_009 -5016.6575135 -5016.514420 -5016.572439 0.00 -5016.569117 -5016.4976610 0.00 
kn13_008 -5016.6573729 -5016.514302 -5016.572214 0.00 -5016.569054 -5016.4980160 0.00 
kn13_004 -5016.6573728 -5016.514302 -5016.572214 - - - - 
kn13_001 -5016.6567449 -5016.513644 -5016.572378 0.00 -5016.568774 -5016.4975508 0.00 
        
3d        
kn13_013 -5210.5856109 -5210.340783 -5210.408077 0.00 -5210.403184 -5210.4549339 0.00 
kn13_011 -5210.5855788 -5210.341796 -5210.406118 0.00 -5210.402634 -5210.4549318 0.00 
        
50        
ks02_042 -10033.3929298 -10033.104189 -10033.194703 0.00 -10033.189135 -10033.0573258 0.00 
ks02_038 -10033.3927713 -10033.104375 -10033.196645 0.00 -10033.190157 -10033.0571647 0.00 
ks02_039 -10033.3922736 -10033.103966 -10033.196127 0.00   0.00 
ks02_003 -10033.3921815 -10033.103941 -10033.198071 0.00 -10033.189771 -10033.0560727 0.00 
ks02_037 -10033.3908662 -10033.102662 -10033.195757 0.00 -10033.188428  0.00 
ks02_040 -10033.3906193 -10033.102392 -10033.196595 0.00   0.00 
ks02_041 -10033.3894988 -10033.101210 -10033.195488 0.00   0.00 
        
51        
ks01_108 -14789.6266544 -14789.598119 -14789.666955 0.00 -14789.663493 -14789.0735976 0.00 
        
52        
ks01_083 -12411.5003651 -12411.341884 -12411.424430 0.00 -12411.416821 -12411.5285638 0.00 
ks01_097 -12411.5002209 -12411.341705 -12411.423409 0.00 -12411.416611 -12411.5283789 0.00 
        
188 
 




−12605.4058751 −12605.147206 −12605.240677 0.00 −12605.232991 −12604.988232 0.00 
        




−12605.3733249 −12605.115643 −12605.208393 0.00 −12605.199519 −12604.95576 0.00 
        
55        
ks01_112 -12605.4421728 -12605.182058 -12605.275534 0.00 -12605.265748 -12605.023727 0.00 
ks01_113 -12605.4422142 -12605.182165 -12605.276281 0.00 -12605.266013 -12605.023752 0.00 
ks01_114 -12605.4421319 -12605.182082 -12605.275692 0.00   0.00 
 



























1       
kn13_005 -193.87237324 -193.774506 -193.803999 -193.9042284 -193.88523394 -193.8456964 
kn13_002 -193.87235922 -193.774498 -193.805682 -193.9042207 -193.88523469 -193.8474005 
       
21       
ks01_085 −12411.5110482 −12411.352496 −12411.427599 −12411.0653400 −12411.5408086 -12411.0086327 
ks01_084 −12411.5104746 −12411.351721 −12411.426373 −12411.0641721 −12411.5412006 -12411.0077780 
ks01_086 −12411.5094574 −12411.351089 −12411.426892 −12411.0649448 −12411.5373398 -12411.0072433 
ks01_006 −12411.5090628 −12411.350600 −12411.426177 −12411.0654693 −12411.5368335 -12411.0073357 
ks01_002 −12411.5089516 −12411.350515 −12411.426285 −12411.0649217 −12411.5367619 -12411.0070469 
ks01_005 −12411.5086638 −12411.350324 −12411.426091  −12411.5363737  
       




−12605.4152459 −12605.156649 −12605.243086 −12604.998245 −12605.4493860 
-12604.8572067 
 
ks01_023 −12605.4151470 −12605.156301 −12605.242495 −12604.9975198 −12605.4480332 -12604.8547355 




−12605.4140028 −12605.155483 −12605.242096 −12604.996697 −12605.4483264 
-12604.8560953 
 














−12605.4133826 −12605.154734 −12605.241274  −12605.4483837  
ks01_019 −12605.4132439 −12605.154567 −12605.240648  −12605.4475184  
ks01_013 −12605.4131086 −12605.154491 −12605.240952  −12605.4465225  




−12605.4126888 −12605.154128 −12605.240981  −12605.4470863  
ks01_022 −12605.4119964 −12605.153462 −12605.240038  −12605.4459708  
       
22b       
ks01_026 −12605.4188114 −12605.160220 −12605.246978 −12605.0022938 −12605.4571148 -12604.8657453 
ks01_040 −12605.4186432 −12605.160117 −12605.246883 −12605.002519 −12605.4565069 -12604.8656040 
ks01_042 −12605.4098360 −12605.151405 −12605.238174  −12605.4472447  
ks01_041 −12605.4098354 −12605.151404 −12605.238174  −12605.4472396  
       
23       
ks01_050 −12605.3825283 −12605.124945 −12605.208368 −12604.9667026 −12605.429241 -12604.8362365 
       
49       
ks01_051 −12605.4032362 −12605.142944 −12605.225409 −12604.9869363 −12605.4457196 -12604.8485740 
       
24       
ks01_014 −12605.4371295 −12605.177082 −12605.259814 −12605.0211343 −12605.4686426 -12604.8723134 
ks01_011 −12605.4371134 −12605.177034 −12605.259735 −12605.0211232 −12605.4685560 -12604.8721689 
ks01_012 −12605.4370486 −12605.177082 −12605.259890  −12605.4680948  




−12605.4367909 −12605.176699 −12605.259407  −12605.4682164  
ks01_015 −12605.4336522 −12605.173626 −12605.256550  −12605.4646365  
       
2d       
kn13_009 -5016.6575135 -5016.514420 -5016.569117 -5016.4976610 -5016.6817050 -5016.4304375 
kn13_008 -5016.6573729 -5016.514302 -5016.569054 -5016.4980160 -5016.6821803 -5016.4314860 
kn13_001 -5016.6567449 -5016.513644 -5016.568774 -5016.4975508 -5016.6810878 -5016.4309043 
       
3d       
kn13_013 -5210.5856109 -5210.340783 -5210.403184 -5210.4549339 -5210.6122602 -5210.2961378 
kn13_011 -5210.5855788 -5210.341796 -5210.402634 -5210.4549318 -5210.6121604 -5210.2955501 
       
50       
ks02_042 -10033.3929298 -10033.104189 -10033.189135 -10033.0571647 -10033.4190869 -10032.8765085 
ks02_038 -10033.3927713 -10033.104375 -10033.190157 -10033.0571647 -10033.4186489 -10032.8774095 
ks02_039 -10033.3922736 -10033.103966     
ks02_003 -10033.3921815 -10033.103941 -10033.189771 -10033.0560727 -10033.4172632 -10032.8757254 
190 
 
ks02_037 -10033.3908662 -10033.102662 -10033.188428    
ks02_040 -10033.3906193 -10033.102392     
ks02_041 -10033.3894988 -10033.101210     
       
51       
ks01_108 -14789.6266544 -14789.598119 -14789.663493 -14789.0735976 -14789.6574140 -14789.1381773 
       
52       
ks01_083 -12411.5003651 -12411.341884 -12411.416821 -12411.0561902 -12411.5285638 -12410.9978263 
ks01_097 -12411.5002209 -12411.341705 -12411.416611 -12411.0559051 -12411.5283789 -12410.9974347 
       




−12605.4058751 −12605.147206 −12605.232991 −12604.988232 −12605.4400322 -12604.8464865 
       




−12605.3733249 −12605.115643 −12605.199519 −12604.95576 −12605.4140140 -12604.8196247 
       
55       
ks01_113 -12605.4422142 -12605.182165 -12605.266013 -12605.023752 -12605.4752537 -12604.7967423 
ks01_112 -12605.4421728 -12605.182058 -12605.265748 -12605.023727 -12605.4751313 -12604.7965707 
















Scheme 47. Reaction mechanism for the addition of propellane (1) to the prenylzinc reagent 
2d via the cubic cluster 50. 
 












1+50 0.0 0.0 
56 -58.4 -11.3 
57 +16.0 +71.6 

















1 + 50 > 56 
-58.4 -11.3 
Step 2: 
56 > 57 
+74.4 +82.9 
Step 3: 
57 > 58 
-30.9 -27.5 
58 + 59 > 21 + 
60 
-103.5 -107.7 
21 + 2d > 
61 + 50 
+11.4 +10.5 
sum of steps (1 
































1        
kn13_005 -193.87237324 -193.774506 -193.803999 0.00 -193.803999 -193.9042284 0.00 
kn13_002 -193.87235922 -193.774498 -193.805682 0.00 -193.805682 -193.9042207 0.00 
        
50        
ks02_042 -10033.3929298 -10033.104189 -10033.194703 0.00 -10033.189135 -10033.0573258 0.00 
ks02_038 -10033.3927713 -10033.104375 -10033.196645 0.00 -10033.190157 -10033.0571647 0.00 
ks02_039 -10033.3922736 -10033.103966 -10033.196127 0.00   0.00 
ks02_003 -10033.3921815 -10033.103941 -10033.198071 0.00 -10033.189771 -10033.0560727 0.00 
ks02_037 -10033.3908662 -10033.102662 -10033.195757 0.00 -10033.188428  0.00 
ks02_040 -10033.3906193 -10033.102392 -10033.196595 0.00   0.00 
ks02_041 -10033.3894988 -10033.101210 -10033.195488 0.00   0.00 
        
56        
ks02_012 -10227.3052237 -10226.916679 -10227.021301 0.00 -10227.012715 -10226.9960038 0.00 
ks02_010 -10227.2984725 -10226.910081 -10227.014552 0.00 -10227.006872 -10226.9905268 0.00 
ks02_001 -10227.2978486 -10226.909531 -10227.013319 0.00 -10227.005947 -10226.9896733 0.00 
ks02_009 -10227.2975953 -10226.909347 -10227.013587 0.00   0.00 
ks02_014 -10227.2975313 -10226.909173 -10227.012846 0.00   0.00 
ks02_013 -10227.2968184 -10226.908633 -10227.013779 0.00   0.00 
194 
 
ks02_011 -10227.2956843 -10226.907444 -10227.014436 0.00   0.00 
ks02_015 -10227.2917191 -10226.903294 -10227.008026 0.00   0.00 
ks02_016 -10227.2902996 -10226.901975 -10227.008498 0.00   0.00 
        
57        
ks02_018 -10227.2626470 -10227.875338 -10227.975248 0.00 -10226.967933 -10226.9542079 0.00 
ks02_008 -10227.2612208 -10226.873876 -10226.974168 0.00 -10226.966646 -10226.9529420 0.00 
        
58        
ks02_033 -10227.2808404 -10226.891156 -10226.989474 0.00 -10226.982642 -10226.9713185 0.00 
        
59        
ks02_044 -4548.92915993 -4548.792373 -4548.841518 0.00 -4548.839792 -4548.7779531 0.00 
        
60        
ks02_035 -2364.73274204 -2364.364799 -2364.436727 0.00 -2364.430222 -2364.7183248 0.00 
        
21        
ks01_085 −12411.5110482 −12411.352496 −12411.432143 0.00 −12411.427599 −12411.0653400 0.00 
ks01_084 −12411.5104746 −12411.351721 −12411.431056 0.00 −12411.426373 −12411.0641721 0.00 
ks01_086 −12411.5094574 −12411.351089 −12411.432633 0.00 −12411.426892 −12411.0649448 0.00 
ks01_006 −12411.5090628 −12411.350600 −12411.432506 0.00 −12411.426177 −12411.0654693 0.00 
ks01_002 −12411.5089516 −12411.350515 −12411.432601 0.00 −12411.426285 −12411.0649217 0.00 
ks01_005 −12411.5086638 −12411.350324 −12411.431980 0.00 −12411.426091  0.00 
        
2d        
kn13_009 -5016.6575135 -5016.514420 -5016.572439 0.00 -5016.569117 -5016.4976610 0.00 
kn13_008 -5016.6573729 -5016.514302 -5016.572214 0.00 -5016.569054 -5016.4980160 0.00 
kn13_004 -5016.6573728 -5016.514302 -5016.572214 - - - - 
kn13_001 -5016.6567449 -5016.513644 -5016.572378 0.00 -5016.568774 -5016.4975508 0.00 
        
61        
ks02_030 -7394.77658141 -7394.763260 -7394.808503 0.00 -7394.807686 -7394.5089863 0.00 
 


























1       
kn13_005 -193.87237324 -193.774506 -193.803999 -193.9042284 -193.88523394 -193.8456964 
kn13_002 -193.87235922 -193.774498 -193.805682 -193.9042207 -193.88523469 -193.8474005 
       
195 
 
50       
ks02_042 -10033.3929298 -10033.104189 -10033.189135 -10033.0571647 -10033.4190869 -10032.8765085 
ks02_038 -10033.3927713 -10033.104375 -10033.190157 -10033.0571647 -10033.4186489 -10032.8774095 
ks02_039 -10033.3922736 -10033.103966     
ks02_003 -10033.3921815 -10033.103941 -10033.189771 -10033.0560727 -10033.4172632 -10032.8757254 
ks02_037 -10033.3908662 -10033.102662 -10033.188428    
ks02_040 -10033.3906193 -10033.102392     
ks02_041 -10033.3894988 -10033.101210     
       
56       
ks02_012 -10227.3052237 -10226.916679 -10227.012715 -10226.9960038 -10227.3338794 -10226.7291323 
ks02_010 -10227.2984725 -10226.910081 -10227.006872 -10226.9905268 -10227.3305239 -10226.7279592 
ks02_001 -10227.2978486 -10226.909531 -10227.005947 -10226.9896733 -10227.3311231 -10226.7280277 
ks02_009 -10227.2975953 -10226.909347     
ks02_014 -10227.2975313 -10226.909173     
ks02_013 -10227.2968184 -10226.908633     
ks02_011 -10227.2956843 -10226.907444     
ks02_015 -10227.2917191 -10226.903294     
ks02_016 -10227.2902996 -10226.901975     
       
57       
ks02_008 -10227.2612208 -10226.873876 -10226.966646 -10226.9529420 -10227.3034165 -10226.6975444 
ks02_018 -10227.2626470 -10227.875338 -10226.967933 -10226.9542079 -10227.3024963 -10226.6963247 
       
58       
ks02_033 -10227.2808404 -10226.891156 -10226.982642 -10226.9713185 -10227.3187442 -10226.7080054 
       
59       
ks02_044 -4548.92915993 -4548.792373 -4548.839792 -4548.7779531 -4548.94937872 -4548.7057855 
       
60       
ks02_035 -2364.73274204 -2364.364799 -2364.430222 -2364.7183248 -2364.76613737 -2364.4461816 
       
21       
ks01_085 −12411.5110482 −12411.352496 −12411.427599 −12411.0653400 −12411.5408086 -12411.0086327 
ks01_084 −12411.5104746 −12411.351721 −12411.426373 −12411.0641721 −12411.5412006 -12411.0077780 
ks01_086 −12411.5094574 −12411.351089 −12411.426892 −12411.0649448 −12411.5373398 -12411.0072433 
ks01_006 −12411.5090628 −12411.350600 −12411.426177 −12411.0654693 −12411.5368335 -12411.0073357 
ks01_002 −12411.5089516 −12411.350515 −12411.426285 −12411.0649217 −12411.5367619 -12411.0070469 
ks01_005 −12411.5086638 −12411.350324 −12411.426091  −12411.5363737  
       
2d       
kn13_009 -5016.6575135 -5016.514420 -5016.569117 -5016.4976610 -5016.6817050 -5016.4304375 
kn13_008 -5016.6573729 -5016.514302 -5016.569054 -5016.4980160 -5016.6821803 -5016.4314860 
kn13_001 -5016.6567449 -5016.513644 -5016.568774 -5016.4975508 -5016.6810878 -5016.4309043 
196 
 
       
61       















Scheme 49. Coordination of [1.1.1]propellane on a lithium atom in cluster 21, leading 
towards the transition state 62. 
 
Table 15. Reaction energies for the systems shown in Scheme 49 (in Hartree) and 













1 + 21 > 61 
-44.8 -2.0 
Step 2: 
61 > 62 
+81.8 +137.6 
Scheme 45:   
Step 1: 
1 + 21 > 22a 
-47.3 -3.1 
Step 2: 
22a > 23 
+47.2 +55.1 
 




























1        
kn13_005 -193.87237324 -193.774506 -193.803999 0.00 -193.803999 -193.9042284 0.00 
kn13_002 -193.87235922 -193.774498 -193.805682 0.00 -193.805682 -193.9042207 0.00 
        
21        
ks01_085 −12411.5110482 −12411.352496 −12411.432143 0.00 −12411.427599 −12411.0653400 0.00 
ks01_084 −12411.5104746 −12411.351721 −12411.431056 0.00 −12411.426373 −12411.0641721 0.00 
ks01_086 −12411.5094574 −12411.351089 −12411.432633 0.00 −12411.426892 −12411.0649448 0.00 
ks01_006 −12411.5090628 −12411.350600 −12411.432506 0.00 −12411.426177 −12411.0654693 0.00 
199 
 
ks01_002 −12411.5089516 −12411.350515 −12411.432601 0.00 −12411.426285 −12411.0649217 0.00 
ks01_005 −12411.5086638 −12411.350324 −12411.431980 0.00 −12411.426091  0.00 
        
61        
ks03_002 -12605.4166014 -12605.157925 -12605.252647 0.00 -12605.244888 -12605.4474671 0.00 
        
62        
ks03_011 -12605.3709199 -12605.114046 -12605.201209 0.00 -12605.196046 -12604.9528455 0.00 
 


























1       
kn13_005 -193.87237324 -193.774506 -193.803999 -193.9042284 -193.88523394 -193.8456964 
kn13_002 -193.87235922 -193.774498 -193.805682 -193.9042207 -193.88523469 -193.8474005 
       
21       
ks01_085 −12411.5110482 −12411.352496 −12411.427599 −12411.0653400 −12411.5408086 -12411.0086327 
ks01_084 −12411.5104746 −12411.351721 −12411.426373 −12411.0641721 −12411.5412006 -12411.0077780 
ks01_086 −12411.5094574 −12411.351089 −12411.426892 −12411.0649448 −12411.5373398 -12411.0072433 
ks01_006 −12411.5090628 −12411.350600 −12411.426177 −12411.0654693 −12411.5368335 -12411.0073357 
ks01_002 −12411.5089516 −12411.350515 −12411.426285 −12411.0649217 −12411.5367619 -12411.0070469 
ks01_005 −12411.5086638 −12411.350324 −12411.426091  −12411.5363737  
       
61       
ks03_002 -12605.4166014 -12605.157925 -12605.244888 -12605.0006701 -12605.4474671 -12604,8568039 
       
62       



































1 0.7691 0.7906 - - 156.3 
22a 0.6557 0.6638 0.1291 0.1489 154.2 
23 0.3393 0.3216 0.2194 0.2452 171.9 
24 0.0579 0.0509 0.4775 0.5092 189.7 
61 0.7260 0.7395 0.0374 0.0639 154.8 
 
The coordination of [1.1.1]propellane (1) to zinc (22a) results in a reduction of the bonding 
order of the central bond indicated by a decrease of the Wiberg Bond Index (WBI). However, 
at the same time the length of the bond decreases by 2 pm. This is in accordance with the 
results of Jemmis,15b who observed similar results when investigating complexes of 
[1.1.1]propellane with electron-accepting halogen-bond donors. Overall, the removal of 
electron density from the mostly non-bonding HOMO seems to increase the strength of the 
central bond. 
As expected, the WBI of the central bond decreases significantly when moving to the 
transition state 23. In the product cluster 24 there is almost no bonding interaction between 
the bridgehead carbons. The WBI of the carbon-zinc bond in the intermediate 22a is 
approximately 4 times smaller than the one of the carbon-zinc bond in the product cluster 24. 
Similar trends were observed for the coordination of [1.1.1]propellane to lithium (61), albeit 
on a significantly smaller scale. 
The NBO presentation of the central bond in [1.1.1]propellane includes two partially occupied 
lone pairs at the bridgehead carbon atoms. A strong donor-acceptor interaction between the 
lone pair of one of the bridgehead carbons and a vacant orbital of the neighbouring zinc in 
intermediate 22a was confirmed by the NBO analysis: 
201 
 
113. (1.60735) LP ( 1) C 25            s( 53.79%)p 0.86( 46.12%)d 0.00( 0.08%)f 0.00( 0.01%) 
141. (0.50812) LV ( 1)Zn  7            s( 99.67%)p 0.00( 0.17%)d 0.00( 0.16%)f 0.00( 0.00%) 
144. (0.74142) LV ( 1) C 26            s( 9.16%)p 9.87( 90.35%)d 0.05( 0.47%)f 0.00( 0.02%) 
 
SECOND ORDER PERTURBATION THEORY ANALYSIS OF FOCK MATRIX IN NBO 
BASIS 
     Threshold for printing:   0.50 kcal/mol 
                                                                                    E(2)       E(NL)-E(L)          F(L,NL) 
      Donor (L) NBO              Acceptor (NL) NBO      kcal/mol        a.u.                   a.u. 
 ====================================================================== 
      113. LP ( 1) C 25           141. LV ( 1)Zn  7           68.37          0.30                  0.129 
 










length of the 
central C-C bond 
in 1 [pm] 
156.3 156.7 156.6 159.4 
 
The Natural Population Analysis (NPA) was employed to examine the charge distribution in 
selected intermediates (Table 20). 
Table 20. Charges of fragments in [1.1.1]propellane in selected intermediates as determined 
by Natural Population Analysis. 
Intermediate 
charge of the 
bridgehead 
carbon next to 
zinc [a.u.] 
charge of the 
bridgehead 
carbon opposite 
to zinc [a.u.] 
charge of the bridge CH2-
groups (hydrogens 
summed into carbons) 
[a.u.] 
total charge of 
the cage 
[a.u.] 
1 0.023 0.023 +0.015 0 
22a 0.322 +0.086 +0.120/+0.119/+0.105 +0.108 




The coordination of [1.1.1]propellane to the metal cluster in intermediate 22a results in a 
localization of electron density at the bridgehead carbon adjacent to the zinc. This is 
compensated by a slight positive charge on the opposite bridgehead carbon and all of the 
CH2-units, resulting in a total charge for the propellane unit of +0.108 e. In the transition state 
23 the negative charge on the bridgehead carbon next to zinc is even larger. The remaining 
cage still holds a positive charge. This is in contrast to previously reported reactions of 
anions with [1.1.1]propellane, where the delocalization of additional electron density onto the 
bridge carbons and the resulting electronic repulsion was found to be responsible for the 
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